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> RHEUMATOID ARTHRITIS, 
ETIOLOGY AND CLINICAL 
ASPECTS
R heu m ato id  a r th r i t i s  (RA) is a c o m m o n  ch ron ic  in f la m m a to ry  d isease m a in ly  
a f fec t ing  the synov ia l  jo in ts .  A p p ro x im a te ly  1% of the w o r ld  po pu la t ion  is a f fec ted w i th  
RA and the  d isease has a th ree fo ld  h ig h e r  p reva lence in fe m a le s  than  in m a le s  (1). RA 
is a m u l t i f a c to r ia l  d is o rd e r  in w h ic h  both  gene t ic  and n o n -g e n e t ic  fac to rs  are involved 
no t on ly  in d isease suscep t ib i l i ty ,  bu t a lso in the chron ic i ty ,  severi ty , and a pa t ien t 's  
re sponse  to the ra p y  (2;3). H e r i ta b i l i ty  of RA has been extensive ly  s tud ied  and has been 
e s t im a ted  at 50 -60%  (4-6). RA can re su l t  in j o in t  and ca r t i la ge  d e s t ru c t io n  (F igure 1), 
and loss of func t iona l i ty .  A pa r t  f ro m  the a r t i c u la r  m a n i fe s ta t io n s  the re  are a lso m u l t i -  
s ys tem ic  ones  and the d isease is fu r th e r m o r e  assoc ia ted  w i th  inc reased com orb id i ty ,  
inc lud ing  a h ig h e r  r is k  of co rona ry  a r te ry  d isease, in fec t ion  and lym p h o m a  as w e l l  as 
reduced life expec tancy  (7).
F i g u r e  1 /  S c h e m a t i c  p r e s e n t a t io n  of  a h e a l t h y  j o in t  a nd  t h e  f e a t u r e s  t h a t  c h a r a c t e r i z e  an  a r t h r i t i c  j o in t
F ig u re  w a s  a d a p te d ,  w i t h  p e r m is s i o n ,  f r o m  t h e  t h e s i s  of  M a r i j e  K o e n d e r s ;  I n t e r l e u k i n  17 and  i ts r e la t i o n  to 








RA has a peak of on se t  in the fo u r th  and f i f th  decades  of l ife. The d isease begins 
w i th  fa t igue, anorexia , genera l ized  w e a k n e s s  and vague m u s c u lo s k e le ta l  s y m p to m s  in 
a p p rox im a te ly  60% of the  pa t ien ts  un t i l  synov it is  be com es  apparen t .  J o in t  invo lvem ent 
p resen ts  i tse l f  as jo in t  in f la m m a t io n  w h ic h  leads to pain, redness, tenderness ,  w a rm th  
and sw e l l ing .  The d isease cou rse  ranges  f ro m  m i ld ,  s e l f  l im i t in g  a r th r i t i s  to a p ro g re s ­
sive m u l t is y s te m  in f la m m a t io n  w i th  p ro found m o rb id i t y  and morta l i ty .  M os t pa t ien ts  
s u f fe r in g  f ro m  RA e xper ience  pe rs is te n t  bu t f lu c tu a t in g  d isease activity. A l th o u g h  every 
jo in t  in the body can be af fec ted by the disease, jo in ts  of  bo th  the  ha nds  and feet are 
o f ten involved and re f lec t  the pa t ien t  ove ra l l  s ta tu s  (8). Pain in the  a f fec ted jo in ts ,  a g ­
gravated by m o vem en t ,  is the m o s t  c o m m o n  m a n i fe s ta t io n  of  RA. In f la m m a t io n  is of ten 
a cco m pan ied  by a genera l ized  s t i f fn ess  a f te r  a per iod of inactivi ty. A s e t  of  c lass i f ica t ion  
c r i te r ia  w a s  developed by the A m e r ic a n  Col lege of R h e u m a t is m  (ACR) to d iagnose  RA 
re l iab ly  and d is t ing u ish  it f ro m  disease w i th  ove r lapp ing  s y m p to m s  (9). These 1987 ACR 
c r i te r ia  are nowadays  m o s t  c o m m o n ly  used fo r  the d iag nos is  of  RA in the c l in ic ,  as w e l l  
as fo r  the de f in i t ion  of pa t ien ts  fo r  research  p ro jec ts  (Table 1).
T a b le  1 /  1987 A m e r i c a n  Co l l e ge of R h e u m a t i s m  c r i t e r i a  f o r  t h e  c la s s i f i c a t i o n  of  R h e u m a t o i d  A r t h r i t i s
C r i t e r i o n S h o r t  t i t l e D e f i n i t i o n
1 M o rn in g  s t if fn e s s M o r n in g  s t i f f n e s s  in and  a r o u n d  t h e  j o in ts ,  l a s t i n g  at le as t  1 h o u r  be fo re  
m a x i m a l  im p r o v e m e n t
2 A r th r it is  o f 3  o r  
m o re  jo in t  a re as
At  leas t  3 jo in t  a re a s  s i m u l t a n e o u s l y  have  had  s o f t  t i s s u e  s w e l l i n g  o r  f lu id  
(not  b on y  o v e r g r o w t h  a lo ne ) o b s e rv e d  by a p hy s ic ian .  T h e  14 p os s ib le  
a re a s  a re  r i g h t  o r  lef t  PIP, MCP,  w r i s t ,  e lb o w ,  knee , ank le ,  a nd  M T P  jo in ts
3 A r th r it is  o f 
h a n d  jo in ts
A t  le as t  1 a re a  s w o l l e n  (as d e f in e d  above ) in a w r i s t ,  MCP,  o r  P IP  jo in t
4 S y m m e tr ic
a r th r i t is
S im u l t a n e o u s  in v o l v e m e n t  of  t h e  s a m e  j o in t  a re a s  (as d e f in e d  in 2) o r  
bo th  s i d e s  of  t h e  b od y  (b i l a t e r a l  i n v o l v e m e n t  of  PIPs , M C Ps ,  o r  M T P s  is 
a c c e p t a b le  w i t h o u t  a b s o lu te  s y m m e t r y )
E R h e u m a to id
n o d u le s
S u b c u t a n e o u s  n o d u le s ,  o v e r  b o n y  p r o m in e n c e s ,  o r  e x te n s o r  s u r fa c e s ,  
o r  in j u x t a a r t i c u l a r  r e g io n s ,  o b s e rv e d  by a phy s ic ian
6 S e ru m
rh e u m a to id  fa c to r
D e m o n s t r a t i o n  of  a b n o r m a l  a m o u n t s  of  s e r u m  r h e u m a t o i d  f a c t o r  by 
a n y  m e t h o d  f o r  w h i c h  t h e  re s u l t  h as  bee n  p os i t iv e  in < 5 %  o f  n o r m a l  
c o n t r o l  s u b je c t s
7 R a d io g ra p h ic
ch an ge s
R a d io g ra p h ic  c h a n g e s  t y p ic a l  of  r h e u m a t o i d  a r t h r i t i s  on p o s t e r o a n t e r i o r  
han d  and  w r i s t  ra d io g ra p h s ,  w h i c h  m u s t  i n c lu d e  e ro s io n s  o r  u n e q u iv o c a l  
bon y  d ec a lc i f i c a t io n  loca l iz ed  in o r  m o s t  m a r k e d  a d ja c e n t  to  t h e  involvec 
j o i n t s  ( o s t e o a r t h r i t i s  c h a n g e s  a lo n e  do  no t qua l i f y)
A pa t ien t  is c lass i f ied  as having rh e u m a to id  a r th r i t i s  if he /she  has s a t is f ied  at 
leas t 4 o r  these  7 c r i te r ia .  C r i te r ia  1 th ro u g h  4 m u s t  have been p resen t  fo r  at least 6 
w eeks .  P at ien ts  w i th  2 c l in ic a l  d iagnoses  are not exc luded. PIP: p ro x im a l  in te rp h a la n -  
geal, MCP: m e ta ca rp o p h a la n g e a l ,  MTP: m e ta ta rsoph a lang ea l .
C u r re n t ly ,  th e re  is no cu re  fo r  RA, t r e a t m e n t  is d i re c te d  a t  s y m p to m  r e d u c ­
t ion  and m in im iz a t io n  of  d isea se  a c t iv i ty  and p ro g re s s io n  (10;11). E a r ly  th e ra p e u t i c  
in te rv e n t io n  is o f  u p m o s t  im p o r ta n c e  fo r  m in im iz in g  j o in t  d a m a g e  and fu n c t io n a l  
d i s a b i l i t y  (12). S e ve ra l  s tu d ie s  have s h o w n  th a t  a th re e  m o n th s  de la y  in the  i n t r o ­
d u c t io n  of  m e d ic a t io n  re s u l t s  in s ig n i f i c a n t l y  m o re  j o in t  d a m a g e  at five y e a rs  (13;14). 
RA t r e a tm e n t  is u s u a l ly  s ta r te d  w i th  m e th o t r e x a te  (MTX) m o n o th e ra p y  a d m i n i s ­
te red  w e e k ly  and fo l lo w s  a f u r t h e r  s te p w is e  a p p ro a c h .  MTX is the  m o s t  c o m m o n ly  
used d ru g  fo r  RA t r e a tm e n t  (12). W hen  p a t ie n ts  s h o w  in s u f f i c ie n t  re s p o n s e  a n d /o r  
a d ve rse  d ru g  even ts ,  MTX can be re p la ce d  by a n o th e r  d isea se  m o d i fy in g  a n t i - r h e u ­
m a t ic  d ru g  (DMARD) o r  a s eco nd  DM ARD  m a y  be a d ded  to the  MTX m o n o th e ra p y .  If 
a p a t ie n t  s t i l l  does  no t  re sp o n d  to th e ra p y  it is a lso  po ss ib le  to s w i tc h  to b io lo g ica ls ,  
a n e w e r  s u b g ro u p  o f  DM A R D s. These  b io lo g ic a ls  can be p re s c r ib e d  as m o n o th e ra p y  
o r  in c o m b in a t io n  w i t h  a n o th e r  DMARD.
A n u m b e r  of s tandard ized  in s t r u m e n ts  have been developed to eva luate  the 
d isease act iv i ty  and p rog ress ion  in a pa t ien t  and judg e  h is /h e r  response  to therapy. 
These in s t r u m e n ts  are used in the  c l in ic  as w e l l  as fo r  the cha ra c te r iza t io n  of pa t ien ts  
in research  pro jects .  A w e l l  s tandard ized  m e a su re  fo r  a ssess ing  d isease act iv i ty  in RA 
is the  D isease Act iv i ty  Score 28 (DAS28). Th is  score  is ca lcu la ted  by a com p lex  m a th e ­
m a t ic a l  f o rm u la  (F igure 2), w h ic h  inc lud es  the n u m b e r  of te n d e r  and sw o l le n  j o in ts  (out 
of  a to ta l  of  28), the e ry th rocy te  s e d im e n ta t io n  ra te  (ESR, a blood m a rk e r  of i n f l a m m a ­
tion), and the pa t ien t 's  a s s e s s m e n t  of g lob a l  hea l th  (ind icated by m a rk in g  a 10 cm  l ine 
be tw een very  good and very  bad).
F i g u r e  2 /  DA S 28  f o r m u le
DA S 28  = 0 .56  •  /  ( t28) + 0 .28  •  /  (sw28 ) + 0 .70  •  Ln(ESR) + 0 .014  •  GH
T h e  f o l l o w in g  p a r a m e t e r s  a re  in c lu d e d  in t h e  c a lc u l a t i o n :  t e n d e r  j o in t  c o u n t s  (t28), s w o l l e n  j o in t  c o u n t s  








A DAS28 sco re  g re a te r  than  5.1 im p l ie s  active d isease, less than  3.2 w e l l  c o n t ro l ­
led d isease, and less than  2.6 re m iss ion  (15). To m e asu re  ind iv idua l  RA t re a tm e n t  
response , the  DAS based European League A ga ins t  R h e u m a t is m  (EULAR) response 
c r i te r ia  w e re  deve loped. These response c r i te r ia  use the ind iv idua l  change in DAS and 
the  level  of DAS reached th ro u g h  t re a tm e n t  to c lass i fy  pa t ien ts  as good, m o d e ra te  or 
n o n - re s p o n d e rs  (Table 2) (16).
T a b le  2 /  E U L A R  re s p o n s e  c r i te r ia
D A S 2 8  a t  e n d p o i n t  I m p r o v e m e n t  in D A S 2 8  f r o m  b a s e l i n e
> 1.2 > 0.6 a n d  < 1.2 < 0.6
< 3.2 Good
> 3.2  a n d  < 5.1 M o d e r a t e
> 5. ' N o n e
Dam age in the j o in t  due to de s t ru c t io n  of ca r t i la ge  and under ly ing  bone is q u a n ­
ti f ied to m e a su re  the seve r i ty  and c l in ica l  cou rse  of RA. J o in t  (or rad io log ica l)  dam age  
is i r revers ib le .  There are a va r ie ty  o f m e th o d s  fo r  s co r in g  ra d io log ica l  dam age ,  the m os t  
f re q u e n t ly  used in s t r u m e n ts  are the  (m od i f ied  ve rs ion  of  the) S harp 's  score  (17) and 
La rsen 's  m e thod  (18). The m od i f ied  S harp 's  m e thod  uses a sys tem  in w h ic h  each jo in t  
is s cored  bo th fo r  space n a r ro w in g  and fo r  e ros ions. In La rsen 's  m e th o d  the hands, 
w r i s t  and feet are scored. It has a range f ro m  0 to 200 and tw en ty  jo in ts  in the hands 
and 10 in the feet are scored. The w r is t s  are eva luated as a s ing le  jo in t .  S cores ranges 
f ro m  0 to 5 and the w r is t s  are w e igh ted  by a fac to r  of 5.
The next few  pa ra g ra p h s  w i l l  f i r s t  focus  on the  p r o - in f la m m a to ry  cy tok ine  
t u m o u r  necros is  fa c to r  (TNF) and its ro le  in RA d isease sever i ty  and as ta rge t  fo r  t r e a t ­
m e n t  (a n t i -T N F  therapy). Next, the re la t ionsh ip  be tw een gene t ic  va r ia t ion  and ind iv idua l  
d i f fe rences  in RA seve r i ty  and a n t i -T N F  the rap y  response  w i l l  be d iscussed, the reby  
in t roduc in g  the t e r m s  ‘ph a rm a co g e n e t ic s '  and p h a rm a c o g e n o m ic s '  . In the las t  p a ra ­
g raph  the ou t l in e  of th is  thes is  is d iscussed.
> TNF AND ITS ROLE IN THE 
TREATMENT OF RA
Even tho ugh  the pa thog ene s is  of RA is no t fu l ly  unders tood ,  it is c o m m o n ly  
accepted  tha t  the  p r o - in f la m m a to ry  cy tok ine  TNF has a key ro le in the  in f la m m a to ry  
process (19). TN F neu tra l iz in g  ap p roa ches  have proven h igh ly  effective in the t re a tm e n t  
of  RA and o th e r  a u to im m u n e  d iseases  (20-23). Though  in th e o ry  T NF n e u t ra l isa t io n  can 
be ach ieved at  m a n y  levels, a l l  TN F  b lock ing  a g en ts  ava ilab le  nowadays prevent ce l l  
s ig n a l l in g  by p revent ing  the in te rac t ion  of TN F  w i th  its c e l l -s u r fa c e  re cep to rs  a n d /o r  by 
b lock ing  m e m b ra n e - b o u n d  TNF (F igure 3).
F i g u r e  3 /  C y t o k i n e - T N F a  re c e p t o r  i n t e r a c t io n
N o r m a l  i n t e r a c t i o n N e u t r a l i z a t i o n  o f  c y t o k i n e s
%
$
S o lu b le  r e c e p t o r
I n f l a m m a t o r y
*
M o n o c lo n a l  a n t ib o d y
i
N o  s ig n a l
B in d in g  of  t h e  c y to k i n e  T N F a  to i ts c e l l - s u r f a c e  r e c e p t o r  le ad s  to  t h e  p ro d u c t io n  of  i n f l a m m a t o r y  e f f e c to r  
m o le c u le s .  D u r in g  a n t i - T N F th e ra p y ,  T N F a  is p re v en ted  f r o m  b in d in g  to  t h e  r e c e p t o r  by a m o n o c lo n a l  a n t i ­








Three a n t i -T N F  a g e n ts  are  c u r r e n t ly  ava i lab le :  e ta n e rc e p t  (E n b re l® ) ,  i n ­
f l i x im a b  (R e m ic a d e ® )  and a d a l im u m a b  (H u m i ra ® ) .  Two n e w  a n t i -T N F  agen ts ,  
g o l im u m a b  (CNTO 148) and c e r to l i z u m a b  pe go l  (C im z ia ® ) ,  have been s u b m i t te d  to 
the  E u ro pean  M e d ic in e s  A g e n cy  (EMEA) re q u e s t in g  a p p rova l  and  w i l l  m o s t  l ike ly  be 
approved  in 2009. E ta n e rce p t  is a h u m a n ,  s o lu b le  d im e r ic  TN F  type II r e c e p to r  l inked  
to the  Fc pa r t  of an IgG1 m o le c u le  th a t  b ind s  to and in a c t iva te s  T N F a .  The m o u s e -  
h u m a n  c h im e r ic  IgG1 m o n o c lo n a l  a n t ib o d y  in f l i x im a b  and the  c o m p le te ly  h u m a n iz e d  
IgG1 m o n o c lo n a l  a n t ib o d y  a d a l im u m a b  b ind to T N F a  w i th  h igh  a f f in i ty  and the re b y  
inac t iva te  it (24;25). The ne w  a n t i -T N F  a g e n ts  g o l im u m a b  and c e r to l i z u m a b  pe go l  
are  a fu l l y  h u m a n  m o n o c lo n a l  a n t i -T N F  a n t ib o d y  and a h u m a n iz e d  m o n o c lo n a l  
a n t i -T N F  an t ibody ,  re s p e c t iv e ly  (26). M o re  p rec ise ly ,  c e r to l i z u m a b  p e g o l  is the  f i r s t  
PEGyla ted, F c - f ree  a n t i -T N F  (27). In The N e th e r la n d s ,  p a t ie n ts  w i l l  s ta r t  t h e i r  f i r s t  
c o u rs e  o f  a T N F -b lo c k in g  a g e n t  w h e n  the y  have a DAS28 > 3.2 at  ba se l in e  and fa i lu re  
on at leas t  tw o  d is e a s e -m o d i fy in g  a n t i r h e u m a t ic  d r u g s  (DMARDs),  one of w h ic h  has 
to be m e th o t re x a te  (MTX) (28).
T h o u g h  T N F  n e u t r a l i s a t io n  is ve ry  e f fec t ive  in RA, l o n g - la s t in g  re sp o n se  
do es  on ly  o c c u r  in a p p ro x im a te ly  70% of the  p a t ie n ts  (28). N o n - re s p o n s e  can be 
c la s s i f ie d  in a p r im a r y  re sponse ,  if th e re  is la c k  of  e f f ica cy  a l re a d y  w i t h in  w e e k s  
f r o m  th e ra p y  in i t ia t io n ,  and  a s e c o n d a r y  re sponse ,  if a f t e r  an in i t ia l  b e n e f i t  f ro m  
the  th e ra p y ,  r e s p o n s e  is los t  w i t h  t im e  (29-31). The ca u s e s  fo r  n o n - re s p o n s e  is 
u n k n o w n .  One e x p la n a t io n  fo r  n o n - re s p o n s e  to a n t i -T N F  t r e a t m e n t  is the  f o r m a ­
t ion  o f  a n t ib o d ie s  d i re c te d  to a n t i - T N F  (h u m a n  a n t i - c h im e r i c  a n t ib o d ie s ,  HACA a n d /  
o r  h u m a n  a n t i - h u m a n  a n t ib o d ie s ,  HAHA).  These a n t ib o d ie s  p o te n t ia l l y  re duce  the  
e f f ica cy  of  t r e a t m e n t  and co u ld  lead to th e ra p y  d is c o n t in u a t io n  (32). B e s id e s  a lack  
o f  re sp o n se ,  a lso  a d ve rse  eve n ts  can o c c u r  d u r in g  a n t i - T N F  t r e a tm e n t  and can be 
the  re ason  fo r  th e ra p y  d is c o n t in u a t io n .  A d ve rse  eve n ts  re p o r te d  d u r in g  a n t i -T N F  
th e ra p y  in c lu d e  an in c re a s e d  s u s c e p t ib i l i t y  to tu b e rc u lo s is  and o th e r  coe x is t in g  
in fe c t io n s ,  ly m p h o m a  and n e u t ro p e n ia .  M o s t  o f ten  re p o r te d  a d ve rse  eve n ts  are 
in je c t io n  and in fu s io n  re a c t io n s  (33;34).
In te r in d iv id u a l  v a r ia b i l i t y  in d ru g  re s p o n s e  and the  o c c u r re n c e  of  adverse  
eve n ts  can be due to g e n e t ic  and e n v i r o n m e n ta l  f a c to rs  in f lu e n c in g  p h a r m a c o k i ­
n e t ic s  and -d y n a m ic s ,  o r  to in te r in d iv id u a l  d i f fe re n c e s  in d ise a se  p a th o g e n e s is  
and e t io lo g y  (F igu re  4) (35). D i f fe re n c e s  in th e ra p y  re s p o n s e  and to x ic i t ie s  be tw een  
in d iv id u a ls  have b e c o m e  the  m o s t  p o w e r fu l  d r ive  fo r  c u r r e n t  p h a rm a c o g e n e t i c  
re s e a rc h ,  e s p e c ia l ly  fo r  d r u g s  th a t  are  h ig h ly  c o s t ly  and th o se  th a t  have a n a r ro w  
th e ra p e u t i c  w indo w .
F i g u r e  4 /  I n t e r i n d i v i d u a l  v a r i a b i l i t y  in t h e r a p y  re s p o n s e
H L A -D R B 1  a l l e le s ,  P T P N 2 2 , c y t o c h r o m e  P 450  e n z y m e s  invol ved  
in p h a r m a c o k i n e t i c s  a n d  p h a r m a c o d y n a m i c s  e.g. d ru g  
t r a n s p o r t e r s ,  d r u g  r e c e p t o r s  
s i g n a l i n g  p a t h w a y s
— N
D is e a s e  d u r a t io n  
d i s e a s e  ac t iv i t y ,  ACPA,  
r h e u m a t o i d  f a c t o r  s t a t u s
A ge ,  g e n d e r ,  h o r m o n a l  s t a t u s  
c o - m o r b id i t y ,  e th n ic i c t y  
p re v io u s  D M A R D  use
Li fe  s t y le  e.g. s m o k in g  
a n d  diet ,  s o c i a l  c la s s
D is e a s e  a c t i v i t y  s c o re  
A C R  c r i te r ia  
H e a l th  A s s e s s m e n t  q u e s t i o n n a i r e  
R a d i o g r a p h i c  s c o re
S e v e ra l  f a c t o r s  (g ene t ic ,  e n v i r o n m e n t a l  and  d e v e lo p m e n t a l )  i n f l u e n c e  t h e  re s p o n s e  of  an  i n d i v id u a l  tc 
th e ra p y ,  a s  m e a s u r e d  by t h e  d i f f e re n t  s c o re s ,  c r i t e r i a  and  q u e s t i o n n a i r e s .  A C P A  = a n t i c i t r u l l i n a t e d  p ro te in  
a n t ib o d ie s ;  A C R  = A m e r i c a n  C o l le g e  o f  R h e u m a t o l o g y ;  D M A R D  = d i s e a s e - m o d i f y i n g  a n t i r h e u m a t i c  d ru g s .  








> PHARMACOGENETICS AND 
PHARMACOGENOMICS
Genera lly , gene t ic  fac to rs  are e s t im a ted  to be respons ib le  fo r  15-30% of the o b ­
served in te r in d iv id u a l  d i f fe rences  in d rug  m e ta b o l is m  and response. For ce r ta in  c lasses  
of d rugs ,  gene t ic  va r ia t ion  can accoun t  fo r  up to 95% of va r ia b i l i ty  in d rug  effects  
observed be tween pa t ien ts  (36-38). P ha rm a co g e n e t ic  research  focuses  on iden t i fy ing 
the  DN A s equence  v a r ia n ts  tha t  in f luence  d rug  response a n d /o r  tox ic i ties. In th is  way, 
re se a rch e rs  hope to develop too ls  to p red ic t  t re a tm e n t  response  p r io r  to t re a tm e n t  
s ta r t  and d e te rm in e  the o p t im a l  t re a tm e n t  re g im e n  fo r  an ind iv idua l  pa t ient.  S ingle 
nu c leo t ide  p o ly m o rp h is m s  (SNPs) are the m o s t  c o m m o n  fo r m s  of gene t ic  v a r ia t ion  in 
h u m a n s  and o c c u r  w i th  a m e a n  f re q u e n cy  o f one every  few  hu nd re d  nuc le o t ide s  (39). 
Mos t of these  S N Ps are th o u g h t  to be h a rm le s s  fo r  the o rg a n is m  s ince  they are located 
in in te rgen ic  o r  in t ron ic  regions. However,  a s m a l l  pe rcen tage  of S N Ps is located in 
p r o m o te r  reg ions  and cod ing seq uence s  and can have fu n c t io n a l  con seque nces  if they 
re su l t  in e.g. a l te ra t io n s  of DNA c o n fo rm a t io n ,  p ro m o te r  activ ity,  o r  RN A and prote in  
qu an t i ty  o r  qual ity.  There fore ,  ce r ta in  S N Ps m a y  a lso p lay a d i re c t  o r  ind i rec t  ro le in 
the rap y  response  and tox ic i t ies  (35). Severa l s tu d ie s  of com p lex  d iseases  a lready  c o n ­
f i rm e d  the re levance of S N Ps in d rug  m e tabo l iz in g  enzymes, t ra n s p o r te rs ,  recep to rs  
and s ig n a l l in g  pa thw ays  in a l te r in g  d rug  response  (36;40;41). S N Ps and o th e r  fo rm s  of 
DN A va r ia t ion  are a lso l ike ly  to be (part ly) respons ib le  fo r  no n - re sp o n se  and adverse 
events  observed in a n t i -T N F  t re a tm e n t  in pa t ien ts  w i th  RA, e.g., gene t ic  fac to rs  m ay  
d e te rm in e  p r im a ry  no n - re sp o n se  as w e l l  as w h y  s o m e  pa t ien ts  develop HACA o r  HAHA.
N o n - re sp o n se  to a n t i -T N F  t re a tm e n t  and adverse events  observed in RA pa­
t ien ts  and the  h igh cos ts  of th is  the ra p y  have dr iven  the  sea rch  fo r  (genet ic) m a rk e rs  
tha t  are able to p red ic t  t re a tm e n t  response  (42). For the  m o s t  part , two ap p roa ches  are 
used to iden t i fy  g ene t ic  fac to rs  under ly ing  m e c h a n is m s  of the ra p y  (non-) response .  The 
f i rs t  approach  is a hypo thes is  dr iven  approach  in w h ic h  DNA p o ly m o rp h is m s  in c a n ­
d ida te  genes  are invest iga ted  fo r  t h e i r  e f fec t  on t re a tm e n t  response . For invest igat ing 
a n t i -T N F  the rap y  response , the  m o s t  obv ious cand ida te  genes  are the genes  e n c o d ­
ing T N F B  and the  T N F - re ce p to rs ,  s ince  they  are d i re c t ly  involved in TN F B  s igna l l ing .  
There fore ,  these  genes  have been invest iga ted  re peated ly  fo r  (43-48;48-63). The ca n d i ­
date  gene approach  is, however, ha m p e re d  by the  l im i te d  know le dge  w e  c u r re n t ly  have 
abou t  pa thw ays  d e te rm in in g  the  k ine t ic s  and dyn a m ics  of  a n t i -T N F  t re a tm e n t .  Th is 
d isadvantage can be com p e n sa te d  by a second approach.  Th is  s o -ca l le d  n o n -h y p o th e ­
s is  dr iven  approach  uses g e n o m e -w id e  a r ray  tech n iq u e s  to iden t i fy  gene t ic  m a rk e rs  fo r
a n t i -T N F  t re a tm e n t  ou tcom e . In a g e n o m e -w id e  assoc ia t ion  s tu d y  (GWAS) it is possib le 
to invest igate  hu nd re d s  of th o u sa n d s  S N Ps across the en t i re  ge n o m e  in one s ing le  
e x p e r im e n t  (64;65). Only one such  GWAS has been pub l ished  fo r  a n t i -T N F  t re a tm e n t  in 
RA, so far, in a very  l im i ted  sized (66). A n o th e r  tech n ique  to sea rch  fo r  gene t ic  m a rk e rs  
in a n o n -h yp o th e s is  d r iven m a n n e r  is the use of w h o le  ge n o m e  express ion  arrays. U s ­
ing these  arrays, it is possib le  to m o n i to r  the express ion  levels of m o s t  of the annota ted  
genes. Genes tha t  are d i f fe ren t ia l ly  expressed in two g roups  (e.g. a n t i -T N F  re spond e rs  
and no n -re sp o n d e rs )  can be iden t i f ied  and fu r t h e r  invest iga ted  fo r  t h e i r  (possib le) role 








> THE ROLE OF GENETIC 
VARIANTS IN DISEASE 
SEVERITY
As m e n t io n e d  in the  f i r s t  pa ra g ra p h ,  RA d isease  seve r i ty  is o f ten  m e a su re d  
by us ing  the  d isease  va r ia b le s  d isease  ac t iv i ty  (m e a su re d  by the  DAS28) and jo in t  
d a m a g e  (m e a su re d  by s c o r in g  ra d io lo g ic  jo in t  dam age ) .  D isease seve r i ty  is pa r t ly  
in f lu e n ce d  by ge ne t ic  fac to rs ,  w i th  the  h u m a n  leukocy te  a n t igen  (H L A ) -D R B I  a l le le s  
iden t i f ied  as one of the se  fa c to rs  (68-70). A s econd ,  m o re  m o des t ,  asso c ia t io n  w i th  
d isease  se ve r i ty  has been iden t i f ied  fo r  the  p ro te in  ty ro s ine  ph o sp h a ta se  n o n - re c e p ­
to r  22 (PTPN22) gene (71 ;72).
Im p o r ta n t ly  fo r  th is  thes is ,  ev idence f ro m  seve ra l  s tud ies  s u g g e s ts  tha t  genes 
involved in RA d isease seve r i ty  are a lso  good cand ida tes  fo r  in f lue nc ing  t re a tm e n t  
response  (49;53;73). This is esp ec ia l ly  the case fo r  T N F -b lo ck in g  the ra p y  s ince  th is  
the rap y  in te r fe res  w i th  the p r o - in f la m m a to ry  TNF pathway.
The m o s t  th o ro u g h ly  s tud ied  p o ly m o rp h is m  in d isease sever i ty  is the -308G>A 
(rs 1800629) p ro m o te r  p o ly m o rp h is m  located in the TNFA gene encod ing  TN F a  itse lf  
(74-85). This fu n c t io n a l  p o ly m o rp h is m  is sug ges te d  to be respons ib le  fo r  a l te r ing  the 
re gu la t io n  of  cy tok ine  p roduc t io n  and m a y  the reb y  no t on ly  a f fec t  the  n a tu ra l  cou rse  of 
the  d isease but a lso the response to TN F  b lockade  (53) (86-88). Resu l ts  of  the  seve ra l  
s tu d ie s  are incons is ten t :  tw o s tud ies ,  p e r fo rm e d  in 34 and 130 RA pat ients ,  sugges ted  
tha t  the -308G a l le le  is assoc ia ted  w i th  rad io log ic  jo in t  da m age  p rogress ion  (82;83), 
w h e re a s  a n o th e r  s tud y  reported  a w o rs e  rad io log ic  j o in t  da m age  in pa t ien ts  car ry ing  
the  A a l le le  in a co h o r t  of  189 RA pa t ien ts  (77). F ina l ly  in a la rg e r  s a m p le  of 283 pa t ien ts  
B r in k m a n  e t al. cou ld  not c o n f i rm  any assoc ia t ion  be tw een  e i th e r  the G o r  A a l le le  and 
rad io log ic  j o in t  da m a g e  (75).
As has been s h o r t ly  m e n t io n e d  above and w i l l  be d iscussed in m o re  de ta i l  in 
the  next chap te r ,  obv ious ly  the -308G>A (rs1800629) p ro m o te r  p o ly m o rp h is m  has also 
been the  p r im e  ta rge t  of  s tud ies  d irec ted  at iden t i fy ing  gene t ic  fac to rs  fo r  a n t i -T N F  
t re a tm e n t  response. A n u m b e r  of  a d d i t iona l  gene t ic  va r ia n ts  located in ( in f la m m a to ry )  
genes  have been invest igated fo r  t h e i r  re la t ion  to d isease severi ty , w i th  conv inc ing 
evidence fo r  HLA-D RB1  and PTPN22 to be indeed assoc ia ted  w i th  d isease sever i ty  (Table 
3) (44;69;71;72;89-104).
T a b le  3 /  G e n e s  in v e s t ig a te d  fo r  t h e i r  (p o ss ib le ) a s s o c ia t i o n  w i t h  RA  d is e a s e  s e v e r i t y
G e n e  s y m b o l G e n e  n a m e R e f e r e n c e
A D A M TS 13 A D A M  m e t a l l o p e p t i d a s e  w i t h  t h r o m b o s p o n d i n  ty p e  1 m o t i f ,  13 (1C5)
ATIC 5 - a m i n o i m i d a z o l e - 4 - c a r b o x a m i d e  r i b o n u c le o t i d e (1C6)
f o r m y l t r a n s f e r a s e  /  IM P  c y c lo h y d ro la s e
CARDS C a s p a s e  r e c r u i t m e n t  d o m a in  fam i l y ,  m e m b e r  8 (1C7-1C9)
CAT Ca ta la s e (11C)
CD4 CD 4 m o le c u le (111)
FCG2A Fc f r a g m e n t  of  IgG, l o w  a f f i n i t y  IIa, r e c e p t o r  (CD32) (112)
FCG2B Fc f r a g m e n t  of  IgG, l o w  a f f i n i t y  IIb, r e c e p t o r  (CD32) (113)
FCG3A Fc f r a g m e n t  of  IgG, l o w  a f f i n i t y  I IIa, r e c e p t o r  (CD16a) (112;114)
FCG3B Fc f r a g m e n t  of  IgG, l o w  a f f i n i t y  I IIb, r e c e p t o r  (CD16b) (112)
GSTK1 G lu ta t h i o n e  S - t r a n s f e r a s e  k a pp a  1 (115-117)
H L A -D R B 1 M a jo r  h i s t o c o m p a t i b i l i t y  c o m p le x ,  c la s s  II, DR  beta  1 (44;69 ;89-1CC)
HMOX1 H e m e  o x y g e n a s e  1 (118;119)
IL1 In t e r l e u k i n  1 (12C-126)
IL1R N In t e r l e u k i n  1 r e c e p t o r  a n t a g o n i s t ( 5 3 ;1 2 2 -1 2 4 ;1 26 ;12 7 )
IL4 In t e r l e u k i n  4 (126)
IL10 In t e r l e u k i n  1C (126;128)
IL16 In t e r l e u k i n  16 (129;13C)
IL1 7 In t e r l e u k i n  17 (131)
IL1S In t e r l e u k i n  18 (132)
ITPA In o s in e  t r i p h o s p h a t a s e (1C6)
LTA L y m p h o t o x in  a lpha (44)
M a l/T IR A P To l l - i n te r le u k in  1 r e c e p to r  (TIR) d o m a in  c o n ta in ing  a d a p to r  p ro te ir (133)
M B L 2 M a n n o s e - b i n d in g  le c t in  ( p ro te in  C) 2, s o lu b le (134;135)
M IF M a c r o p h a g e  m i g r a t i o n  in h i b i t o r y  f a c to r (136-138)
M TH FR 5 , 1 C - m e t h y l e n e t e t r a h y d r o f o l a t e  r e d u c t a s e  (N A D P H ) (1C6)
N L R P 3 N L R  fam i l y ,  py r in  d o m a in  c o n t a i n i n g  3 (1C7)
NOS2A N i t r i c  ox id e  s y n th a s e  2 (11C;139)
PADI4 P e p t id y l  a r g i n i n e  d e im in a s e ,  t y pe  IV (14C-143)
P TP N 22 P ro te in  t y ro s in e  p h o s p h a ta s e ,  n o n - r e c e p t o r  t y p e  22 (71 ;72;1C1-1C4)
SOD2 S u p e ro x i d e  d i s m u t a s e  2 (11C)
SOD3 S u p e ro x i d e  d i s m u t a s e  3 (11C)
TAP1 T r a n s p o r t e r  1, A T P - b i n d in g  c a s s e t te ,  s u b - f a m i l y  B (M DR/TA P) (144)
TAP2 T r a n s p o r t e r  2, A T P - b i n d in g  c a s s e t te ,  s u b - f a m i l y  B (M DR/TA P) (144)
TGFB1 T r a n s f o r m i n g  g r o w t h  fa c to r ,  be ta  1 (53;145)
TLR2 T o l l - l i k e  r e c e p t o r  2 (146)
TLR4 T o l l - l i k e  r e c e p t o r  4 (1 33;146 ;147)
TNFA T u m o r  n e c r o s i s  f a c t o r (74 -8 5 ;87 ;11C ;148 )
TNFRSF1A T u m o r  n e c r o s i s  f a c t o r  r e c e p t o r  s u p e r f a m i l y ,  m e m b e r  1A (149)
TNFR SF1B T u m o r  n e c r o s i s  f a c t o r  r e c e p t o r  s u p e r f a m i l y ,  m e m b e r  1B (4 5 ;4 9 ;1 4 9-1 5 1)
TNFSF11 T u m o r  n e c r o s i s  f a c t o r  ( l igand) s u p e r f a m i l y ,  m e m b e r  11 (89)









Given th e i r  ro le in in f la m m a t io n ,  these  genes  are a lso obv ious can d ida te s  for 
in f lu e n c in g  t re a tm e n t  response  to an t i -TN F , and m a ny  o f th e m  have been invest igated 
fo r  th is  phenotype, too (44;49;52;53;83;114;143).  There fore ,  s tu d ie s  inves t iga t ing  the 
gene t ic  ba ckground  of RA sever i ty  can a lso be used as a too l  to iden t i fy  m a rk e rs  for 
in te r - in d iv id u a l  response  to a n t i -T N F  t re a tm e n t ,  s ince  of ten the s a m e  in f la m m a to ry  
pa thw ays  are involved.
> AIM AND OUTLINE OF 
THE THESIS
The p ro jec t  lead ing to th is  the s is  a im e d  at iden t i fy ing  gene t ic  b io m a rk e rs  that 
p red ic t  response to a n t i -T N F  t re a tm e n t  in pa t ien ts  w i th  RA. In the con tex t of p e rs o n a l ­
ized the rap eu t ics ,  we  hope tha t  p h a rm a co g e n e t ic  research  can lead to m o re  ta i lo r -  
m a de  in i t ia l  t re a tm e n t  dec is ions  in pa t ien ts  w i th  RA.
The f i rs t  pa r t  of the  thes is ,  desc r ibed  in c h a p te rs  2 to 6, is focused on the 
ana lys is  of seve ra l  S N Ps and one var iab le  n u m b e r  of ta n d e m  repeats  (VNTR) p o ly m o r ­
ph ism  located in cand ida te  genes  fo r  in f lue nc ing  d isease seve r i ty  and a n t i -T N F  (non-)  
re sponse  (hypothes is  dr iven  approach),  the la t te r  a f te r  having given an ove rv iew  of 
ex is t ing s tu d ie s  in th is  field.
The second pa r t  (chap te rs  7 to 10) assesses w h e th e r  gene express ion  p r o f i l ­
ing is a viable (n on -h ypo th es is  dr iven) approach  to iden t i fy  m a rk e rs  o r  p ro f i les  able to 
d is t ing u ish  a n t i -T N F  re sp o n d e rs  and no n - re sp o n d e rs ,  a f te r  having given an ove rv iew  of 
the pub l ished  gene exp ress ion  s tu d ie s  focus ing  on RA.
C hap te r  2 rev iews c u r re n t  l i te ra tu re  c o n ce rn in g  DN A p o ly m o rp h is m s  inves t i ­
ga ted in cand ida te  genes  fo r  a n t i -T N F  the rap y  response. D i f fe ren t tech no log ies  and 
s t ra te g ie s  fo r  p h a rm a c o g e n e t ic  research  are a lso  d iscussed.
In c h a p te r  3, a (GT)n-repeat,  located in the  p r o m o te r  reg ion of  the he m e  oxygen­
ase-1 (HMOX1) gene, is invest igated . Th is  repeat  d e te rm in e s  the level of  indu c t ion  of  the 
h e m e -d e g ra d in g  HMOX1 enzyme. The enzym e p ro tec ts  ce l ls  aga ins t  in f la m m a to ry  and 
oxidative s t re ss  (154) and w a s  recen t ly  sh o w n  to p ro tec t  aga ins t  the on se t  of RA (119). 
We invest iga ted  w h e th e r  the leng th  of the (GT)n-repeat is assoc ia ted  w i th  RA disease 
seve r i ty  and rad io log ic  jo in t  damage.
C hap te r  4 focuses  on the  676T>G (rs1061622) p o ly m o rp h is m  in the t u m o u r  
ne c ros is  fac to r  re ce p to r  s u p e r fa m i l i y  m e m b e r  1b (TNFRSF1B) gene and its re la t ion  to 
RA d isease seve r i ty  and a n t i -T N F  response . Th is  gene encodes  one of the two TN F B  
re cep to rs  and the re fo re  is a l ike ly  cand ida te  fo r  these  phenotypes.
C h a p te r  5 and 6 fo c u s  on the  -3 0 8 G > A  ( rs1800629) p o ly m o r p h is m  loca ted  in 
the  p r o m o t e r  re g io n  of the  t u m o u r  n e c ro s is  f a c to r  A (TNFA) gene. It is in ve s t ig a te d  if 
the  p o ly m o r p h is m  is a s s o c ia te d  w i t h  TNFA e xp re ss io n ,  d isea se  se v e r i ty  a n d /o r  a n t i -  
T N F  re sponse .  C h a p te r  5 d e s c r ib e s  the  s tu d ie s  of  the  f i r s t  tw o  ph eno typ e s .  C h a p te r  
6 is a m e ta -a n a ly s is  of the  in v o lv e m e n t  of the  p o ly m o r p h is m  in the  re s p o n s e  to 
a n t i - T N F  t r e a tm e n t ,  i n c lu d in g  p u b l is h e d  and u n p u b l i s h e d  da ta f r o m  14 i n t e r n a ­








In c h a p te r  8 the pub l ished  g e n o m e -w id e  exp ress ion  p ro f i l ing  s tu d ie s  regard ing  
RA suscep t ib i l i ty ,  seve r i ty  and a n t i -T N F  response are reviewed.
In c h a p te r  9 w e  a t te m p te d  to va l ida te  prev ious ly  pub l ished  exp ress ion  s ign a tu re s  
p red ic t ing  a n t i -T N F  response in an inde pen den t  cohort .  Secondly , a new  express ion  
prof i le  ab le  to d is t ing u ish  a n t i -T N F  re sp o n d e rs  and n o n - re s p o n d e rs  in RA is presented .
C hap te r  10 d iscusses  the s ig n a l  re g u la to ry  p ro te in  B1 (SIRPB1) gene, w h ic h  is 
iden t i f ied  as a gene sh o w in g  d i f fe ren t ia l  express ion  in a n t i -T N F  re spond e rs  and n o n ­
re sp o n d e rs  by express ion  pro f i l ing .  The exp ress ion  d i f fe rences  tu rn  ou t to be due to a 
f re q u e n t  copy n u m b e r  va r ia n t  (CNV) w i th in  the gene. This CNV is s u b s e q u e n t ly  e va lu ­
ated as a po ten t ia l  m a r k e r  fo r  a n t i -T N F  response.
Final ly, the f ind in gs  de sc r ibed  in th is  thes is  are s u m m a r iz e d  and the  po ten t ia l  
fo r  p h a rm a c o g e n e t ic s  and p h a rm a c o g e n o m ic s  in RA is d iscussed in ch a p te r  11.
Chapter 1 > General in tro d u c tio n  23
24
> CHAPTER 2
M arieke  J.H. Coenen 
Erik  J.M. Toonen 
Hans S che f fe r  
T im o th y  R.D.J. Radstake 
P i la r  B arre ra  
B arba ra  Franke






















T u m o r  ne c ro s is  fa c to r  a lpha  (TNFa) b lock in g  s t ra te g ie s  are w id e ly  used in 
the  t r e a tm e n t  of r h e u m a to id  a r th r i t i s  (RA). Th ree  a n t i -T N F  a g e n ts  are re g is te re d  fo r  
the  use in RA; e ta ne rcep t ,  in f l i x im a b  and a d a l im u m a b .  A l th o u g h  a n t i -T N F  th e ra p y  is 
ve ry  e f fec t ive  in c o n t ro l l in g  d isease  ac t iv i ty  and s lo w in g  do w n  ra d io lo g ic a l  dam age ,  
p ro lo n g e d  re sponse  is seen on ly  in a b o u t  70% of the  pa t ien ts .  The cau ses  fo r  n o n ­
re sponse  in the  re m a in in g  p a t ie n ts  have no t been e lu c id a te d  yet. P h a rm a c o g e n e t ic  
s tu d ie s  fo cu s in g  on ge nes  involved in RA e t io lo gy  (a n d /o r  p rog re ss ion )  and in the 
p h a rm a c o k in e t i c s  of T N F a  b lo ck in g  a g e n ts  have iden t i f ied  m a rk e rs  a sso c ia ted  w i th  
a n t i - T N F t r e a tm e n t  ou tco m e .  In the  fu tu re ,  m o re  exhaus t ive ,  less h y p o th e s is -d r iv e n  
se a rch  s t ra te g ie s  are expec ted  to d is co ve r  a d d i t io n a l  m a rk e rs .  Ide n t i f ica t io n  of  these 
m a r k e r s  m ig h t  be v iew ed  as a the  f i r s t  s tep  to w a rd s  ta i lo red  T N F a  b lo ck in g  the rap y  
fo r  p a t ie n ts  w i th  RA. N eve r the le ss ,  re p l ica t io n  and la rge  p rospec t ive  s tu d ie s  w i l l  be 
needed to d e m o n s t ra te  the  va l id i ty  of  the  iden t i f ied  ge ne t ic  m a r k e r s  be fore im p le ­
















T u m o r  nec ros is  fa c to r  a lpha (TNFa) is a key in f la m m a to ry  m e d ia to r  in r h e u m a ­
to id a r th r i t i s  (RA). Evidence fo r  the  c e n t ra l  ro le of T N F a  in the  p a thog ene s is  of RA has 
re su l ted  in the d e ve lopm en t  of th e ra p e u t ic  in te rven t io ns  reduc ing  the  excess of TNFa 
seen in these  patients .
Three  a n t i -T N F  a g e n ts  are no w adays  c o m m e rc ia l ly  ava i lab le .  E tane rcep t  (En­
b r e l® )  is a fus io n  p ro te in  c o n s is t in g  of  tw o p75 TN F  re c e p to rs  l inked  to the  Fc p a r t  of 
h u m a n  IgG1. Th is  a g en t  b ind s  to T N F B  and ly m p h o to x in  a lpha  (LTA) th e re b y  p re v e n t ­
ing b ind ing  of the se  m o le c u le s  to th e i r  ce l l  s u r fa c e  re c e p to rs  and s u b s e q u e n t  ce l l  
s ig n a l in g .  B es ides  e ta n e rce p t ,  two m o n o c lo n a l  a n t ib o d ie s  a g a in s t  T N F a  are ava ilab le ;  
the  c h im e r ic  a n t ib o d y  in f l i x im a b  (R e m ic a d e ® )  and the  fu l l y  h u m a n iz e d  v a r ia n t  ad a l i -  
m u m a b  (H u m i ra ® ) .  These a n t ib o d ie s  d i re c t ly  b ind to T N F a  lead ing  to n e u t ra l iz a t io n  
of the  m o le cu le .
Despite  the  c l in ica l  e f f icacy o f a l l  th ree  a n t i -T N F  s tra teg ies ,  30% of the pa t ien ts  
do not improve. Pa t ien ts  no t respond ing  to the rap y  can be div ided in two groups, p r i ­
m a ry  n o n - re s p o n d e rs  s h o w in g  a lack  of  e f f icacy s ta r t in g  at the f i r s t  a d m in is t ra t io n  of 
a n t i -T N F  and seco n d a ry  n o n - re s p o n d e rs  w h o  s h o w  an in i t ia l  bene f i t  f ro m  the the rap y  
w h ic h  d im in is h e s  w i th  t im e  (29-31). In add i t ion, s o m e  adverse events  are observed in a 
s m a l l  pe rcen tage  of pa t ients ,  inc lud ing  an inc reased susce p t ib i l i ty  to tu b e rc u lo s is  and 
o th e r  coex is t ing  in fec t ions, l ym p h o m a  and neu tropen ia .  In jec t ion and in fus ion  react ions 
are the adverse events  m o s t  o f ten repor ted  (155). P r im a ry  and se co nda ry  ine f f icacy  of 
a n t i -T N F  the rap y  in a cons id e ra b le  pe rcen tage  of pa t ien ts ,  adverse e f fec ts  and the high 
cos ts  of  a n t i -T N F  b lock ing  agen ts  have dr iven the sea rch  fo r  m a rk e rs  tha t  can pred ic t  
t re a tm e n t  ou tcom e . One area of such  research  involves genet ics .  Ins igh t  into  the p h a r ­
m a cogen e t ics '  of a n t i -T N F  the ra p y  w i l l  e.g. fac i l i ta te  the cho ice fo r  the m o s t  su i tab le  
a n t i -T N F  agen t  fo r  the  ind iv idua l  pa t ien t  and in fo rm  the dec is ion  on dos ing  s t ra teg ies ,  
re su l t ing  in an op t im ized  t re a tm e n t  re g im e n  in da ily  c l in ica l  practice.
In recen t  y ea rs  p rog re ss  has been made  in the  fie ld of a n t i -T N F  p h a rm a c o g e n e t ­
ics. The m a in  focus  has been on gene t ic  v a r ia t ion  in genes  th a t  can be d i re c t ly  l inked to 
the  m e c h a n is m  of ac t ion  of the b io log ica ls  and genes  involved in RA in genera l .  H o w ­
ever these  s tu d ie s  have no t yet iden t i f ied  (sets of) gene t ic  m a rk e rs  p red ic t ing  ou tcom e 
of a n t i -T N F  the ra p y  w i th  h igh spe c if ic i ty  and sensit iv ity.
This rev iew w i l l  d iscuss  the c u r re n t  l i te ra tu re  con ce rn in g  a n t i -T N F  p h a rm a c o ­
g e ne t ics  as w e l l  as tech no log ies  tha t  can be used fo r  the  iden t i f ica t ion  of ad d i t iona l  
gene t ic  d e te rm in a n ts  of a n t i -T N F  response.
Study cohorts
A sys tem a t ic  PU BM ED  sea rch  w as  p e r fo rm e d  us ing the fo l low ing  sea rch  te rm s  
e tanercep t ' ,  enbre l ' ,  in f l ix im a b ' ,  rem icade ',  a d a lu m im a b ' ,  h u m ira ' ,  p o ly m o rp h is m ' ,  
assoc ia t ion '  and rh e u m a to id  a r th r i t is '  a lone  o r  in com b ina t io n .  The s tu d ie s  had to 
m a tch  the  fo l low in g  c r i te r ia ,  pub l ished  a f te r  2001, involv ing p h a rm a c o g e n e t ic s  of 
a n t i -T N F  the rap y  and inc lud ing  RA pat ients .  In to ta l  23 s tu d ie s  fu l f i l led  these  c r i te r ia ;  
pa t ien t  cha rac te r is t ic s ,  the a n t i -T N F  agen t  used and the  invest iga ted  genes  are s u m ­
m a r ized  in Table 1.
The m a jo r i t y  o f  the  s tu d ie s  inc luded  pa t ien ts  m e e t ing  the A m e r ica n  Col lege of 
R h eu m a to logy  (ACR) c r i te r ia  fo r  RA (9). Two s tu d ie s  did no t spec ify  the  c r i te r ia  fo r  the 
d iagnos is  of RA (43;156). The response  c r i te r ia  used in m o s t  of the  s tu d ie s  w ere  the two 
m o s t  w idesp read ,  va l ida ted  (objective) m e th o d s  to de f ine  response  to therapy, those 
of  the ACR and those of  the  European League A ga ins t  R heu m a to id  A r th r i t i s  (EULAR) 
(157;158). Both c r i te r ia  requ ire  (a) th ree  a sse sso r-d e r ive d  m easures ,  te n d e r  jo in t  count,  
sw o l le n  j o in t  co u n t  and phys ic ian g loba l  asse ssm en t ,  (b) one labo ra to ry  tes t  of e i th e r  
the e ry th rocy te  se d im e n ta t io n  ra te  (ESR) o r  o f  C -reac t ive  pro te in  (CRP) levels and (c) 
th ree  pa t ien t  s e l f - r e p o r t  m e a s u re s  of fu n c t io n a l  d isab i l it y ,  pain and pa t ien t  g lob a l  a s ­















Table 1 /  S tu d y  c h a r a c t e r i s t i c s
N u m b e r  o f  R A  p a t i e n t s  
(%  f e m a l e )
E th n i c  b a c k g r o u n d  A n t i - T N F  a g e n t :  d o s e
n= 123 (81%) NS E ta n e r c e p t :  2 x 25 m g / w e e k
n =4 57  (72%) NS E ta n e r c e p t :  2 x 25 o r  10 m g / w e e k
n = 50 (76%) 
n = 70 (93%) 
n = 59 (78%) 
n =78  (77%) 
n =20  (95%). 
n=9  (NS) 
n =22  (NS) 
n =1 98  (75%) 
n =49  (95%) 
n =58  (79%) 
n =20  (95%) 
n =30  (NS)
G e r m a r
K o r e a r
NS
NS







W h i te
H is p a n ic
A f r i c a n - A m e r i c a n
As ia n
E ta n e r c e p t :  2 x 25 m g / w e e k  
E ta n e r c e p t :  2 x 25 m g / w e e k  
I n f l i x im a b :  3 m g / k g  at t=0, 2, 6, 14, 22 w e e k s
I n f l i x im a b :  3 m g / k g  at t=0, 2, 6 
I n f l i x im a b :  3 m g / k g  at t=0, 2, 6 
I n f l i x im a b :  3 m g / k g  at t=0, 2, 6 
I n f l i x im a b :  3 m g / k g  at t=0, 2, 6 
I n f l i x im a b :  3 m g / k g  at t=0, 2, 6 
I n f l i x im a b :  d o s e  no t  s p e c f i i e c  
I n f l i x im a b :  d o s e  no t  s p e c i f i e d  
A d a l i m u m a b :  40 m g  e v e ry  o t h e r  w e e k  
E ta n e r c e p t ,  I n f l i x im a b ,  A d a l i m u m a b :  d o s e  no t s p e c i f i e d
e v e ry  8 w e e k s  t h e r e a f t e r  
14 w e e k s
e v e ry  8 w e e k s  t h e r e a f t e r  
e v e ry  8 w e e k s  t h e r e a f t e r  
e v e ry  8 w e e k s  t h e r e a f t e r
n = 54 (69%) 
n =66  (94%) 
n =2 82  (78%) 
n = 1 05 0  (77%)
NS
Ital ian
S w e d is h
UK
E ta n e r c e p t ,  I n f l i x im a b ,  A d a l i m u m a b :  d o s e  no t s p e c i f i e d  
E ta n e r c e p t :  2 x 25 m g /w e e k ,  In f l i x im ab:  3 o r 10 m g / k g  every 4 o r  8 w e e k s  
E ta n e r c e p t ,  I n f l i x im a b :  d os e  no t  s p e c i f i e d  
E ta n e r c e p t ,  I n f l i x im a b ,  A d a l i m u m a b :  d o s e  no t s p e c i f i e d
n= 388  (78%) 
n = 113 (78%) 
n=91 (89%) 
n =78  (68%) 
n =1 05  (71%0
Fre n ch
S p a n is h
S p a n is h
F re n ch
Ital ian
A d a l i m u m a b :  d o s e  n o t  s p e c i f i e d  
I n f l i x im a b :  3 m g / k g  e ve ry  8 w e e k s  
I n f l i x im a b :  3 m g / k g  at w e e k  0, 2 a n d  6 
In f l i x im a b
E ta n e r c e p t :  2 x 25 m g / w e e k ,  I n f l i x im a b :  3 m g / k g  at w e e k  0, 2 a n d  6 
A d a l i m u m a b :  40 m g  e v e ry  o t h e r  w e e k
NS : n o t  s p e c i f i e d ,  ACR:  A m e r i c a n  C o l le g e  of  R h e u m a t o l o g y ,  E U L A R :  E u r o p e a n  L e a g u e  A g a in s t  R h e u m a t i s m
R e s p o n s e  c r i t e r i a R e s p o n s e g e n e s  i n v e s t i g a t e d R e f e r e n c e
1% r e s p o n d e r s )
A CR2 0,  DAS28,  E U L A R B a s e d  on A C R 2 0  a n d  DAS28 : TNFA, IL10, TGFB1, IL1 R N (53]
Good 76%, N o n :  3 4%
A CR2 0,  A CR5 0,  A C R 7 0 A C R 5 0 :  84% HLA, TNFA, LTA, TNFRSF1A, (441
TNFRSF1B, FCGR2A, FCGR3A, FCGR3B
E ULAR Good: 50%, M o d .:  34% , N o n :  16% IL10 (159]
A CR2 0,  A C R 7 0 A C R 2 0 :  86%, A C R 7 0 :  20% TNFA, LTA (50]
E ULAR Resp .:  72%, N o n :  28% TNFA (54]
E ULAR Resp .:  53%, N o n :  47% HLA, M ICA, TNF, BAT2 (160]
A CR2 0,  A C R 5 0 A C R 2 0 :  >8 5 % ,  A C R 5 0 :  >5 6 % TNFA (55]
E ULAR Resp .:  48%, N o n :  52% TNFA (56]
E ULAR NS TNFA (161]
A CR2 0,  E U L A R A C R > 2 0 :  66% HLA, IL1B , IL1R N , TNFA (58]
E ULAR Resp .:  29%, N o n :  71% IL1B , IL1 R N (162]
E ULAR Good: 47%, M o d :  31% , N o n :  22% TNFR1, TNFR2, TNFA (43]
A CR2 0,  E U L A R Resp .:  86% (59]
Good R e s p o n s e :  > 70% T o ta l  g r o u p  R A  and  p s o r i a t i c  a r t h r i t i s FCGR3A (156]
i m p r o v e m e n t  in P hG A  and p a t i e n t s  (n=35):  Resp. :  66% ,  N o n :  3 4%
the  SJC and  TJC and  > 50%
im p ro v e m e n t  in ESR o r  CRP
levels and  PGA o r  dura t io n
of  m o r n i n g  s t i f f n e s s
E ULAR NS TNFA (60]
E ULAR NS TNFR 2 (45]
ACR, E U L A R ACR20: 66%, ACR50:  35%, ACR70: 9%, FCGR3A (114]
DA S28,  E U L A R E U L A R :  Good: 26%, M o d :  54%, TNFA, LTA, LST-1 (52]
N o n :  20%, DAS28 : NS
A C R 5 0 Resp .:  40% TNFA, H LA (62]
E ULAR Resp .:  58.4% TNFA, H LA (63]
A CR2 0,  A CR5 0,  A C R 7 0 ACR20: 45%, ACR50:  12%, ACR70: 3% FCGR2A, FCGR3A (163]
A CR2 0,  A CR5 0,  A C R 7 0 ACR20: 56%, ACR50:  35%, ACR70: 22% FCGR3A, TNFR SF1B (47]















Pharmacogenetics of anti-TNF treatm ent
The m e c h a n is m s  of ac t ion of a n t i -T N F  ag en ts  have given d i re c t ion  to the  p h a r-  
m a co g e n e t ic  s tu d ie s  p e r fo rm e d  so fa r  (164;165). A l th o u g h  it has  been de m o n s t ra te d  
tha t  pa t ien ts  not respond ing  to a ce r ta in  a n t i -T N F  agen t  m a y  benef i t  f ro m  t re a tm e n t  
w i th  a second TN F an tagon is t ,  w h ic h  w o u ld  su g g e s t  d i f fe ren t  m e c h a n is m s  of action 
fo r  the  a n t i -T N F  d ru g s  and invo lvem en t  of d iverse gene t ic  va r ia n ts  in c l in ica l  response 
(166;167), in a large s tud y  in 856 pa t ien ts  w h o  sw i tched  to a second a n t i -T N F  agen t  the 
reason fo r  no n - re sp o n se  to the f i rs t  d rug  w a s  re la ted  to the reason fo r  s top p ing  the
T a b le  2 /  G e n e t i c  v a r ia n t s n g e n e s  s t u d ie d  fo r  t h e i r  a s s o c ia t i o n  w i t h  a n t i - T N F  re s p o n s e
G en e P o l y m o r p h i s m
TNFA -1 0 3 1 T > C  (rs1 799964),  - 8 6 3 C > A  (rs1800630 ) 
- 8 5 7 C > T  (rs1 799724)
-3 0 8 G > A  (rs1800629 )
-2 3 8 G > A  (rs361 525)
4 8 8 G > A  (rs1800610 )
T N F  h a p lo ty p e s
IL1B -5 1 1 C > T  (rs16944 ) 
3 9 5 4 C > T  (rs1 143634)
IL10 -1 0 87 G  >A  ( r s 1800896 ) 
M i c r o s a t e l l i t e s  IL10 .R  a n d  IL10 .G
TGFB1 915 G > C  (p .R 25P , rs1 8 00 47 1 )
IL1R N V N T R  in i n t ro n  2 
2 0 1 8 T > C  (p .A39A, rs 419598 )
H L A  reg io n S h a re d  e p i t o pe
MICA M i c r o s a t e l l i t e
D6S273 M i c r o s a t e l l i t e
BAT2 M i c r o s a t e l l i t e
D6S 222 M i c r o s a t e l l i t e
LTA 2 4 9 G > A  ( r s909253)
3 6 5 G > C  (r s746868)
177A>G (p .R13C, rs2 2 29 09 4 ) 
3 1 9 (7 2 0 )C > A  (p .T60N, rs1 0 41 98 1 ) 
E x -1 A > T  (rs2239704 )
LST-1 E x-5  ( rs1052248 ),  Int 2 ( r s 2256965 )
TNFRSF1A -6 0 9 G > T  (rs4149570 ),  - 5 8 0 A > G ,  (rs4 149621 ),  - 3 8 3 A > C  (rs2234649 ) 
3 6A > G  (p .P12P, rs1 13941 7)
TNFR SF1B 676T>G  (p .M 196R,  rs 1 0 64622 )
FCGR2A 5 5 0 G > A  (p .H 166R, rs1 8 01 27 4 )
FCGR3A 681 G >T  (p .V212F, r s396991 )
FCGR3B N A 1 /N A 2
second  d rug  (ine ff icacy o r  adverse events). This fac t  has lend va l id i ty  to the invest igat ion 
of  the s a m e  gene t ic  va r ia n ts  fo r  a l l  th ree  a n t i -T N F  agen ts  (166).
The m os t  obvious candidate gene, TNFA, cod ing fo r  TNFa, the ta rge t  of an t i -T N F  
therapy, has been invest igated in m a ny  s tud ies  in re la t ion to a l l  th ree  a n t i -T N F  agents  
(Table 1). A lso the genes encoding TNF receptors,  involved in the suscep t ib i l i ty  to and 
severi ty  of RA have been invest igated fo r  th e i r  associa tion w i th  a n t i -T N F  the rapy  ou tcom e 
(Table 1). The fo l low ing pa ragraphs  w i l l  provide an overv iew of the genet ic  v a r ian ts  s tudied 
in re la tion to the d i f fe ren t a n t i -T N F  biologicals . A s u m m a ry  of  the invest igated p o ly m o r ­
ph ism s  o f each s tudy  and th e i r  possib le func t ion  can be found in Table 2.
( p o s s ib l e )  f u n c t i o n a l  r o l e  o f  t h e  g e n e t i c  v a r i a n t R e f e r e n c e s
P o s s ib le  i n f l u e n c e  on T N F a  p r o d u c t i o r (50-52)
A f f e c t s  t h e  t r a n s c r i p t i o n  e f f i c i e n c y  o f  T N F a (43;50;168)
I n f l u e n c e  on T N F a  p r o d u c t i o r (4 3 ;4 4 ;4 8 ;5 0 ;5 2 -6 3 )
P o s s ib le  i n f l u e n c e  on T N F a  p ro d u c t io n (4 3 ;4 4 ;5 0 ;5 2 ;5 8 ;5 9 ;6 2 ;1 6 3 ;1 6 9 ;1 7 0 )
U n k n o w n (43;44;62 )
L in k e d  to  T N F a  - 3 0 8 G > A (44;160)
In c r e a s e d  IL1B  p ro d u c t io n (162;171 )
P o s s ib l y  a s s o c ia t e d  w i t h  I L I b e t a  p ro d u c t io n (5 8 ;1 62 ;172 ;173)
A s s o c i a t e d  w i t h  IL10  p ro d u c t io n (53;174)
A s s o c i a t e d  w i t h  IL10  s e c r e t i o n (159;175 )
I n f l u e n c e  on TG F61 p ro d u c t io n (53;176)
A s s o c i a t e d  w i t h  e n h a n c e d  IL1 be ta  p r o d u c t io n (53 ;162;173 )
U n k n o w n (58)
A s s o c i a t e d  w i t h  R A  s u s c e p t i b i l i t y  a n d  s e v e r i t y  a n d  M TX  re s p o n s e (4 4 ;5 8 ;6 2 ;6 3 ;1 60)
U n k n o w n (160)
U n k n o w n (160)
U n k n o w n (160)
U n k n o w n (160)
LTA h a p lo ty p e  e f f e c t  on in v i t r o  T N F a  p ro d u c t io n (44 ;52 ;1 77 ;177 )
LTA h a p lo ty p e  e f f e c t  on in v i t r o  T N F a  p ro d u c t io n (44;50;177)
LTA h a p lo ty p e  e f f e c t  on in v i t r o  T N F a  p ro d u c t io n (44;50;52 )
LTA h a p lo ty p e  e f f e c t  on in v i t r o  T N F a  p ro d u c t io n (44;50;52 )
LTA h a p lo ty p e  e f f e c t  on in v i t r o  T N F a  p ro d u c t io n (52)
U n k n o w n (52)
U n k n o w n (44)
U n k n o w n (43)
E ffec t  on a p o p t o s is (43-48)
E ffec t  on t h e  a f f i n i t y  f o r  t h e  b in d in g  o f  h u m a n  IgG (44 ;163;178 )
E ffec t  on t h e  a f f i n i t y  f o r  t h e  b in d in g  o f  h u m a n  IgG (4 4 ;4 7 ;1 14 ;156 ;163)
















A to ta l  of fo u r  s tu d ie s  has assessed the e f fec t  of gene t ic  va r ia t ion  on response 
to e ta ne rcep t  (44;50;53;159). Three of these  s tu d ie s  inc lud ed  s ing le  nu c leo t ide  po ly ­
m o rp h is m s  (SNPs) in the  p ro m o te r  o f the  TNFA gene. A lso p o ly m o rp h is m s  in the  genes 
encod ing  T N F a  re cep to rs  and cy tok ines  involved in RA as w e l l  as the  HLA reg ion and Fc 
re cep to rs  w e re  invest iga ted  fo r  t h e i r  re la t ion  w i th  e ta ne rcep t  response.
The f i rs t  p h a rm a c o g e n e t ic  s tud y  re la ted  to e ta ne rcep t  t re a tm e n t  in RA pa t ien ts  
focused on p o ly m o rp h is m s  in genes  encod ing  cy tok ines  w i th  an im p o r ta n t  ro le in the 
p a thog ene s is  of RA (53). The hypo thes is  of the s tud y  w a s  tha t  pa t ien ts  d isp lay ing  d i f ­
fe ren t  cy tok ine  levels in j o in ts  show ed  d i f fe ren t  re sponse s  to TNF b lock ing  therapy.
In each of  the genes  cod ing fo r  the  cy tok ines  TNFa, in te r le u k in  10 (IL10), t r a n s fo r m ­
ing g row th  fa c to r  beta 1 (TGFO) one p ro m o te r  S N P  w a s  analyzed fo r  assoc ia t ion  w i th  
e ta ne rcep t  response , as w a s  a va r iab le  n u m b e r  o f  ta n d e m  repeats  (VNTR) in in tron 
2 of  the IL1 re cep to r  a n tago n is t  gene (IL1RN). A l l  these  p o ly m o rp h is m s  w e re  known 
to in f luence  the express ion  of the respect ive  gene. The a u th o rs  a lso invest iga ted  the 
H LA -D R  a l le les,  w h ic h  are assoc ia ted  w i th  RA c ou rse  and the  response to con ven t iona l  
d ise a se -m o d i fy in g  a n t i - r h e u m a t ic  d ru g s  (DMARD) t re a tm e n t .  In a to ta l  of 123 pa t ien ts  
no s ign i f ica n t  assoc ia t ions  w e re  found. C om b ined  ana lys is  of the SN Ps in the TNFA and 
IL10  genes, de f in ing  pa t ien ts  w i th  a p re s u m a b ly  lo w e r  p ropens i ty  fo r  an in f la m m a to ry  
response , sho w e d  tha t  the -308 GG TNFA genotype to g e th e r  w i th  the  -1087 GG IL10 
genotype w a s  m o re  f re que n t ly  en coun te red  in re sp o n d e rs  than  in n o n - re s p o n d e rs  a f te r  
th ree  m o n th s  of the rap y  (p<0.05). Ana lys is  of  the com b in e d  genotypes  fo r  IL1R N  and 
TGFB1 (associated w i th  s t ro n g  in f la m m a to ry  reactiv ity) sho w e d  tha t  a c o m b in a t io n  of 
tw o - re p e a t  a l le les  of the  IL1R N  VNTR w i th  the +915 CG genotype of TGFB w as  s ig n i f i ­
can t ly  assoc ia ted  w i th  poor  response to e ta ne rcep t  (p<0.05).
The second  study, inc lud ing  50 pa t ients ,  focused on two m ic ro s a te l l i te  po ly ­
m o rp h is m s  in the IL10 gene (IL10.R  and IL10.G) (159). These p o ly m o rp h is m s  had been 
re la ted  to IL10 p roduc t io n  (175). The IL10.R3  a l le le  (p=0.0113) and the IL10.R3-G9 hap lo -  
type (p=0.0212) w ere  assoc ia ted  w i th  good response to e ta ne rcep t  therapy. The IL10.G13 
a l le le  and the IL10.R2-G13  hap lo type  w e re  indicative of m o d e ra te  o r  n o n -re spon se .
C r isw e l l  and co l lea gue s  s tud ied  a g roup  of  457 pa t ients ,  301 of these  pa t ien ts  
w e re  trea ted  w i th  e ta ne rcep t  (44). The genes  encod ing  TNFa, lym pho tox in  a lpha (LTA) 
w h ic h  can both  bind to e ta ne rcep t  and the genes  cod ing fo r  the tw o TNF recep to rs  
(TNFRSF1A; TNFRI and TNFRSF1B; TNFRII) w e re  analyzed in th is  study. The au th o rs  
a lso inc luded  HLA-DRB1  a l le les  and the Fc re cep to r  pa thw ay  (Fc g a m m a  re cep to rs  2A, 
3A and 3B), involved in the  de g rad a t ion  of e ta n e rc e p t -T N F  com plexes .  In to ta l  13 s ing le  
nu c leo t ide  p o ly m o rp h is m s  and 5 m ic ro s a te l l i te s  w e re  invest igated . In s ing le  m a rk e r
ana lyses  the  on ly  s ig n i f ica n t  assoc ia t ion  w a s  fo r  the H LA-D RB1  a l le le s  and the ACR50 
response  ( ind icat ing 50% im p ro v e m e n t  in d isease activ ity) at  12 m o n ths .  Pat ien ts 
w i th  one o r  two cop ies  of  the sha red  ep itope w e re  m o re  l ike ly  to respond to e ta n e r -  
cep t  therapy. Severa l s tu d ie s  have d e m o n s t ra te d  tha t  the assoc ia t ion  of HLA  w i th  RA 
s u s ce p t ib i l i t y  and ou tco m e  p robab ly  invo lves o th e r  loci c loseby  and is the re fo re  d i f f icu l t  
to analyze (180-182).  To ove rcom e th is  p rob lem  extended hap lo types  w e re  genera ted  
inc lud ing  HLA-DRB1  and s ix  p o ly m o rp h is m s  in the  LTA and T N F genes. Two of these 
hap lo types  inc lud ing  H LA-DR B1*0404, the o th e r  H LA -D R B 1*0101 , both  encod ing  the 
sha red  ep itope, w e re  assoc ia ted  w i th  t re a tm e n t  response  at 12 m o n th s .  The assoc ia t ion  
w i th  e ta ne rcep t  response  w a s  a lso observed in a m u lt iv a r ia te  log is t ic  regress ion  fo c u s ­
ing on the  two assoc ia ted  hap lo types  and inc lud ing  covar ia tes  (odds ra t io  (OR) 2.5 and 
4.9 fo r  the *0404 and *0101 con ta in ing  haplo types, respective ly).
The invo lvem en t  of p o ly m o rp h is m s  in the  TNFA and LTA genes  in e tanercep t  
t re a tm e n t  o u tc o m e  w a s  th o ro u g h ly  s tud ied  by Kang and c o -w o rk e rs  (50). Five S N Ps in 
the TNFA p r o m o te r  reg ion and 2 n o n -s y n o n y m o u s  S N Ps in LTA w e re  tested fo r  a s so c ia ­
t ion w i th  the ra p y  response in 70 pa t ients .  M a rg ina l  assoc ia t ion  of  the -857C>T S N P  in 
the TNFA p r o m o te r  w i th  t re a tm e n t  response w a s  found on ly  w h e n  c o m p a r in g  ACR20 
n o n - re s p o n d e rs  to ACR70 re sp o n d e rs  (p (corrected)=0.054).  An assoc ia t ion  of the 
-857C >T p o ly m o rp h is m  w i th  the response to a n t i -T N F  the ra p y  m a y  be exp la ined by the 
fac t  tha t  the  OCT1 t ra n s c r ip t io n  fa c to r  can bind to the p r o m o te r  of TNFA on ly  w h e n  a C- 
a l le le  is p resent ,  lead ing to h ig h e r  TN F a  produc t ion .  In c o n t ra s t  to the  s tud y  by C r isw e l l  
no assoc ia t ion  w i th  t re a tm e n t  response  cou ld  be found fo r  the sha red  ep itope. This 
m ig h t  be re la ted  to the  e thn ic  ba ckground  of the s tud y  popu la t ions ,  the  a l le le s  found by 
C r isw e l l  are ra re in the Korean po pu la t io n  invest iga ted  by Kang and co l lea gue s  (44), but 
m ig h t  a lso  be due to po w e r  issues
Infliximab
The effect of genet ic  var ia t ion has also been exam ined in re la t ion to the response 
to in f l ix im ab  in RA patients . Four s tud ies  focused on the -308G>A p o lym o rp h ism  in 
the TNFA promoter.  The A -a l le le  of th is  po lym o rp h ism  is tho ugh t  to be associa ted w i th  
increased T N F a product ion  (54 -57 ;161 ;183). Four o th e r  s tud ies  com b ined  the analys is  of 
th is  po lym o rp h ism  w i th  tha t of genet ic  va r ian ts  in the HLA region a n d /o r  o th e r  candidate  
genes (43;58;63; 160). Two o th e r  s tud ies  focused on p o lym o rp h ism s  located in o th e r  c a n ­
didate  genes fo r  th e i r  possib le in f luence on in f l ix im ab  response: Canete et al. investigated 
po ly m o rp h is m s  in the Fc g a m m a  recep to r  genes FCGR2A and FCGR3A (163) and Rooryck 















M u g n ie r  and c o -w o rk e rs  pu b l ished  the  f i r s t  s tud y  inves t iga t ing  the re la t ion  b e ­
tw een  the response to in f l ix im a b  and the  -308G>A S N P  in the  TNFA p ro m o te r  in 59 RA 
pa t ien ts  (54). P a t ien ts  w i th  the GG genotype w e re  tw ice as l ike ly  to respond to in f l ix im a b  
the rap y  as the  g roup  w i th  the  AG o r  AA  genotype (p=0.0086).
Balog and co l leagues  p e r fo rm e d  a very s m a l l  s tu d y  analyz ing the  e f fec t  of the 
-308G>A p o ly m o rp h is m  on response to in f l ix im a b  (56). Due to the  s m a l l  pa t ien t  n u m b e r  
they  did not p e r fo rm  a s ta t is t ica l  ana lys is  bu t cou ld  d e te rm in e  tha t  the n o n - re s p o n d e rs  
to the ra p y  c a r r ied  the A a l le le  m o re  o f ten than  the  G al le le.
Fonseca and c o -w o rk e rs  d e m o n s t ra te d  tha t  pa t ien ts  w i th  the GG genotype at the 
-308G>A p o ly m o rp h is m  have a b e t te r  response  to in f l ix im a b  than the  pa t ien ts  w i th  an 
AG genotype (57), the reb y  c o n f i rm in g  the  f ind in gs  by Balog and M u g n ie r  (54;56).
Cuchacovich and co l leagues used a more  hypothes is -dr iven approach (55). They 
f i rs t  de te rm ined  the genotype of  the -308G>A SNP in 132 patients. Subsequently, they 
selected 10 pa t ients w i th  a GA and 10 pa t ients w i th  a GG genotype w ho  w ere  treated w ith  
3m g /kg  in f l ix imab at in i tiation and at w eeks  2, 6 and 14. No s ign i f icant d if fe rences in the 
ACR20 and ACR50 im p rovem en t  were  found be tween genotypes at the diverse t im e  points.
Pinto  and c o w o rk e rs  invest iga ted  w h e th e r  p o ly m o rp h is m s  at pos it ion  -238 and 
-308 at the p r o m o te r  reg ion of the  TNFA gene, and the p resence of  the  DR3 and sha red  
ep itope (SE) a l le les,  are ab le  to p red ic t  response to lo n g te rm  in f l ix im a b  the ra p y  (30 
m o n th ts )  in a RA co h o r t  of  113 pa t ients .  Th e i r  data  did not s u p p o r t  the concep t  tha t  a 
ce r ta in  c o m b in a t io n  of a l le l ic  f o rm s  w a s  assoc ia ted  w i th  response  to in f l ix im a b  (63).
A lso M aro t te  et al. inc lud ed  the -308G>A p r o m o te r  p o ly m o rp h is m  of the TNFA 
gene in th e i r  s tudy  (58). In add i t ion  they  invest igated the -2 3 8 G > A  p ro m o te r  p o ly m o r ­
ph ism  of th is  gene, the sha red  ep itope and p o ly m o rp h is m s  in the  IL1B  and IL1RN  
genes. A l l  p o ly m o rp h is m s  chosen  fo r  th is  s tud y  had p rev ious ly  been assoc ia ted  w i th  
RA severity.  A to ta l  of 198 pa t ien ts  receiv ing in f l ix im a b  the rap y  w e re  inc luded  in the 
study. The a u th o rs  cou ld  not de tec t  an assoc ia t ion  of the response  to in f l ix im a b  w i th  the 
invest iga ted  p o ly m o rp h is m s .  However they d e m o n s t ra te d  an assoc ia t ion  be tw een  the 
se lec t ion  fo r  t re a tm e n t  w i th  in f l ix im a b  and the sha red  ep itope, in tha t  pa t ien ts  w i th  the 
sha red  ep itope w e re  m o re  l ike ly  to be se lec ted  fo r  in f l ix im a b  t re a tm e n t .
M a r t inez  and c o -w o rk e rs  invest igated the  response to in f l ix im a b  t re a tm e n t  in 
re la t ion  to HLA  and m ic ro s a te l l i te s  in the ne a rby  t u m o r  ne c ros is  fa c to r  genes (TNFA, 
TNFB, TNFC, TNFD, TNFE), MHC c lass  I c h a in - re la te d  gene A (MICA) and H L A -B -a s s o c i -  
ated t r a n s c r ip t  2 (BAT2), as w e l l  as two m ic ro s a te l l i te s  in the s a m e  reg ion (D6S273 and 
D6D2223) in a s a m p le  of 78 RA pa t ien ts  (160). An inc reased f re que ncy  o f the TNFa11;b4 
hap lo type  w a s  de tec ted  in the re sp o n d e r  g roup  (p=0.01) w h e re a s  the  f re que ncy  of the 
D6S273_3 a l le le  w as  decreased in th is  g roup  (p=0.04). A f te r  B on fe r ron i  c o r rec t ion  fo r  
m u l t ip le  tes t ing  the  de tec ted  asso c ia t ions  w e re  no lo n g e r  s ign i f ican t.
Tolusso and co l leagues  s tud ied  the IL1 gene com p lex  (IL1A, IL1B  and the IL1R N ) 
in a g roup  of 49 pa t ien ts  t rea ted  w i th  in f l ix im a b  (162). They d e m o n s t ra te d  tha t  n o n ­
re sp o n d e rs  to in f l ix im a b  the rap y  had a h ig h e r  IL1R N *3  a l le le  f requency. The genotype 
c o m b in a t io n  IL1R N * lon g / long ,  IL1B  -511CC and IL1B  +3953CC w as  exc lus ive ly  found in 
pa t ien ts  no t respond ing  to in f l ix im a b  the ra p y  (p=0.05). The assoc ia t ion  w i th  the IL1RN  
VNTR is l ike ly  due to a type I e r ro r ,  however,  as it w a s  no t found by M aro t te  and c o l ­
leagues  us ing a m u ch  la rg e r  pa t ien t  po pu la t io n  (n=198) (58).
A recen t  s tud y  inves t iga t ing  S N Ps in the  genes  encod ing  T N F a  and TNF re cep ­
to r  (TNFR) I and II in 58 pa t ien ts  d e m o n s t ra te d  tha t  on ly  a c o m b in a t io n  of S N Ps w as  
assoc ia ted  w i th  t re a tm e n t  response (43). Good re sp o n d e rs  c a r r ied  the TNFR2 +676T 
a l le le  and the TNFA -857C and +489G a l le les  m o re  f re q u e n t ly  c o m pare d  w i th  the poor 
re sp o n d e rs  (p=0.0008).
Canete  and c o -w o rk e rs  assessed the re la t ionsh ip  be tw een the p o ly m o rp h is m s  
550G>A and 681G>T in respect ive ly  the Fc g a m m a  re ce p to r  genes  FCGR2A and 
FCGR3A and the  response  to in f l ix im a b  in 91 RA pat ients .  At w e e k  6 of fo l lo w -u p ,  the 
p ropo r t ion  of  pa t ien ts  ach iev ing ACR50 and EULAR good response s  w ere  s ign i f ican t ly  
h ig h e r  am o n g  hom ozygo tes  of the FCGR3A GG genotype w h e n  c o m pare d  to the  GT-TT 
genotype (ACR50: p=0.003; EULAR: p=0.04). At w e e k  30, hom ozygo tes  of the FCGR2A 
GG a l le le  had a b e t te r  ACR20 response w h e n  c o m pare d  to the AA-GA genotype g roup 
(p=0.035) (163).
In the s tud y  o f Rooryck and co l lea gue s  is w as  d e te rm in e d  w h e th e r  two f u n c ­
t ion a l  p o ly m o rp h is m s ,  681G>T in the FCGR3A, and 676T>G in the  TNFRSF1B  genes  c o r ­
re la te  w i th  rh e u m a to id  a r th r i t i s  su sce p t ib i l i ty  and response  to a n t i -T N F -a lp h a  therapy. 
The reported  a s ign i f ica n t  co r re la t io n  be tw een 676G a l le le  c a r r ie rs  and low  response  to 
in f l ix im a b  the ra p y  (47).
Adalimumab and studies focusing on more than one anti-TNF agent
Two s tu d y  has been desc r ibed  th u s  fa r  inves t iga t ing  the  e f fec t  of  gene t ic  po ly ­
m o rp h is m s  on the response  to a d a l im u m a b  (59;62). Six o th e r  s tu d ie s  focused on more  
than  one a n t i -T N F  agent,  fo u r  of th e m  inc lud ing  a d a l im u m a b  (45;48;52;60;114;156).
Cuchacov ich  et  al. invest igated the  -3 0 8 G > A  S N P in the TNFA gene in a g roup of 
70 pa t ien ts  t rea ted  w i th  a d a l im u m a b  (59). They found a h ig h e r  pe rcen tage  of re s p o n d ­
e rs  acco rd ing  to the  DAS28 (d isease act iv i ty  score  based on 28 i tem s) in the GG g e n o ­
type g roup at w e e k  24 of t re a tm e n t  (p=0.05). P a t ien ts  w i th  the GG genotype a lso showed 
a s ign i f ica n t ly  h ig h e r  m e an  DAS28 im p ro v e m e n t  (p<0.05). No s ign i f ica n t  assoc ia t ion  















M ice l i -R ich a rd  and c o w o rk e rs  invest igated th ree  p o ly m o rp h is m s  in the TNFA 
locus  (TNFA -238G>A, -308G>A and -857C>T) fo r  th e i r  capab i l i ty  to p red ic t  the rapy  
ou tco m e  in a co h o r t  of 388 RA pa t ien ts  t rea ted  w i th  a d a l im u m a b .  No assoc ia t ion  w as  
de tec ted  be tween the th ree  p o ly m o rp h is m  and the response  to a d a l im u m a b  w h e n  the 
p o ly m o rp h is m s  w ere  tested separate ly .  However, hap lo type c o n s t ru c t io n  of the TNFA 
locus  revealed th a t  the GGC haplo type (-238G/-308G/-857C) in a ho m ozygo us  fo rm  w as  
assoc ia ted  w i th  response  to a d a l im u m a b  a f te r  12 w e e k s  of t re a tm e n t  (p=0.015) (62).
Seitz and co l leagues  also s tud ied  the -3 0 8 G > A  TNFA p ro m o te r  p o ly m o rp h is m  in 
54 pa t ien ts  w i th  RA. They c om b in e d  a l l  th ree  a n t i -T N F  ag en ts  in th e i r  ana lys is  (60). The 
a u th o rs  d e m o n s t ra te d  an assoc ia t ion  be tw een a posit ive a n t i -T N F  t re a tm e n t  ou tcom e  
and the -308 GG genotype (p<0.001) as w e l l  as the absence of the A -a l le le  at pos it ion 
-308 (p<0.001).
M axw e l l  and c o -w o rk e rs  invest igated 7 kno w n  p o ly m o rp h is m s  s u r ro u n d in g  
the  TNF locus, inc lud ing  the  genes  cod ing fo r  lym ph o tox in  a lpha (LTA) and leucocyte  
spec if ic  t ra n s c r ip t  1 (LST-1) fo r  t h e i r  assoc ia t ion  w i th  response  to a l l  th ree  a n t i -T N F  
a g en ts  in a co h o r t  of 1050 pa t ients .  The fo l low ing  p o ly m o rp h is m s  w ere  inc luded :  TNFA 
-238G>A, -308G>A, -1031C>T, LTA exon-1, LTA in t ron -1 ,  LST-1 exon-5  and LST-1 in- 
t ro n -2 .  They re por ted  an assoc ia t ion  of the TNFA -308G>A p o ly m o rp h is m  w i th  a n t i -T N F  
response  over the  en t i re  co h o r t  (p=0.001). A f te r  s t ra t i f ica t io n  by a n t i -T N F  agent,  the 
TNFA -308AA genotype w a s  assoc ia ted  w i th  a p o o re r  response to e ta ne rcep t  w h e n  c o m ­
pared to the TNFA -308GG genotype (p=0.001). No assoc ia t ion  w as  de tected  be tween 
the  TNFA -308G>A p o ly m o rp h is m  and in f l ix im a b  the rap y  (p=0.8). Conversely , the TNFA 
-238GA genotype w a s  assoc ia ted  w i th  a p o o re r  response  to in f l ix im a b  (p=0.028) bu t not 
to e ta ne rcep t  (p=0.6). The n u m b e r  of pa t ien ts  tak ing  a d a l im u m a b  w a s  too s m a l l  for 
m e a n in g fu l  ana lys is  as a sep ara te  g roup  (52)
Fabris  and c o -w o rk e rs  s tud ied  the  TNFR2 gene in 66 pa t ien ts  t rea ted  w i th  
e ta ne rcep t  o r  in f l ix im ab .  They con c lu ded  tha t  the p resence of one G-a l le le  at posit ion 
+676 in TNFR2 p red isposes  to no n - re sp o n se  du r in g  the ra p y  (45).
Tu tunca and co l leagues  focused th e i r  s tudy  on the gene encod ing  Fc g a m m a  
re ce p to r  IIIA. The invest iga ted  p o ly m o rp h is m  (valine 158 to ph eny la la n ine  (V158F)) has 
an e f fec t  on the a f f in i ty  of the re ce p to r  fo r  b ind ing  of h u m a n  IgG (156). Th ir ty  pa t ien ts  
t rea ted  w i th  one of the th ree  a n t i -T N F  ag en ts  w e re  s tud ied .  The a u th o rs  de tec ted  an 
assoc ia t ion  of the  low  a f f in i ty  F/F genotype w i th  the ra p y  response c om pare d  to the 
c o m b in a t io n  of V/V and V/F genotypes  (p <0.01).
K as tbo m  and c o -w o rk e rs  inva l idated the  above assoc ia t ion  us ing a large pa t ien t  
s a m p le  (n=282) t rea ted  w i th  e i th e r  in f l ix im a b  o r  e ta ne rcep t  (114). No s ig n i f ica n t  a s s o ­
c ia t ion  be tw een response to t re a tm e n t  and FCR3A genotype cou ld  be found e i th e r  using 
the  ACR o r  the  EULAR response  cr i te r ia .
In the  s tud y  o f Ongaro and co l lea gue s  it w as  analyzed w h e t h e r  the p o ly m o r ­
p h is m s  676T>G in the  t u m o r  nec ros is  fa c to r  re cep to r  s u p e r  fa m i ly  1B (TNFRSF1B; TNF 
re ce p to r  II TNFR-II) gene and -308G>A in the TNFA p r o m o te r  gene m ay  in f luence  the 
re sponse  g rad ing  to in f l ix im a b  and a d a l im u m a b  t re a tm e n t  in RA pa t ien ts .  They enro l led  
and genotyped 105 RA pa t ien ts  t rea ted  w i th  e ta ne rcep t  (n = 55), in f l ix im a b  (n = 40) 
and a d a l im u m a b  (n = 10). Pa t ien ts  h a rbo r ing  the  TNFSF1B  676TG genotype showed  a 
s ig n i f ica n t  lo w e r  ACR response , c o m pare d  w i th  the TNFSF1B  676TT, at th ree  and twelve 
m o n th s .  No assoc ia t ion  w as  observed be tw een the TNFA -308G>T p o ly m o rp h is m  and 
a n t i -T N F  response  (48).
Replication and meta-analysis
The ph a rm a co g e n e t ic  s tud ies  p e r fo rm e d  so fa r  m a in ly  invest igated re la tively 
s m a l l  pa t ien t groups. This resu l ted  in a low  po w e r  to de tec t d i f fe rences  be tween re ­
sp o n d e rs  and n o n - re sp o n d e rs  to an t i -T N F  the rapy  (184; 185). On the o th e r  hand, s m a l l  
s a m p le  s izes m a y  a lso lead to ove res t im a t ion  of the s t re ng th  of a cer ta in  associa t ion 
find ing  by fo r  ins tance chance o r  s a m p l in g  biases. Repl ica t ion of assoc ia t ion  f ind in gs  by 
d if fe ren t  re search ers  and across d iverse sa m p le s  is esse n t ia l  to d ra w  defin i tive c o n c lu ­
s ions  abou t  w h e th e r  an assoc ia t ion  rea l ly  exists. The HLA-DRB1  a l le les  have been inves­
t iga ted in th ree  s tud ies .  One of th e m  en com passed  457 ind iv idua ls  sug ges t ing  tha t  there 
is indeed an assoc ia t ion  be tween the HLA reg ion and a n t i -T N F  response (44;58;160). For 
the FCGRIIIA p o ly m o rp h is m  the re su l ts  are m o re  convinc ing. Two large s tud ies  (including 
301 and 282 pat ients,  respectively) indicate  a lack  of assoc ia t ion  be tw een th is  gene and 
a n t i -T N F  response (44; 114), w h e re a s  the s tud y  tha t  did de tec t  assoc ia t ion  be tween the 
FCGRIIIA gene and t re a tm e n t  response had a very  s m a l l  n u m b e r  of pa t ien ts  (30 pa tients) 
(156). C onf l ic t ing  re su l ts  have a lso been reported  fo r  the genes cod ing fo r  the TNF 
re cep to r  2 as w e l l  as IL1R N  (43-45;58;162). C om p ar iso n  of s tud ies  focus ing on the sam e  
gene is often com p l ica ted  by the fact tha t  d i f fe ren t  genet ic  va r ia n ts  in the genes are 
invest igated ; these can have d if fe ren t  e f fects  on t re a tm e n t  response (53; 159). F u r th e r ­
more , so fa r  m o s t  genes  have not tho rou gh ly  invest igated. This m ig h t  be the reason why 
an ex is ting assoc ia t ion  be tween a genes and a n t i -T N F  response is not de tected, as the 
s tud ies  m ig h t  not have focused on the r ig h t  var iant.  Only the HLA region and the ad ja ­
cen t  TNFA and LTA genes  have been invest igated m o re  com p le te ly  by c rea t ing  hap lotypes 
of  d iverse m a rk e rs  in the genes. Cover ing the genes w i th  a su b s ta n t ia l  n u m b e r  o f  SNPs 
o r  o th e r  genet ic  m a rk e rs  can enhance  the de tec t ion  of assoc ia t ions  w i th  a phenotype 
th a t  are e i th e r  due to d irec t  causa l  e f fec ts  of the p o ly m o rp h is m s  o r  due to the fac t  that 















For the p o ly m o rp h is m  tha t  has been invest igated m o s t  often, the -3 0 8 G > A  TNFA 
p r o m o te r  p o ly m o rp h is m ,  a m e ta -a n a lys is  has been p e r fo rm e d  to ove rcom e the  p ro b ­
lem  of s m a l l  s tu d ie s  (61). M e ta -a na lys is  is a s ta t is t ica l  p rocedu re  in te g ra t in g  re su l ts  
f ro m  seve ra l  s tu d ie s  to p roduce a s ing le  e s t im a te  w i th  enhanced  prec is ion  (186). Thus 
fa r  one m e ta -a n a ly s is  has been pub l ished  c o m b in in g  data of the s tu d ie s  address ing . In 
to ta l , da ta of 311 pa t ien ts  w e re  inc lud ed  in the  m e ta -a n a lys is  (50;53-57). Pa t ien ts  w ere  
trea ted  w i th  e i th e r  e ta ne rcep t  o r  in f l ix im a b  and s tan da rd  d isease act iv i ty  sco res  (ACR or  
DAS28 scores) w e re  used to assess the response to the  a n t i -T N F  therapy. The au th o rs  
com b in e d  the ra re  AA genotype w i th  the AG genotype. A na lys is  po in ted ou t tha t  the 
A -a l le le  c a r r ie rs  w e re  s ign i f ica n t ly  less l ike ly  to be long to the re s p o n d e r  g roup  than  p a ­
t ien ts  w i th  the GG genotype (OR=0.33. p=0.0008). This m e ta -a n a lys is  th u s  s u g g e s ts  tha t  
the re  is indeed an e f fec t  of  the -3 0 8 G > A  S N P  on the response to TN F therapy. H o w ­
ever, a new  (not yet pub l ished) m e ta -a n a ly s is  regard ing  the  -3 0 8 G > A  TNFA p ro m o te r  
p o ly m o rp h is m ,  w h ic h  inc lud ed  over 2800 RA pa t ien ts  f ro m  13 s tud ies ,  s ta ted  th a t  the 
p o lu m o r p h is m  is not assoc ia ted w i th  response  to a n t i -T N F  the rap y  (chap te r  6).
Genome-wide association studies
The focus  of a n t i -T N F  p h a rm a c o g e n e t ic  s tu d ie s  so fa r  has been exc lus ive ly  on 
p o ly m o rp h is m s  in the m o s t  obv ious cand ida te  genes, w h ic h  are those  kn o w n  to be 
involved in RA, im p l ica ted  in TN F  m e c h a n is m s  of ac t ion o r  involved in the degrada t ion  
of the an t i -T N F agen ts .  A less h yp o the s is -d r ive n  (p ha rm a co g e n o m ics )  approach  to the 
s ea rch  fo r  genes  involved in an t i -T N F re sp o n se  is the use of g e n o m e -w id e  sc re en ing  of 
p o ly m o rp h is m  fo r  t h e i r  assoc ia t ion  w i th  a n t i -T N F  respone.
Recently, the s tudy  of com p lex  genet ic  d iseases has undergone  a d ra m a t ic  revo lu ­
tion due to the deve lopm ent of g e n o m e -w id e  assoc ia t ion s tud ies  (GWAS). Advances in 
techno logy  have enabled hundreds  of tho usan ds  of SN Ps to be genotyped in thousands  
of sa m p le s  in a s ing le  exper im ent ,  a l low ing  s tud ies  to achieve good coverage of c om m on  
var ia t ion in the hu m a n  genom e. An impressive GWAS w as  under taken  by the W ellcome 
Trust Case Contro l  C onso r t ium  (WTCCC). This con so r t ium , w h ich  is a co l labo ra t ion  of 
over 50 research g roups  w i th in  the UK, invest igated 2000 case sa m p le s  and 3000 con tro ls  
fo r  seven com p lex  d iseases, inc lud ing RA. Two w e l l -d o c u m e n te d  RA suscep t ib i l i ty  genes 
(HLA-DRB1 and PTPN22) and nine new va r ian ts  w ere  found to be associa ted w i th  RA 
suscep t ib i l i ty  in th is  s tudy  (187). This unbiased ge n o m e -w id e  approach is also been used 
to identi fy  c o m m o n  genet ic  var ia t ion tha t  cou ld  be respons ib le  fo r  d i f fe rences in an t i -T N F  
response. Liu and c o -w o rk e rs  conducted  a GWAS using the I l lum ina  HapMap300 SNP a r ­
ray to invest igate 89 RA pat ien ts  fo r  th e i r  response to an t i -T N F  tre a tm e n t .  Several SNPs
showed s ign i f ican t  assoc ia t ions w i th  loci inc lud ing  the MAFB  ( v -m a f  m uscu loap one u ro t ic  
f ib rosa rcom a oncogene hom o log  B) gene on ch ro m o s o m e  20. A lso s ign i f ican t  assoc ia ­
t ions  w e re  reported fo r  S NPs located w i th in  o r  nearby the genes IFNk  (type I in te rfe ron] 
on c h ro m o so m e  9, PON1 (paraoxonase I) on ch ro m o s o m e  7 and IL10 ( in te r leuk in  10) on 
ch ro m o s o m e  1 (66). Both  IL10  and IFNk  are involved in im m u n i ty  and reduced expression 
of PON1 is associa ted w i th  Crohn's  d isease (188), indicating tha t  these are in te rest ing 
candidate  genes fo r  f u r th e r  s tudy  on an t i -T N F  response and RA in genera l.
Other approaches to identify markers for anti-TNF response
A n o th e r  less hypothes is -d r iven  approach to identi fy  genet ic  m a rk e rs  fo r  a n t i -TN F  
response is the use of gene expression prof i l ing s tra teg ies .  Several s tud ies  analyzed 
d i f fe ren t ia l ly  expressed genes using m ic ro a rrays  in responders  and n o n -re spon de rs  to 
an t i -T N F  the rapy  (73; 189-192). These s tud ies  are descr ibed in m ore  de ta i l  in ch a p te r  8, 
s ince th is  ch a p te r  focuses on expression prof i l ing  in RA pa t ien ts  t reated w i th  anti -TNF.
Also at the level of the p ro teom e possib le m a rk e rs  fo r  a n t i -T N F  t re a tm e n t  o u t ­
com e have a lready been invest igated, though  a l l  s tud ies  have been l im i ted  to (single) 
pro te ins  known to be involved in RA (193-196). Nowadays hypothesis  free approaches  to 
p ro teom e analys is  are also available,  l ike tw o -d im e n s io n a l  ge l e lec t rophores is  o r  s u r ­
face -enhanced lase r  d e so rp t io n / ion iza t ion - t im e  of f l igh t  (SELDI-TOF) analys is. Using tw o ­
d im e n s io n a l  gel e lec t rophores is  it has de m ons t ra te d  tha t  the MRP8/M RP14 heterodup lex 
m ig h t  be a m a rk e r  fo r  a n t i -T N F  the rapy  (197). SELDI-TOF analys is  has a lready proven to 
be use fu l  to identi fy  p ro te ins  re la ted to t re a tm e n t  ou tcom e  fo r  o th e r  b io log ica ls  (198).
P o ly m o rp h is m s  in genes  iden t i f ied  us ing these  a p p roa ches  m ig h t  the re fo re  be 
good cand ida tes  fo r  fu tu re  p h a rm a c o g e n e t ic  s tu d ie s  in re la t ion  to a n t i -T N F  response.
Expert commentary
A l th o u g h  p rog ress  has been m a de  in the sea rch  fo r  gene t ic  p o ly m o rp h is m s  
re la ted  to a n t i -T N F  response (Table 1 and 2) so fa r  on ly  the -3 0 8 G > A  S N P  in the TNFA 
p r o m o te r  has been iden t i f ied  as a (weak) m a rk e r  p red ic t ing  t re a tm e n t  ou tcom e . This 
m a y  be a t t r ib u te d  to the low  po w e r  of m o s t  p h a rm a co g e n e t ic  s tud ies ,  the use of d i f f e r ­
en t  e thn ic  g roups  and d i f fe ren t  ou tco m e  de f in i t ions  a n d /o r  the l im i ted  n u m b e r  o f genes 
s tud ied  so far. It w o u ld  su re ly  be w o r th w h i le  to sea rch  fo r  genes  involved in t re a tm e n t  
response  in a non h yp o the s is -d r ive n  m a n n e r ,  co m p a ra b le  to the gene express ion  p ro f i l ­















A n o th e r  s uch  hyp o the s is - f ree  m e thod  tha t  has not yet been used in the  search  
fo r  p re d ic to rs  of a n t i -T N F  response  is the w h o le  ge n o m e  assoc ia t ion  approach  (64).
The ava i lab i l i ty  o f re la t ive ly  inexpensive a r rays  a l low ing  the  ana lys is  of  hu nd re d s  of 
th o u sa n d s  of  S N Ps in one s ing le  e x p e r im e n t  has recen t ly  m a de  th is  approach  feasib le 
(64;65). A ssoc ia t ion  is de tec ted  via a s u r ro g a te  m a r k e r  (SNP) in l inkage  d is e q u i l ib r iu m  
w i th  the  t ru e  causa l  va r ian t .  Large, w e l l - c h a ra c te r iz e d  pa t ien t  s a m p le s  w i l l  be needed 
fo r  such  an approach.  W ho le  g e n o m e  assoc ia t ion  s tu d ie s  re p re se n t  a f i rs t  s tep  of 
ana lys is  and need to be fo l low ed up by m o re  focused s tu d ie s  s ea rch ing  fo r  the  causa l  
v a r ia n ts  in the reg ions  of in te res t  identi fied.
Of course, rep l ica t ion  of  the f ind in gs  in a d d i t iona l  pa t ien t  s a m p le s  is of u tm o s t  
im p o r ta n c e  fo r  a l l  a p p roa ches  th a t  can be used fo r  the  iden t i f ica t ion  of  m a rk e rs  p re ­
d ic t ing  a n t i -T N F  response , as f ind in gs  in one s a m p le  w i l l  no t  g u a ran tee  th e i r  va l id i ty  
and genera l izab i l i ty .
C om b ina t io n  of the  above desc r ibed  te ch n iq u e s  is p robab ly  the  m o s t  p o w e r fu l  
w ay  to iden t i fy  genes  involved in the response  to a n t i -T N F  therapy. The in te g ra t io n  of 
da ta w i l l  a lso provide us w i th  a w e a l th  of a d d i t iona l  in fo rm a t io n  abou t  the w ay  in w h ich  
gene t ic  fac to rs  exe r t  th e i r  e f fec ts  on t re a tm e n t  (e.g. via a l te ra t io n s  in RNA express ion 
and t ra n s la t io n  e ff ic iency, pro te in  fo ld ing  o r  via seco n d a ry  e f fec ts  on o th e r  genes). It is 
h igh ly  l ike ly  tha t  w e  w i l l  no t  be ab le  to iden t i fy  a s ing le  gene t ic  va r ia n t  tha t  w i l l  p red ic t  
t re a tm e n t  ou tco m e  in a n t i -T N F  the ra p y  w i th  s u f f ic ie n t  sens it iv i ty  and specif ic i ty . R ather  
it is to be expected tha t  a se t  of genes  and gene t ic  va r ia n ts  in those  w i l l  to g e th e r  f o rm  a 
m a r k e r  fo r  t re a tm e n t  response . In th is  respec t  it is im p o r ta n t  to take addit ive  e f fec ts  as 
w e l l  as in te ra c t io n s  be tw een gene t ic  p o ly m o rp h is m s  into c on s id e ra t ion  in p h a rm a c o g e -  
ne t ic  s tud ies .  F u r th e rm o re ,  tho ugh  S N Ps are the m o s t  f re q u e n t  p o ly m o rp h is m s  in the 
h u m a n  ge n o m e  and are m o s t  am e n a b le  to h igh th ro u g h p u t  gene t ic  analys is , a l l  types 
of p o ly m o rp h is m s  ( inc lud ing  repeat  p o ly m o rp h is m s ,  in s e r t io n /d e le t io n s  and la rge  scale 
copy n u m b e r  var ian ts )  sh o u ld  be cons ide red  in the  p h a rm a c o g e n e t ic  stud ies.
An a d d i t iona l  fa c to r  needed to be taken into  a cco un t  in these  s tu d ie s  is the 
p resence  of  no n -g e n e t ic  fac to rs  in f lue nc ing  the response to a n t i -T N F  t re a tm e n t .  For 
ins tance s m o k in g  is assoc ia ted w i th  no n - re sp o n se  in pa t ien ts  w i th  C rohn 's  d isease and 
RA t rea ted  w i th  in f l ix im a b  (199;200).
F o rm a t io n  of  a n t ib o d ie s  d i re c ted  to a n t i -T N F  a g e n ts  m ig h t  a lso  be a reason 
w h y  p a t ie n ts  do no t re spond  to a n t i -T N F  agen ts .  An e a r ly  s tu d y  d e m o n s t ra te d  th a t  at 
leas t  8% of the  p a t ie n ts  t re a te d  w i th  in f l i x im a b  p roduce d  a n t ib o d ie s  to th is  a n t i -T N F  
a g e n t  (30). Th is  s tu d y  s ug g e s te d  th a t  the re  w e re  no d i f fe re n ce s  be tw een  the  ACR20 
re sponse  of p a t ie n ts  w i th  and w i t h o u t  a n t i - in f l i x im a b  a n t ib o d y  fo rm a t io n .  However,  
o th e r  s tu d ie s  s ince  have d e m o n s t ra te d  tha t  n e a r ly  h a l f  o f the  p a t ie n ts  fo rm e d  a n t i ­
in f l i x im a b  a n t ib o d ie s  upon t r e a tm e n t  and th a t  the  fo r m a t io n  of  the se  a n t i - in f l i x im a b
a n t ib o d ie s  can be co r re la te d  w i th  the  re sponse  to in f l i x im a b  in the  p a t ie n ts  (201). In a 
p h a rm a c o g e n e t i c a l  sense  re s e a rc h e rs  have a l re a d y  s ta r te d  to a d d ress  th is  issue by 
inves t ig a t ing  ge n e s  kn o w n  to be involved in an t ig e n  p re s e n ta t io n  and d e g ra d a t io n  of 
an t ibod ie s .  Th is  inves t ig a t ion  s h o u ld  be in te ns i f ied  as it m ig h t  ide n t i fy  p a t ie n ts  prone 
to the  fo r m a t io n  of a n t ib o d ie s  d i re c ted  a g a in s t  the  a n t i -T N F  agen ts .  W h ich  p e rc e n t ­
age of the  n o n - re s p o n s e  to the  d i f fe re n t  a n t i -T N F  a g e n ts  w i l l  be exp la ined  by the  f o r ­
m a t io n  of  the  a n t i - a n t i - T N F  a n t ib o d ie s  is no t c le a r  yet, bu t it s e e m s  safe to a s s u m e  
th a t  a d d i t io n a l  m e c h a n is m s  are involved.
In con c lu s ion ,  a very  de ta i led  c h a ra c te r iza t io n  of ( large, hom oge neo us )  pa t ient 
s a m p le s  w i l l  be necessary  to a r r ive  at an a ccu ra te  p red ic t ion  of the  response  to an t i -  
TNF therapy.
Future perspective
P h a rm a co g e n e t ic  s tud ies  desc r ibed  so fa r  co n s t i tu te  a fi rs t ,  cau t ious  step 
to w a rd s  the  e luc id a t ion  of  the gene t ic  v a r ia n ts  involved in the m o d u la t io n  of a n t i -T N F  
response . The f ind in gs  up to now  a lready  su g g e s t  tha t  t re a tm e n t  response  to a n t i -T N F  
is a m u l t i f a c to r ia l  event, in f luenced  by seve ra l  (genet ic  and no n-gene t ic )  fac tors ,  w i th  
p robab ly  s m a l l  e f fec ts  of ind iv idua l  fac tors .  As m o re  and m o re  pa t ien ts  are t rea ted  w i th  
a n t i -T N F  agen ts  the need fo r  m a rk e rs  p red ic t ing  t re a tm e n t  o u tc o m e  w i th  h igh s e n ­
s i t iv i ty  and spe c if ic i ty  is s t ro n g ly  inc reas ing  to ensu re  e f fective t re a tm e n t  of ind iv idua l  
pa t ients ,  prevent u n n ecessa ry  d isease p rog ress ion  and keep t re a tm e n t  cos ts  at  a m in i ­
m u m .  In the fu tu re  the fu l l  s p e c t ru m  of poss ib i l i t ie s  in gene t ic  research  as w e l l  as re ­
la ted d isc ip l ine s  need to be em p loyed  to iden t i fy  m a rk e rs  fo r  t re a tm e n t  ou tcom e . With  
seve ra l  c l in ica l  t r ia ls  a l ready  reg is te red  at s i tes  like w w w .c l in ic a l t r ia ls .g o v  it s e e m s  
th a t  indeed m a n y  e f fo r ts  are c u r re n t ly  ongo ing  to d e te rm in e  the fac to rs  in f lue nc ing  the 
re sponse  to a n t i -T N F  therapy.
Large, very w e l l - c h a ra c te r iz e d  pa t ien t  s a m p le s  w i l l  m ake  it poss ib le  to use 
w h o le  ge n o m e  assoc ia t ion  ap p roa ches  as w e l l  as t r a n s c r ip t o m ic s  and p ro te o m ic s  for 
the iden t i f ica t ion  of m a rk e rs  tha t  can p red ic t  t re a tm e n t  ou tco m e  in a su b s ta n t ia l  part 
of  the pa t ien ts .  W ha t  is needed now  m o re  than  ever is a good c o l lab o ra t ion  be tween 
d i f fe ren t  research  g roups  and d isc ip l ines ,  to en su re  fas t  d iscovery  as w e l l  as e f f ic ien t 
tes t ing  of  va l id i ty  and ge ne ra l iza t ion  of f ind in gs  and serve the in te res t  of the pa t ient 
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Object ive :  The (GT)n - re p e a t  in the  he m e  oxygenase-1 (HMOX1) p r o m o te r  d e ­
te r m in e s  the level  of indu c t ion  of the  h e m e -d e g ra d in g  HMOX1 enzym e th a t  p ro tec ts  
aga ins t  in f la m m a to ry  and oxidative s tress . Ind iv idua ls  w i th  s h o r t  (GT)n - rep e a ts  (SS; 
n<25) ind uce m o re  rap id ly  h ig h e r  levels of HMOX-act iv i ty  than  those w i th  long repeats  
(LL; n> 25). Recently,  it w as  d e m o n s t ra te d  tha t  HMOX-act iv i ty  p ro tec ts  aga ins t  the 
on se t  of  rh e u m a to id  a r th r i t i s  (RA). The a im  of th is  s tudy  w a s  to d e te rm in e  w h e t h e r  the 
(GT) n - re p e a t  leng th  w i th in  the  HMOX1 p ro m o te r  reg ion is assoc ia ted  w i th  RA d isease 
seve r i ty  and rad io log ic  jo in t  damage.
M e thod s :  A coh o r t  of 325 w e l l - c h a ra c te r iz e d  RA pa t ien ts  and 273 c o n t ro ls  w as  
invest iga ted  by D N A - f ra g m e n t - le n g th  ana lys is  fo r  the assoc ia t ion  of (GT)n - rep e a ts  in 
the HMOX1 p ro m o te r  reg ion w i th  RA d isease s u s ce p t ib i l i t y  and severity.
R esu l ts :  A l th o u g h  no s ign i f ica n t  d i f fe rences  in genotype o r  a l le le  f requency  
w a s  found be tw een c o n t ro ls  and RA pat ients ,  the odds  ra t ios  c o r respo nde d  w e l l  to the 
p rev ious ly  d e sc r ibed  cohort .  A m o n g  pa t ients ,  those  w i th  the S S-genotype had a m ore  
favorab le  rad io log ic  o u tc o m e  over n ine y ea rs  than  those ca r ry ing  the LL -geno type .  This 
w a s  unexpec ted  s ince  no d if fe rence  in d isease ac t iv i ty  be tw een the genotypes  o r  a l le les  
w a s  found.
C o n c lu s io n :  P at ien ts  w i th  the  S S-genotype have a b e t te r  lo n g - t im e  rad io log ic  
ou tco m e  desp i te  bad p rognos t ic  m a rk e rs  at base l ine  and s im i l a r  d isease act iv i ty  at 
fo l lo w -u p .  This sug ges ts  tha t  the  HM O X -sys tem  is involved in the  u n coup l in g  of d isease 
























A l th o u g h  the exact e t io logy  o f rh e u m a to id  a r th r i t i s  (RA) re m a in s  e lus ive it is 
th o u g h t  tha t  ox idative and in f la m m a to ry  s t re ss  is involved in RA jo in t  dam age .  It has re ­
cen t ly  been d e m o n s t ra te d  tha t  he m e  oxygenase-1 (HMOX1), the enzym e tha t  degrades  
he m e  into  b i l ive rd in /b i l i ru b in ,  ca rbon  m onox ide  and iron, is s t ro n g ly  induced in in f lam ed  
synov ia l  t issue  a f f l ic ted  w i th  RA (202).
HMOX1 a t te n u a te s  in f la m m a t io n  and oxidative s t re ss  in a w ide  range of co n d i ­
tions, w h e re a s  inh ib i t ion  of  HMOX-act iv i ty  e xacerba tes  in f la m m a t io n  (154). This is 
exe m p l i f ied  by the observa t ion  tha t  ove rexpress ion  of HMOX1 in synov ia l  t issues  a t ­
ten ua te s  the  express ion  of in f la m m a to ry  c y tok ines  w h e re a s  inh ib i t ion  of HMOX-act iv ity  
leads to oppos i te  e f fec ts  (202).
The leng th  of  a g u a n in e - th y m id in e  (GT)n - re p e a t  p o ly m o rp h is m  in the p ro m o te r  
reg ion of  the HMOX1 gene has been d e m o n s t ra te d  to d e te rm in e  the level of HMOX1 
indu c t ion  (203). W hen given the s a m e  s t im u lu s ,  people  hom ozygous  fo r  a (GT)n - re p e a t  
n<25 express s ign i f ica n t ly  m o re  HMOX1 than  people  ho m ozygo us  fo r  a (GT)n - repea t  
n>25 (203). Of im p o r ta n ce  is tha t  the  s ize of th is  (GT)n-repeat c o r re sp o n d s  c l in ica l ly  
w i th  d i f fe re n t ia l  s u s ce p t ib i l i ty  to va r io us  cond i t ions .  For exam p le  ind iv idua ls  h o ­
m o zygous  fo r  the  s h o r t  repea ts  are p ro tec ted  aga ins t  e m p h yse m a  and co rona ry  a r te ry  
d isease, bu t have a h ig h e r  r is k  fo r  deve lop ing a m e la n o m a  (204). Recently, it has been 
d e m o n s t ra te d  tha t  people  ca r ry ing  a long (GT)n - repea t,  have an inc reased su sce p t ib i l i ty  
fo r  deve lop ing  RA, c om pare d  to people ca r ry ing  a s h o r t  (GT)n - repea t,  and, s u b se q u e n t ly  
inc reased  HMOX1 express ion  (119).
Since HMOX-act iv i ty  p ro tec ts  aga ins t  in f la m m a to ry  and oxidative in ju ry  w e  p o s ­
tu la ted  tha t  am o n g  RA pa t ien ts ,  the people ca r ry ing  a HMOX1 p ro m o te r  p o ly m o rp h is m  
lead ing to less HMOX1 induc t ion ,  w o u ld  have w o rse n e d  o u tc o m e  than  those h a rbou r ing  
a p o ly m o rp h is m  re su l t ing  in high HMOX-1 levels.
> PATIENTS AND METHODS
Patient cohort
Genotyping w a s  p e r fo rm e d  in pa t ien ts  w i th  RA p a r t ic ipa t in g  in an ea r ly  inception 
s tud y  tha t  s ta r ted  in 1985 and is s t i l l  ru n n in g  at the d e p a r tm e n t  of R h eu m a to logy  of the 
Radboud U n ive rs i ty  N i jm e g e n  M ed ica l  Centre  (RUNMC) in the  N e th e r la n d s .  The s tudy  
inc lud ed  on ly  those  pa t ien ts  w h o  m e t  the A m e r ic a n  Col lege of R h eu m a to logy  c r i te r ia  
fo r  RA, had a d isease d u ra t ion  of  <1 year,  and had no p r io r  use of d isea se -m od i fy ing  
a n t i - r h e u m a t ic  d ru g s  o r  b io log ica l  agen ts  be fore inc lus ion .  A l l  pa t ien ts  in the  ea r ly  
incep t ion  co h o r t  are w e l l  c h a rac te r ized  w i th  regard  to d e m o g ra p h ic s  and are re gu la r ly  
m o n i to re d  fo r  d isease act iv i ty  and ou tcom e . C on t ro ls  w ere  re c ru i ted  f ro m  an onym o us  
he a l thy  blood d o no rs  of the c a tc h m e n t  area of the RUNMC. The s tud y  w a s  approved by 
the loca l  e th ics  c o m m i t te e  of the RUNMC.
D em o g ra p h ic  da ta such  as g e n d e r  and age at  d isease onset,  as w e l l  as the 
p resence  of  rh e u m a to id  fa c to r  (RF), C -reac t ive  p ro te in  (CRP), and e r y th ro c y te -s e d im e n -  
ta t ion  ra te  (ESR) w e re  inc luded  in the analys is . D isease Act iv i ty  Score 28 (DAS28) w as  
m e asu re d  every  th ree  m o n ths ,  a f te r  w h ic h  the average at base l ine  and a f te r  3, 6 and 9 
yea rs  of f o l lo w -u p  w a s  used fo r  o u r  s tudy  (15). R ad io log ica l  da m a g e  w a s  assessed at 
base l ine  and du r ing  3, 6 and 9 yea rs  of d isease fo l lo w -u p .  The ra d io g ra p h s  w ere  scored 
by 1 b l inded ob se rve r  in acco rdance  w i th  the Rat ingen rad io log ica l  da m a g e  sco r ing  
sys tem  (205).
Genotyping of the (GT)n -repeat in the HMOX1 gene promoter
Genom ic  DNA w a s  ex trac ted  f ro m  leukocy tes  in p e r ip h e ra l  venous  blood from 
325 RA pa t ien ts  tha t  have been fo l low ed in t im e  and 273 c o n t ro ls  as p rev ious ly  d e ­
sc r ibe d  (206). The HMOX1 gene 5 ' - f la n k in g  reg ion w a s  a m p l i f ie d  by PCR us ing e i th e r  a 
FAM, VIC, NED o r  PET f lu o re sce n t ly - la b e le d  sense p r im e r  (5 '- label-AGAGCCTGCAGCT- 
TCTCAGA-3') and an un la be l led  an t isense  p r im e r  (5 '-ACAAAGTCTGGCCATAGGAC-3') 
f lan k in g  the (GT)n - re p e a t  (207). PCR p roduc ts  w e re  genera ted  in a f ina l  v o lu m e  of 10 |_il 
con ta in ing  1 U A m pl iTaq Gold D N A  po lym era se  (Applied B iosys tem s,  N ie u w e k e rk  a/d 
IJssel,  The N e th e r lan ds ) ,  6 0 m M  T r is -H C L  (pH 8,5), 15 m M  (N H 4 ^S O 4 ,  1,5 m M  M g C l2 , 
0,25 m M  of each dNTP, 5 p m o l  of each, p r im e r  and 50 ng g e n o m ic  DNA. A m p l i f ica t io n s  






















the  N e th e r lan ds )  us ing a 10 m in  d e n a tu ra t io n  per iod at 95 °C fo l lowed by 32 cyc les of 
94 °C fo r  1 m in ,  62,4°C fo r  1 m in  and 72°C fo r  1 m in .  A f ina l  ex tens ion  step of 10 m in 
at 72°C com p le ted  the  react ion. PCR p roduc ts ,  con ta in ing  fo u r  d i f fe ren t  f luo rescen t  
labe ls ,  w e re  pooled 1:1 fo r  f u r t h e r  analys is . Genotyp ing w as  p e r fo rm e d  us ing 1,5 |_il of 
the  pooled PCR p roduc t  to g e th e r  w i th  9,7 |_il f o r m a m id e  and 0,3 |_il GeneScan-500 LIZ 
SIZE S tandardTM  (Applied B iosys tem s) on an ABI3100 Genetic A na lyze r  acco rd ing  to 
the  p ro toco l  of the m a n u fa c tu re r  (Applied B iosystem s).  F r a g m e n t - le n g th  d e te rm in a t io n  
w a s  done us ing G en eM a ppe r  s o f tw a re  v e rs ion  4.0 (Applied B iosystem s).  A l le l ic  repeats 
w e re  div ided into  tw o sub c la sse s  based on prev ious s tu d ie s  (4). The s h o r t  (S)-a l le le w as  
c lass i f ied  as n<25 (GT) and long (L ) -a l le les  w i th  n>25 (GT). The d e te rm in a t io n  of  the 
geno types  and d o c u m e n ta t io n  of the re su l ts  w a s  done by two inde pen den t  resea rch e rs  
b l inded  fo r  the c l in ica l  var iab les .  For bo th  the RA and co n t ro l  cohort ,  5% of the sa m p le s  
w e re  genotyped inde pen den t ly  tw ice  as in te rn  con tro ls .
Statistical analysis
X-ray  data fo r  the f i rs t  th ree years  of fo l low -up  w ere  available fo r  225 (69%) of the 
325 RA pa t ien ts  of the inception cohort .  Frequency of HMOX1 genotypes (LL, LS, SS) was 
the sam e  in com p le te  and s ub -sam p les .  M iss ingness w as  unre la ted  to c l in ica l  var iables, 
spec if ica l ly  age, gender, rheum a to id  fac to r  posit iv i ty  and the DAS28 score. Dif ferences 
in base l ine var iab les  be tween pa t ien ts  g rouped accord ing to genotype w ere  pe r fo rm ed  
using ch i-square ,  one-w ay  ANOVA o r  K ru ska l-W a l l is  tes ts  as approp r ia te .  An assoc ia ­
tion be tween genotype and m ed ica t ion  is a p r io r i  unlikely. Gender,  age at diagnosis, and 
m ed ica t ion  use w as  not s ign i f ican t ly  d i f fe ren t be tween the genotype groups  (data not 
shown). Jo in t  dam age  progress ion w as  ca lcu la ted a f te r  3, 6 and 9 years as the dif fe rence 
w i th  baseline. D if ferences in jo in t  d a m age  progress ion be tween genotype groups  were 
analyzed us ing l inea r  regress ion w i th  d u m m y  var iab les  fo r  genotype groups. To improve 
m o d e l  fit, the analys is  w as  repeated us ing ro o t - t ra n s fo rm e d  progress ion scores and 
these p-va lues  w ere  in te rpre ted  fo r  b e tw een -g ro up  differences. To s tudy  d if fe rences in 
the trend over t im e  the analys is  w as  add i t iona l ly  pe r fo rm ed  using long i tud ina l  regression, 
thu s  co r rec t ing  fo r  repeated m e asu re s  over t im e  (mixed models).
> RESULTS
HMOX1 genotype and allele frequency in RA patients and controls
In o rd e r  to ver i fy  th a t  the n u m b e r  of (GT)n - repea ts  in the  HMOX1 p r o m o te r  is 
assoc ia ted  w i th  RA d isease suscep t ib i l i ty ,  as d e m o n s t ra te d  in the s tu d ie s  of Rueda et 
al. (119), the n u m b e r  of G T-repeats  of 325 pa t ien ts  and 273 c o n t ro ls  w a s  d e te rm in e d  
(Table 1). Five pe rcen t  of the  s a m p le s  in bo th  c o h o r ts  w e re  genotyped tw ice as in te rna l  
con tro ls .  We observed no geno typ ing  e r ro rs  in both  the RA and co n t ro l  cohort .  Repeat 
leng th  ana lys is  show ed  tha t  the  n u m b e r  o f  (GT)-repeats ranged f ro m  13 to 41, w i th  23 
and 30 repea ts  as m o s t  c o m m o n ,  both  in con t ro ls  and in RA pa t ien ts  (data no t shown). 
In both  the pa t ien t  and c o n t ro l  g roup, the ho m ozygo us  L -geno type  w a s  m o s t  f re que n t ly  
p resent .  The S S-genotype w as  ra res t  in both  pa t ien ts  and c o n t ro ls  (Table 1). A l th o u g h  
co m p a r is o n  of the genotype and a l le le  f re q u e n c ie s  be tw een pa t ien ts  and c o n t ro ls  did 
no t s h o w  s ta t is t ica l ly  s ign i f ica n t  d i f fe rences  (Table 1), the Odds Ratios w e re  s im i l a r  to 
those  in Rueda's  la rg e r  s tudy  (119).
T a b le  1 /  HO-1 (GT)n m i c r o s a t e l l i t e  d i s t r i b u t i o n  in RA  p a t i e n t s  a n d  c o n t r o l s *
|G T )n m i c r o s a t e l l i t e  R A  p a t i e n t s  C o n t r o l s  p - v a l u e  OR (9 5 %  CI) OR (9 5 %  CI)
n |% )  n |% )  P r e s e n t  s t u d y  R u e d a  e t  a t (119)
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Association of HMOX1 promoter polymorphism with joint damage in RA patients, but 
not with disease activity
We invest igated the  HMOX1 (GT)n repeat  in re la t ion  to RA d isease act iv i ty  and 
rad io log ic  j o in t  da m a g e  in a c o h o r t  of  225 pa t ien ts  (F igure 1; Table 2). No d i f fe rences  
in m e d ica t ion  use be tw een the  s u b je c ts  ca r ry ing  d i f fe ren t  HMOX-1 p ro m o te r  p o ly m o r ­
p h is m s  w e re  found. The m e d ian  (p25-p75) n u m b e r  of d isea se -m o d i fy in g  a n t i - rh e u m a t ic  
d ru g s  used w a s  3 (2-5) in a l l  th ree  groups. In pa r t icu la r ,  the re  w e re  no s ign i f ica n t  
d i f fe rences  in the  pe rcen tage  of pa t ien ts  be tw een  the th ree  genotype g roups  (SS, SL 
o r  LL), w h o  used m e tho trexa te ,  su l fasa laz ine ,  o ra l  p redn isone,  m e thy lp re dn iso lo ne ,  
o r  a n t i -TNF. No s ig n i f ica n t  d i f fe rences  existed be tween the genotypes  o r  a l le les  w i th  
re spec t  to d isease activi ty, CRP, RF (Table 2), and ESR (data no t shown).
L in e a r  re g ress io n  ana lyses  (Table 2) sho w e d  th a t  a f te r  9 ye a rs  of d isease  f o l ­
lo w -u p ,  th e re  w a s  s ig n i f i c a n t ly  less  d a m a g e  in p a t ie n ts  h o m o z y g o u s  fo r  the  S -a l le le  
w h e n  c o m p a re d  to h o m o zyg o u s  L -a l le le  (P=0.047). The co u rse  ove r  t im e  of X - ra y  
s c o re s  d e m o n s t ra te d  th a t  indeed the  RA p a t ie n ts  w i th  the  S S -gen o type  had s ig n i f i ­
can t ly  less  severe j o in t  d a m a g e  ove r t im e  w h e n  c o m p a re d  to the  L L -  o r  S L -g e n o typ e  
(F igure  1). The re g ress io n  c o e f f ic ie n ts  are in te rp re te d  as the  d i f fe re n ce s  of L L -  and 
S L -g e n o ty p e s  w i th  the  S S -gen o type  (genotype ana lys is )  o r  the  d i f fe ren ce  be tw een  
L-  and S -a l le le s  (a lle le  ana lys is )  in p ro g re ss io n  of jo in t  d a m age .  In a lo n g i tu d in a l  r e ­
g ress ion  an a lys is  the  p ro g re ss io n  of jo in t  d a m a g e  (F igure  1) w a s  s ig n i f i c a n t ly  less fo r  
SS- co m p a re d  to L L -p a t ie n ts  (p=0.022). D i f fe rences  be tw een  LL and SL (p=0.066) and 
be tw e e n  SS and SL (p=0.26) fa i led to reach  s ta t is t ic a l  s ign i f ica nce .  A b o x -p lo t  ana lys is  
of the  e ros ion  sco re s  at  y e a r  9 d e m o n s t ra te d  a ske w e d  bu t  u n im o d a l  d is t r ib u t io n  of 
the  S S-gen o type  (F igure  1B).
In add i t ion  to genotype d is t r ib u t io n  w i th in  the RA pa t ien t  g roup, w e  a lso  p e r ­
fo rm e d  a l le le  analys is  (Table 2). A f te r  9 y ea rs  of  d isease du ra t ion ,  the rad io log ic  jo in t  
da m a g e  w a s  s ign i f ica n t ly  lo w e r  in pa t ien ts  ca r ry ing  an S -a l le le  w h e n  c om pare d  to 
pa t ien ts  w i th  an L -a l le le  (Table 2; P=0.013). A lso a f te r  3 and 6 yea rs  the j o in t  da m age  
w a s  less m a rked ,  a l th o u g h  th is  failed to reach s ta t is t ica l  s ign i f icance.
L o n g i tu d in a l  regress ion  d e m o n s t ra te d  s ta t is t ica l ly  s ign i f ica n t  d i f fe rences  in jo in t  
da m a g e  p rog ress ion  be tw een S -a l le le  and L -a l le le  c a r r ie rs  (p=0.0096). A l l  m o d e ls  w e re  
co r rec te d  fo r  RF-posit iv i ty ,  age at  d iagnos is  and m e an  DAS28.
T a b le  2 /  I n f l a m m a t o r y  p a r a m e t e r s  a n d  j o in t  d a m a g e  p r o g r e s s io n  in RA  p a t ie n t s
RA p a t ie n t G e n o ty p e p - v a l u e
C h a ra c te r is t ic s
LL SL SS
N 122 8 ' 22
RF p os i t iv i ty 86 (70%) 63 (78%) 19 (86%) 0.21
DA S 28  b a s e l in e 5.2 (1.6) 5 . '  (1.1) 4.9 (1.3) 0.68
A v e r a g e  DA S 28  y e a r  0-3 3.9 (1.2) 3.9  ( ' . ' ) 4.1 (0.9) 0.60
A v e r a g e  DA S 28  y e a r  3 -6 3.6 (1.3) 3.5  ( ' . ' ) 3.5 (0.5) 0.69
A v e r a g e  DA S 28  y e a r  6 -9 3.6 (1.3) 3.6  ( ' . ' ) 3.5 (0.9) 0 .84
C R P  b a s e l in e  (m g /L ) 5 (0-22) 3 (C-21) 3 (0-20) 0.90
A v e r a g e  C R P  y e a r  0 -3 5 (1-15) 5 (C-21) 6 (1-11) 0.93
A v e r a g e  C R P  y e a r  3 -6 4 (0-12) 3 (C-13) 5 (1-12) 0.67
A v e r a g e  C R P  y e a r  6 -9 3 (0-8) 2 (C-8) 5 (1-12) 0.49
X - r a y  s c o r e  > 0 b a s e l i n e 48 (40%) 33 (44%) 8 (40%) 0 .84
X - r a y  s c o r e  b a s e l in e 0 (0-2) C (C-2) 0 (0-1) 0.75
D iffe re n c e s  in  Y e a r  0 - 3  (n =2 2 5 ) Y e a r  0 - 6  (n=154) Y e a r  0 - 9  (n =1 17)
ini titju iiii  u a iiic iy c
p ro g re s s io n  E s t im a te  SE p - v a l u e E s t i m a te  SE p - v a lu e E s t im a te SE p - v a l u e
G e n o t y p e  L L  4.4 2 .4  0 .26 6 .5  4.2 0 .3 6 12.1 5.9 0 .0 4 7
SL  2.9 2 .4  0 .88 3 .3  4.3 0 .8 6 8.2 6.1 0 .3 9
SS*  c - -  - - C - - - - C - - - -
C o n s t a n t  C.1 2.6 0.065 C 4.6 0 .066 -2 .2 6.6 0.27
A l l e l e  L 2.2 1.1 0 .078 3 .5  1.8 0 .1 6 5.9 2.7 0 .0 1 3
S*  C - -  - - C - - - - 0 - - - -
C o n s t a n t  2.C 1.4 0.0001 2.2 2.4 0.0001 3.1 3.6 0 .0023
V a lu e s  a re  n u m b e r  (%), m e a n  (SD) o r  m e d ia n  (P 25-P75) .  P - v a lu e s  a re  f r o m  u n iv a r i a t e  p a r a m e t r i c  o r  n o n -  
p a r a m e t r i c  a n a ly s e s ,  as a p p r o p r i a te
SS is t h e  r e f e r e n c e  c a te g o r y  f o r  g e n o t y p e  a n a ly s i s  a n d  S is t h e  re f e r e n c e  c a te g o r y  f o r  a l l e le  a na ly s is .  The 
d i f f e r e n c e s  b e t w e e n  L L  a n d  SS, and  SL  a nd  SS (g e n o ty p e  ana ly s is )  a nd  b e t w e e n  L a n d  S (a l l e le  ana ly s is )  
a re  p r i n t e d  bo ld  a n d  t h e s e  a re  t h e  d i f f e r e n c e s  to be in t e r p re t e d .  B o th  g e n o t y p e  a n d  a l l e le  a n a ly s e s  are 
c o r r e c t e d  fo r  r h e u m a t o i d  f a c t o r  pos i t iv i t y ,  m e a n  DAS28,  b a s e l in e  j o in t  d a m a g e  a n d  age  at b a s e l i n e .  P- 
v a l u e s  a re  f o r  r o o t - t r a n s f o r m e d  p ro g re s s io n  sc o re s .




























A  > S e v e r i t y  of  j o in t  d a m a g e  
p r o g r e s s io n  (X - ra y  sco re ) in 
t i m e  w i t h i n  t h e  RA  p a t ie n t  
c o h o r t  f o r  t h e  d i f f e r e n t i a l  p r e s ­
e n c e  o f  H M O X '  g e n o t y p e s
y e a r s
1 4 0 ^  
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B > A  b o x p lo t  of  t h e  X - ra y  
s c o r e s  d e m o n s t r a t e s  in m o r e  
d e t a i l  t h e  d i s t r i b u t i o n  o f  t h e  d i f ­
f e r e n t  g e n o t y p e s  at y e a r  9. The 
t w o  ope n  c i r c l e s  d e p ic t  o u t l i e r s  
a n d  w e r e  o n ly  p re s e n t  w i t h i n  t h e  
S L - g e n o t y p e .  N o te :  A l t h o u g h  
c r o s s - s e c t i o n a l l y  o n ly  s t a t i s t i ­
c a l l y  s i g n i f i c a n t  c h a n g e s  w e re  
f o u n d  b e t w e e n  S S -g e n o t y p e  a nc  
S L -  o r  L L - g e n o t y p e  a f t e r  n ine  
y e a r s  (P=0 .047 ),  p a t i e n t s  w i t h  
an S S - g e n o t y p e  had  le ss  j o in t  
d a m a g e  d u r i n g  t h e  d i s e a s e  in 
l o n g i t u d i n a l  a n a ly s i s  (P=0.022).
5
0 3 6 9
> DISCUSSION
In th is  s tud y  the (GT)n - re p e a t  leng th  in the  p ro m o te r  reg ion of the h u m a n  
HMOX1 gene w as  found to m o d u la te  RA d isease s u s ce p t ib i l i t y  and j o in t  dam age ,  bu t not 
d isease activity. The d is t r ib u t io n  of genotype and a l le le  f re que ncy  and the odds ra t ios  
c o r respo nde d  w e l l  w i th  p rev ious ly  pub l ished  obse rva t io ns  in a Span ish  c o h o r t  (119), 
s t re n g th e n in g  the resu lts .
S ta t is t ica l  ana lys is  d e m o n s t ra te d  tha t  w i th in  the pa t ien t  cohort ,  sub je c ts  w i th  
the S S-genotype had s ign i f ica n t ly  less jo in t  da m a g e  p rog ress ion  a f te r  nine yea rs  of 
f o l lo w -u p  as c o m pare d  to pa t ien ts  w i th  the LL -geno type .  S ince the m e an  d isease ac t iv ­
ity over t im e  w as  not d i f fe ren t  be tween the  d iverse genotypes, it appeared  tha t  pa t ien ts  
ho m ozygo us  fo r  the S -a l le le  tended to be b e t te r  p ro tec ted  aga ins t  jo in t  da m age  than 
pa t ien ts  w i th  an S L- o r  LL -geno type .  These d i f fe rences  w e re  s ig n i f ica n t  acco rd ing  to 
the lo n g i tu d in a l  reg ress ion  on the co m p le te  m o n i to re d  cou rse  of the d isease up to 9 
yea rs  (P=0.022). A lso a l le le  ana lys is  s ho w e d  s ign i f ica n t ly  less jo in t  da m age  progress ion  
a f te r  3 and 9 yea rs  fo r  the S -a l le le  w h e n  c om pare d  to the L -a l le le ,  s u p p o r t in g  o u r  hy­
po thes is  th a t  the S S-genotype is p ro tec t ive  in pa t ien ts  w i th  RA. D i f fe rences  in t re a tm e n t  
did no t exp la in  the resu l ts .
Our f ind in gs  are in l ine w i th  prev ious re p o r ts  d e m o n s t ra t in g  tha t  HMOX-act iv ity  
p ro tec ts  aga ins t  a w ide  range  of  in ju r io u s  in su l ts  (154). S tud ies  by o u r  g roup  have 
sh o w n  th a t  HMOX-act iv i ty  decreases  in f la m m a to ry  adhes ion  m o le c u le s  and leukocyte  
in f i l t ra t io n  (154). Moreover,  Kobayashi e t al. d e m o n s t ra te d  tha t  HMOX1 is expressed in 
RA synov ia l t issue s  and a t te n u a te s  in f la m m a t io n  (202). In synov ia l ce l ls  it w a s  found 
th a t  HMOX1 indu c t ion  inh ib i ted  the  p roduc t io n  of in f la m m a to ry  cy tok ines, w h e re a s  in ­
h ib i t ion  of HMOX1 us ing RNAi enhanced  th is  exp ress ion  (202). In teres t ing ly ,  RA pa t ien ts  
to w h ic h  h igh levels of the  H M O X -e f fec to r  m o le cu le  b i l i ru b in  w a s  a d m in is te red ,  had 
a t tenua t ion  o r  co m p le te  re so lu t ion  of jo in t  pa in  and sw e l l ing ,  u n d e rs c o r in g  the im p o r ­
tance  of HMOX1 indu c t ion  in p ro tec t ing  aga ins t  the in f la m m a to ry ,  and oxidative injury. 
O the r  s tud ies  us ing a n im a l  m o d e ls  of a r th r i t i s  d e m o n s t ra te d  tha t  indu c t ion  of HMOX- 
ac t iv i ty  by cob a l t  p ro to p o rp h y r in  (CoPP) a t tenua ted  in f la m m a to ry  da m age  (208;209| 
In te res t ing ly ,  a lso inh ib i t ion  of HMOX-act iv i ty  by the p h a rm a c o lo g ic a l  in h ib i to r  s tann ic  
p ro to p o rp h y r in  (SnPP) has been reported  to m ed ia te  be ne f ic ia l  e f fec ts  via decreased 
ang ioge nes is  (208).
In te res t ing ly ,  w e  found no d i f fe rences  be tw een the genotype g roups  in te rm s  
of RF posit iv ity, CRP and DAS28 at base l ine, but S S-genotype pa t ien ts  had less jo in t  






















ess of  uncoup l in g  be tw een  d isease act iv i ty  and rad io log ic  j o in t  da m a g e  (210;211). The 
unexpec ted  lack  of e f fec t  on in f la m m a t io n  by d i f fe rences  in HMOX1 genotype w a r ­
ra n ts  fu r t h e r  invest iga t ions. However,  fo r  the  p rog ress ion  of  erosive d isease is synovia l 
i n f la m m a t io n  l ike ly  less im p o r ta n t  co m p a re d  to os teoc las togenes is .  In fact,  Zw e r ina  et 
al. d e m o n s t ra te d  tha t  HMOX1 sup p re sse s  o s te oc las to gen es is  both  in v i t ro  and in vivo 
(212), su p p o r t in g  a ro le fo r  HMOX1 in su p p re ss in g  bone eros ion  in RA pa t ients .  It w as  
a lso found tha t  h igh c o n c e n t ra t io n s  of  HMOX1 are p resen t  in synov ia l  t issue  of pa t ien ts  
w i th  RA, espec ia l ly  in the m a c ro p h a g e s  and f ib ro b la s ts  (212). This cou ld  ind ica te  tha t 
ind iv idua ls  w i th  a h igh HMOX1 re spons iveness  b e t te r  s u p p re ss  bone re so rp t io n  than 
ind iv idua ls  w i th  lo w e r  enzyme activity.
Taken toge the r ,  HMOX-1 indu c t ion  o f fe rs  no t on ly  p ro tec t ion  aga ins t  the onset 
of RA (119), bu t a lso p ro tec ts  aga ins t  the p rog ress ion  of jo in t  dam age .  We p ropose tha t 
s ince  pa t ien ts  ca r ry ing  the  s h o r t  G T-repeats  exh ib i t  less p rog ress ion  of jo in t  dam age , 
HMOX-1 indu c t ion  m a y  provide a novel th e ra p e u t ic  and prevent ive ta rge t  in the t r e a t ­
m e n t  of RA.
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Objective. The purpose of th is  study was to assess the effect of a functiona l 
po lym orph ism  (676T>G, M196R) in the Tum or Necrosis Factor Receptor super fam ily 1b 
(TNFSFIb) gene on disease activity, radiologic jo in t damage and response to in flix im ab 
and ada lim um ab therapy in patients w ith  rheum atoid a rth r it is  (RA).
Methods. Two RA patient cohorts were genotyped fo r the 676T>G polym orphism  
(rs1061622) in exon 6 of the TN FSFIb  gene by res tric tion  fragm ent length polym orphism  
analysis. One cohort (n=234) included patients from  the Dutch Rheumatoid A rth ritis  
M onitoring (DREAM) reg is try  w ith  detailed in fo rm ation  on the ir response to anti-TN F 
therapy (in flix im ab and adalim um ab), the o ther concerned patients from  a long -te rm  
observational early inception cohort at ou r center (n=248).
R esults. The 676T>G po lym orph ism  was not associated w ith  anti-TN F response 
a fte r three o r six m onths of therapy. L inear regression analysis showed no s ign ificant 
difference in the progression of rad io logic jo in t damage during the firs t three and six 
years of disease between the three genotype groups (TT, TG and GG). No difference in 
mean disease activity between genotypes was observed a fte r three and six years of 
disease, e ithe r
Conclusion. Despite its dem onstrated functiona lity , the 676T>G  polym orphism  
in the TNFSFIb  gene does not play a m ajor role in e ithe r the response to anti-TN F 































Tumor necrosis factor alpha (TNFa) plays a centra l role in the pathogenesis of rheu­
matoid a rth ritis  (RA). This is confirmed by the beneficial effects observed during treatm ent 
w ith  TNF blocking agents though unfortunately approximately 30% of the patients do not 
respond to these agents (42). Pharmacogenetics has the potential of increasing drug ef­
ficiency by identifying genetic factors responsible for lack of treatm ent response or toxicities 
(213). In the case of TNF blocking agents, variation in genes involved in the mechanisms of 
action of these agents and the pathogenesis of RA have been investigated (42).
The m ost investigated po lym orph ism  in re lation to anti-TN F therapy is the 
-308G>A single nucleotide po lym orph ism  (SNP) in the gene encoding TNFa., showing 
association w ith  anti-TN F therapy response even a fte r m eta-analysis (61). However, it 
is not like ly that the -308G>A SNP alone is responsible fo r anti-TN F response. Other 
in teresting candidate genes include the TNF receptor superfam ily, m em ber 1a encoded 
by TNFRSFIa (TNF-RI, p55) and the TNF receptor superfam ily, m em ber 1b, the prod­
uct of TN FR SFIb (TNF-RII, p75) (45;149-151;214;215). Both TNF receptors can exist 
as m em brane bound or so luble proteins, com pris ing only the ex trace llu la r domains. 
These soluble prote ins are derived from  the m em brane-bound fo rm s by the p ro teo­
lytic actions of a d is in tegrin  m eta llopro te inase called TN Fa-converting enzyme (TACE) 
(150;216). A fte r cleavage, so luble TNF receptors (sTNFRs) retain th e ir  ligand-b ind ing 
capacity and can act as na tura l inh ib ito rs  of TNFa. sTNFRs levels are elevated in the 
serum  and synovial flu id  of RA patients (217;218) but these levels seem s to be insu f­
fic ien t to prevent chronic in flam m ation  prom oted by TNFa (218).
In the TN FRSFIb  gene, m ost stud ies have analyzed a single nucleotide poly­
m orph ism  (SNP) located in exon 6 (rs1061622, 676T>G). This po lym orph ism  causes a 
non-conservative am ino acid substitu tion  (m ethionine (M) to arginine (R)) at codon 196 
(M196R) w ith in  the fourth  cyste ine-rich  domain of the ex trace llu la r dom ain and m ight 
a ffect the binding site  fo r TACE (150). This suggests a d isturbed processing of m em ­
brane-bound TNF-RII by th is  enzyme and m ight affect the levels and function of TNFR 
(150;151;215). sTNFR levels can be im portan t in the response to anti-TN F trea tm ent as 
the receptor acts as an endogenous TNF antagonist (45). Several studies have sug ­
gested that genes involved in response to anti-TN F may also be involved in RA severity 
(53;213). The 676T>G polym orphism  has not been associated w ith  rad io log ica l p rogres­
sion or disease activity in previous studies (149;215). The present study is aimed to test 
w he the r the TN FR SFIb  676T>G po lym orph ism  is associated w ith  anti-TN F response, 
disease activity and /o r radio logic jo in t damage in a large sam ple of RA patients.
> MATERIAL AND METHODS
A ll patients in th is  study fu lfilled  the ACR crite ria  (9), attended the Departm ent of 
Rheumatology of the Radboud University N ijm egen Medical Centre or the St. Maartens 
hosp ita l in N ijm egen and had given in form ed consent.
For the analysis of the response to anti-TN F trea tm ent, DNA of 234 patients 
treated w ith  the m onoclona l antiboedies in flix im ab or ada lim um ab was available from  
the Dutch Rheumatoid A rth rit is  M onitoring (DREAM) reg is try  (w w w .d ream -reg is try .n l) 
(219). This reg is te r encompass patients who s ta rt th e ir  firs t course of a TNF blocking 
agent according to the indication in the N etherlands (DAS28 > 3.2 and fa ilu re  on at least 
two d isease-m odify ing an tirheum atic  drugs (DMARDs), one of w hich has to be m e th ­
otrexate (MTX)). The DAS28 scores at trea tm ent s ta rt and a fte r 3 and 6 m onths were 
used to ca lcu late the c lin ica l response according to the EULAR crite ria  (16).
The cohort used fo r the analysis of disease activity and radiologic jo in t damage 
included 248 RA patients from  a long -te rm  observational early inception cohort (220) 
from  w hom  DNA was available. Patients in th is  cohort have a disease duration <  1 year 
at en ro llm en t and no p rio r use of DMARDs. Radiographs of hands and feet at baseline 
and a fte r 3 and 6 years were scored using the Ratingen m ethod. This is a m odification 
of the Larsen score and evaluates 38 jo in ts  separately. The am ount of surface des truc ­
tion fo r each jo in t is graded from  0 to 5 (m axim um  score 190). Each grade represents 
20% of jo in t surface destruction (205).
Periphera l blood sam ples (10 ml) collected in EDTA tubes were obtained from 
each patient and were stored at -80°C. Genomic DNA was extracted from  leucocytes 
in periphera l venous blood according to standard protocols and res tric tion  fragm ent 
length po lym orph ism  (RFLP) analysis was used to d istingu ish between the 676T and 
676G a lle les as described previously (221).
Hardy-W einberg equ ilib rium  (HWE) was tested in both cohorts using the Chi- 
square test, no deviations from  HWE were observed. To assess the e ffect in anti-TN F 
response, a tw o-ta iled  F isher's exact test was used in com parison between the three 
genotype groups and the EULAR response crite ria  in a 3 x 3 table. For analysis at the 
level of alleles, the F isher's exact test was used, using the two a lle les and the EULAR 
response c rite ria  in a 2 x 3 table. L inear regression m odelling  was used to test w hether 
a po lym orph ism  genotype o r a lle lotype was associated w ith  the course of jo in t damage. 































Clinical response to anti-TNF treatm ent
Table 1 shows patients' characteristics, anti-TNF therapy distribution, mean disease 
activity (DAS28) at baseline and DAS28 improvement after 3 (n=234) and 6 (n=207) months of 
treatm ent according to the three categories of the EULAR response criteria (good, moderate 
or no response). Table 2 shows the genotype and allelotype distribution for the three catego­
ries after 3 and 6 m onths of treatm ent. There was no association between genotypes and 
anti-TNF therapy response after 3 (p=0.22) and 6 (p=0.79) m onths in th is sample. Although 
the TG group was s lightly overrepresented in the moderate responder group compared to 
the homozygotes after 3 months of therapy, this did not reach statistical significance. Also in 
the analysis at the allele level no differences in anti-TNF response between the two alleles 
were observed after 3 (p=0.5) and 6 (p=0.9) months. Moreover, there was no association 
between the genotypes and the decrease in DAS28 a fte r 3 (p=0.4) and 6 (p=0.1) months.
Tab le 1 /  B ase l ine  charac ter is t ics ,  disease activi ty and DAS28 im provem ent  fo r the DREAM coho rt 
according  to the EULAR response cri ter ia
Good Moderate Non-
response response response
N (basel ine and 3 m on ths  fol low-up) 54 (23%) 115 (49%) 65 (28%)
Female gender 37 (69%) 76 (66%) 45 (69%)
Age (mean ± SD) 54 (11.6) 56 (12.1) 59 (12.2)
RF posit ivi ty 43 (83%) 92 (81%) 60 (87%)
Inf l ix imab 40 (74%) 73 (63%) 44 (68%)
A d a lim um ab 14 (26%) 42 (37%) 21 (32%)
DAS28 base l ine (mean ± SD) 5.1 (1.0) 6.0 (1.1) 5.6 (1.3)
DAS28 decrease a fte r  3 m onths  of an t i-TNF therapy (mean ± SD) 2.1 (0.9) 1.8 (0.8) 0.1 (0.8)
N ( 6 m on ths  fo l low-up) 51 (25%) 96 (46%) 60 (29%)
DAS28 decrease a fte r  6 m onths  of an t i-TNF therapy (mean ± SD) 2.7 (1.0) 2.0 (1.0) 0.0 (0.8)
Base l ine  cha rac ter is t ics ,  mean DAS28 at base l ine and DAS28 im provem ent  a fte r  3 and 6 m on ths  of anti-  
TN F therapy are indicated. Resul ts  are n u m b e r  (percentage) o r  mean (SD). Percen tages are expressed ir  
re lat ion to the to ta l n u m b e r  of pa tients for each response group except fo r the to ta l n u m b e r  of pat ients
Table 2 /  676T>G genotype and al lele dist r ibu t ion  according  to the EULAR response cr i ter ia  for  the 
DREAM regist ry
Good response M odera te  response N o n-re sp o n se
Response a f te r  3 m on ths  (n=234l
Genotype
TT 30 (56%) 54 (47%) 38 (58%)
TG 18 (33%) 55 (48%) 23 (36%)
GG 6 (11%) 6 (5%) 4 (6%)
A l le le
T 78 (72%) 163 (71%) 99 (76%)
G 30 (28%) 67 (29%) 31 (24%)
Response a f te r  6 m on ths  (n=207l
Genotype
TT 27 (53%) 49 (51%) 32 (54%)
TG 19 (37%) 43 (45%) 23 (38%)
GG 5 (10%) 4 (4%) 5 (8%)
A l le le
T 73 (72%) 141 (73%) 87 (73%)
G 29 (28%) 51 (27%) 33 (27%)
Genotype and al lele di s tr ibu t ion  a fte r 3 and 6 m on ths  of an t i-TN F  therapy are indicated. Pe rcen tages are 
expressed in re lat ion to the to ta l n u m b e r  of pat ients  fo r each response group
Disease activity and radiologic joint damage
Table 3 shows the main cha racte ris tics  of the patients from  the early inception 
cohort according to genotype, as w e ll as mean disease activity and jo in t damage at 
baseline, and three and six years later. There were no s ta tis tica lly  s ign ifican t d ifferences 
between genotype groups w ith  regard to baseline cha racte ris tics  o r disease activity 
at a ll three tim e points. L inear regression analysis shows a s ign ifican t difference in 
progression of jo in t damage between the three genotype groups during the 3-years 
fo llow -up  (p=0.02, Table 3) w hich lost sign ificance a fte r correction fo r m u ltip le  testing 
(corrected p value fo r 3 tests; p=0.06). D ifferences between the three groups were not 






























Table 3 /  Basel ine character ist ics,  disease activi ty and joint damage over t im e  for the Early Inception Cohort
C harac te ris tics Genotype P-va lue
TT TG GG
N (basel ine and year  3 fo l low-up) 143 (58%) 87 (35%) 18 (7%) -
Female gender 93 (65%) 56 (64%) 10 (55%) NS
Age (mean ± SD) 55 (12) 52 (15) 48 (10) NS
RF posit ivi ty at basel ine 110 (77%) 63 (72%) 13 (72%) NS
DAS28 base l ine 0-3 (mean ± SD) 5.3 (1.3) 5.0 (1.5) 5.5 (1.7) NS
DAS28 mean year  0-3 (mean ± SD) 4.0 (1.1) 3.9 (1.2) 4.1 (0.9) NS
DAS28 mean year  0-6 (mean ± SD) 3.9 (1.1) 3.9 (1.1) 4.0 (1.0) NS
Jo in t dam age at base l ine (mean + range) 0 (0-3) 1 (0-3) 4 (0-14) NS
Jo in t dam age progression after 3 years (mean + range) 4 (0-14) 7 (1-15) 13 (3-20) 0.02*
N (year 6 fo l low-up) 99 (58%) 57 (33%) 16 (9%) -
Jo in t dam age progression after 6 years (mean + range) 12 (1-25) 12 (5-22) 15 (2-27) NS
NS: not s ignif icant . Resul ts  are n u m b e r  (perce ntage) or  mean (SD). Pe rcen tages are expressed ir reLatior
to the to ta l n u m b e r  of pat ients for  each genotype group. Jo in t dam age is according to the Ratingen score 
at basel ine, year  3 and year  6 (mean and range). P-va lues  of r o o t - t ra ns fo rm ed  sco res at base l ine and root- 
tr a n s fo rm e d  progress ion ra tes between 0-3 and 0-6 years, cor rected  for base l ine Ratingen score, age, 
gender, RF posit ivi ty and mean DAS28 are shown
*Ana lys is  at year  3 showed that  the contrast  between TT and GG w as  sta t i s t i ca l l y  s ig ni f ican t (p=0.01), the 
TT and TG cont ras t  (p=0.09) and the TG and GG cont rast  (p=0.12) we re  not. The p-values  fo r the unco r ­
rected m ode ls  were  s l i gh t ly  less sign if icant , but did not lead to o the r  conc lus ions
> DISCUSSION
In the present study we set out to c larify the relation between the 676T>G (M196R) 
polym orphism  in the TNFRSFIb  gene and response to anti-TNF treatm ent, disease activ­
ity and progression in RA. We could not replicate the previously reported association be­
tween the TNFRSFIb  676T>G SNP and response to anti-TNF treatm ent (45). Furtherm ore, 
we were unable to detect an association w ith  disease severity. We found nom inal associa­
tion between the polym orphism  and radiologic jo in t damage progression w ith in  the firs t 
three years but not a fter 6 years of disease course. The association after the 3-years time 
point was lost upon correction for m ultip le  testing. This lack of association is supported 
by other large studies w ith  disease fo llow -up varying between 1 and 4 years (149;215). 
Constatin and co-w orkers reported association between the 676T>G polym orphism  and 
functiona l but not s truc tu ra l severity in patients w ith early RA (215). Polym orphism s in 
TNFR genes are ideal candidate genes for disease severity in RA, as the receptors m edi­
ate the actions of TNFa. The 676T>G polym orphism  has been pointed out as a m arker for 
anti-TNF response in an ea rlie r study (45). Fabris and co-w orkers reported a threefold 
higher chance of responding to anti-TNF therapy in the TT group w ith respect to the TG/ 
GG group using a cohort of 66 patients receiving in flix im ab (n=47) or etanercept (n=19]
(45). We could not confirm  th is finding in a large (n=234) and w e ll characterized cohort of 
patients treated w ith  monoclonal anti-TNF antibodies. This also m ight be due to e thn ica l­
ly differences between the two investigated cohorts. Although both cohorts were Cauca­
sian, Fabris and co-w orkers investigated Italian Caucasians whereas our cohort consisted 
of Dutch Caucasians. Thereby, it is known that sm a ll sample sizes can lead to spurious 
findings (222). Another reason for not confirm ing the results of Fabris et al. m ight be the 
fact that we did not include patients receiving etanercept whereas Fabris and co-w orkers 
did. We focused on patients treated w ith  anti-TNF m onoclonal antibodies (inflix im ab and 
adalimumab), as these probably have s im ila r working m echanism s (223). Differences in 
pharm acokinetics between m onoclonal antibodies and the soluble receptor (etanercept) 
may exist. Therefore, it is possible that the 676T>G polym orphism  is associated with 
response to etanercept but not w ith  response to in flix im ab and adalim um ab. It would be 
interesting to investigate th is hypothesis in the near future. Thereby, it is unlikely that one 
independent polym orphism  is responsible for anti-TNF response. Chatzikyriakidou and 
co-w orkers suggested that a combined study of polym orphism s 676T>G (TNFRSFIb  and 
-857C>T (TNFA) could predict anti-TNF response in patients w ith RA (43). In conclusion, 
despite its potentia l functionality, the TNFRSFIb  676T>G polym orphism  probably does not 
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Aim  of the  study. To investigate w he the r the -30 8 G > A  p rom oter po lym orphism  
in the tu m o r necrosis facto r alpha (TNFA) gene is associated w ith  disease severity in 
patients w ith  rheum atoid a rth r it is  (RA).
Methods. A long -te rm , observational, early RA inception cohort (n=208) w ith 
detailed in fo rm ation  about disease severity and radio log ic damage a fte r 3, 6 and 9 years 
of disease was genotyped fo r the TNFA -308G>A prom ote r po lym orph ism  (rs1800629) 
using a TaqMan SNP genotyping assay. To learn more about the m echanism  behind the 
e ffect of the polym orphism , RNA isolated from  periphera l blood of 66 RA patients was 
used fo r TNFA gene expression analysis by quantita tive PCR.
R esults. To our knowledge, th is  report describes the effects of the TNFA 
-308G>A prom oter po lym orph ism  in one of la rgest sam ples of patients w ith  RA.
A long itud ina l regression analysis showed a s ign ifican t d ifference between GG 
and GA+AA groups in jo in t damage (p=0.002). No sign ifican t d ifferences in TNFA gene 
expression were observed for the d iffe ren t genotypes.
Conclusion. Our data con firm  that the TNFA -308G>A prom oter polym orphism  is 
associated w ith  radiologic jo in t damage in patients w ith  RA. This does not seem to be 



















Tum or-necrosis  facto r (TNF) plays a key role in the pathogenesis of rheum atoid 
a rth r it is  (RA) and o ther au to-im m une diseases (20). Several genetic variants in the 
TNFA gene, w h ich codes fo r TNFa, have been investigated in re lation to disease suscep­
tib ility  and severity (74;75;77;80;83;84) but none of them  appears to be highly specific 
and /o r sensitive. The m ost thoroughly investigated TNFA po lym orphism  is the -308G>A 
(rs1800629) po lym orph ism  located in the prom oter of the gene (74-85) s tudies focusing 
on th is  po lym orph ism s have yielded conflic ting  resu lts  (74;75;77-80;82-85). Concerning 
the association of th is  polyporphism  w ith  radiologic jo in t damage two stud ies (82;83] 
perform ed in, 34 and 130 RA patients, respectively, showed an association of the G 
alle le  w ith  a more pronounced radiologic jo in t damage, though they did not provide 
in fo rm ation  concerning radio logic jo in t damage progression. Another study reported a 
w orse radiologic jo in t damage in patients carrying the A alle le  in a cohort of 189 RA pa­
tien ts (77). F inally in a la rge r sam ple of 283 patients B rinkm an e t al. could not confirm  
any association between e ithe r the G o r A alle le  and radio logic jo in t damage (75).
As the -308G>A varian t is located w ith in  the TNFA prom oter, several studies 
have also investigated the po lym orph ism  in relation to TNFA transcrip tion  w hich could 
in fluence TNFa production and in tu rn  disease activity and severity (86-88). Five studies, 
(224-228), suggested that the A alle le is associated w ith  an increased TNFA tra n sc r ip ­
tion whereas three o ther studies, (229-231), did not. Another im portan t study by Knight 
e t a l., using the haploChIP m ethod fo r h igh -th roughpu t screening of com m on DNA po l­
ym orph ism s that (m ight) effect gene regulation in vivo, also reported that the -308G>A 
po lym orph ism  was not associated w ith  TNFA expression in human B -ce lls  (232). S im ila r 
conflic ting  resu lts  have been reported for the re lation of the -308G>A polym orphism  
and in v itro  TNFa protein production in cu ltured whole blood ce lls  o r periphera l blood 
m ononuclear ce lls  (PBMCs) (86;161;233-239).
In o rder to c la rify  these con trad ic to ry results, we investigated the possible asso­
cia tions of the -308G>A p rom oter po lym orph ism  w ith  TNFA expression and w ith  disease 
activity, rad io log ic jo in t damage a fte r 3, 6 and 9 years fo llow -up  in a large (n=208), w e ll 
characterized early RA patient cohort (240).
> MATERIAL AND METHODS
Patients
AH patients in th is  study fu lfilled  the Am erican College of Rheumatology (ACR) 
c rite ria  fo r RA (9), had given in form ed consent and attended the Departm ent of Rheu­
m atology of the Radboud University N ijm egen Medical Centre o r the St. M aartenshospi- 
ta l in N ijmegen, The Netherlands. The study was approved by the local eth ics c o m m it­
tee. The im pact of the TNFA -308G>A po lym orph ism s on disease severity was analyzed 
using DNA isolated from  blood of 208 patients from  a long -te rm  observational early RA 
inception cohort (220). Patients in th is  cohort have a disease duration <1 year at e n ro ll­
m ent and no p rio r use of DMARDs. Disease severity was assessed using the disease 
activity score (DAS28) (15) at each patient visit. For th is  study we used the 3, 6 and 9 
years averaged DAS. Radiologic jo in t damage at baseline and a fte r 3, 6 and 9 years of 
disease duration was measured using radiographs of hands and feet, read in chrono­
logica l o rder according to the Ratingen score. The la tte r is a validated m odifica tion  of 
the Larsen score and evaluates jo in t surface destruction, graded from  0 to 5, in 38 hand 
and feet jo in ts , separate ly (range 0 -  190) (205).
TNFA expression analysis was assessed in RNA from  blood of a subset of 66 
patients w ith  active RA as defined by a DAS28 of >3.2. A ll patients visited the same 
hosp ita l and blood fo r RNA iso lation was always collected between 9 and 10 o 'c lock in 
the m orn ing to avoid potentia l circadian fluctuations.
Molecular analysis
A ll DNA and RNA analyses were perform ed in a CCKL (Coördinatie Commissie 
te r bevordering van de Kwalite itsbeheersing van het Laboratorium onderzoek) -ac ­
credited laboratory at the departm ent of Human Genetics at the Radboud University 


















Genotyping of the -308G>A TNFA polymorphism
Genomic DNA was extracted from  periphera l venous blood (10 m l/sam ple) ac­
cording to standard protocols (206). Both patients cohorts, thus a to ta l of 274 patients 
were genotyped fo r the -308G>A (rs1800629) p rom oter polym orphism  using a TaqMan 
SNP genotyping assay (ID. C7514879_10) on the 7500 Fast Real-Tim e PCR system 
(Applied Biosystems, Foster City, CA, USA). Results were analyzed using the A lle lic  
D iscrim ination  software version 1.4 (Applied Biosystems).
RNA isolation, synthesis of cDNA and quantitative PCR
RNA was isolated from  whole blood w ith in  0.5 hours a fte r co llection, using 
the RNeasy m idi k it (Qiagen Benelux B.V. Venlo, The Netherlands). The qua lity  and 
quantity of the purified RNA was checked on a NanoDrop spectrophotom eter (Nano­
drop technologies, Montchanin, DE, USA). Degradation of RNA was contro lled  fo r by 
agarose gel e lectrophoresis. Per sam ple 1 pg of to ta l RNA was reverse-transcribed 
using 200 ng random  hexanucleotides (Invitrogen, Breda, The N etherlands) and 200 
un its of M-MLV Reverse Transcriptase (Invitrogen). For quantita tive expression analysis 
a predesigned and validated gene-specific  probe-based TaqMan gene expression 
assay (ID: Hs00174128_m1) was used according to the protocol of the m anufactu re r 
(Applied Biosystems). Samples were run on the 7500 Fast Real-Time PCR System 
(Applied Biosystems) using standard protocol. The genera l housekeeping gene B2M  
(B e ta -2 -m icrog lobu lin , TaqMan gene expression assay ID: Hs99999907_m1) was used 
as endogenous contro l. Threshold cycle num bers (referred to as Ct) were obtained us­
ing the 7500 System SDS softw are version 1.4 (Applied Biosystems). A ll sam ples were 
measured twice, duplicate sam ples w ith  a standard deviation (SD) la rge r than 0.5 were 
excluded from  the analysis. The relative quantity (RQ) of the gene-specific mRNA was 
calculated from  the average value of the ACt ((TNFA Ct) -  (endogenous con tro l gene 
Ct)). D ifferences in expression between two groups of sam ples were calculated by the 
2AACt method (241).
Statistical analysis
Hardy-W einberg equ ilib rium  (HWE) was tested in both patient sam ples using the 
C hi-square test. Baseline d ifferences between genotype groups were analyzed using a 
ch i-square test, a S tudent T -test or a Wilcoxon test, as appropriate. Longitud ina l analy­
sis of radiologic jo in t damage was done using generalized linear regression m odels 
w ith  random  coeffic ients (mixed models). The jo in t damage score was the dependent 
variable, genotype the independent variable, under addition of tim e, tim e squared, and 
confounders. As the d is tribu tion  of jo in t damage scores is skewed, the analysis was 
also perform ed using a square-roo t transfo rm a tion  of the jo in t damage scores. Regres­
sion assum ptions were checked by evaluating the d is tribu tion  of residua ls and by a plot 
of observed and predicted jo in t damage scores. Mean d ifferences in TNFA expression 
(ACt; (TNFA Ct) -  (endogenous con tro l gene Ct)) were analysed using the independent 
Student's T-test. A p-value of <0.05 was considered s ta tis tica lly  s ign ifican t in each s itu ­
ation. Analyses were perform ed using SPSS fo r W indows, version 14.0 (SPSS, Chicago, 



















Relation of TNFA -308G>A with disease activity and radiologic joint damage
The frequency of the A alle le  of the TNFA -308G>A po lym orph ism  in the incep­
tion cohort partic ipan ts was 18.3%, genotype frequencies were 66.3% for the GG group, 
30.8% for the GA group and 2.9% fo r the AA group. Due to the sm a ll AA genotype group, 
the GA and AA genotype groups were merged and analyzed as one group. Demographic 
and disease cha racte ris tics  were s im ila r in the GG and GA+AA genotype groups at 
baseline (Table 1). No s ign ifican t d ifferences in disease activity were observed between 
genotype groups.
Tab le 1 /  D em ograph ics  incept ion coho rt (N=208)
n GG |n=138] GA+AA (n=64+6] P-va lue
Age 52 (13) 50 (13) 0.21
Female gender 89 (64%) 50 (71%) 0.32
RF posit ivi ty 105 (76%) 55 (79%) 0.69
DAS28, mean (SD)
Basel ine 208 5.2 (1.4) 5.3 (1.3) 0.38
3 year  average 208 4.0 (1.1) 3.9 (1.0) 0.85
6 year  average 159 4.0 (1.0) 3.7 (1.0) 0.10
9 year  average 115 4.0 (1.0) 3.7 (1.0) 0.12
Pa tients  w i th  eros ions  at basel ine, nr  (%) 208 76 (55%) 44 (63%) 0.28
Ratingen score, med ian (range)*
Basel ine 208 0 (0-2) 0 (0-2) 0.17
At 3 years 208 7 (0-15) 4 (0-10) 0.08
At 6 years 160 12 (2-26) 10 (1-21) 0.18
At 9 years 116 22 (10-38) 14 (3-24) 0.07
Resul ts  are mean (SD), n u m b e r  (percentage), o r  med ian (range). Pe rcen tages are expressed in re lat ion tc 
the  to ta l n u m b e r  of pat ients fo r each genotype group. *B e tw e en -g rou p  dif ferences in erosion score were 
tested using Wilcoxons' test.
In a long itud ina l regression analysis (mixed model) w ith  radiologic jo in t damage 
score as the dependent variable, corrected fo r gender and average DAS28, a sign ificant 
difference between GG and GA+AA groups in progression of jo in t damage was observed 
(p=0.002), w ith  more pronounced jo in t damage in patients w ith  the GG genotype (Table 
2 and Figure 1). However, the progression of jo in t damage over nine year fo llow -up  was 
s im ila r  in both genotypes (p=0.61). A fte r confounder correction for gender and DAS28 in 
the regression model, a correction fo r rheum atoid facto r and age was unnecessary.
Table 2 /  Long itud in a l regress ion of jo in t damage and TNFA. -308G>A genotype (N=208)
Effect Est im ate SE (es t im a te ] P-va lue
Intercept 5.8 1.18 <0.0001
Genotype GA+AA -5.0 1.62 0.0020
Year 1.6 0.38 <0.0001
Year2 -0.13 0.020 <0.0001
Genotype GA+AA* Year 0.17 0.34 0.61
Male gender -1.18 0.79 0.14
Averaged DAS28 -0.59 0.20 0.0039
Averaged DAS28 * year 0.34 0.063 <0.0001
Genotype GA+AA * Averaged DAS28 0.77 0.30 0.0094
Shown are the variables in the long itud inal  regression analysis over 9 years, w ith  joint  erosion score as the 
dependent  variable and TNFA -308G>A and TNFA -308G>A * Year as dependent  var iab les of main interest 
Gender and t ime-ave raged DAS28 of the previous period between two rad iographs we re  confounders, rheu ­
mato id factor  and age were  not. Year2 al lows for a non -l inea r  course of jo int progression score over t ime.
Using a square-roo t transfo rm ation  of the jo in t erosion score as the depend­
ent variable to m in im ize potentia l e ffects of skewing showed s im ila r  results, w ith  a 
s ign ifican tly  more jo in t damage in the GG group (p=0.0031), but no s ign ifican t d iffe r­
ence (p=0.34) in radiologic progression between the groups. Also the o ther m odels to 
study the influence of the skewed score d is tribu tion  of the Ratingen scale confirm ed 
the assum ptions made fo r the regression m odel used: The residuals of the regres­
sion analysis w ith  the un transform ed skewed jo in t damage score showed a Gaussian 

















m odel plotted against the actually observed jo in t erosion scores showed a high degree 
of linear corre la tion. Since the d ifferences in radio logic damage could not be explained 
by d ifferences in disease activity, we also assessed potentia l d ifferences in the use of 
TNF and IL-1 blocking agents genotype groups. These agents can uncouple disease 
activity and jo in t damage (242). The num ber of patients w ith  past or present trea tm ent 
w ith  TNF and /o r IL-1 b locking agents was genera lly  low and s im ila r in both genotype 















TNFA expression, role of the -308G>A promoter polymorphism
To assess w he ther the difference in radiologic damage between G homozygotes 
and A alle le  carrie rs, could be explained at the level of expression of th is p ro -in fla m m a ­
tory cytokine, we m easured the RNA expression levels of TNFA dependent on -308G>A 
genotype in a sam ple of 66 patients w ith  active RA. Again, the GA and AA genotypes 
were merged and analyzed as one group. No differences in TNFA expression was ob­
served between the GG group when compared to the GA+AA group (p=0.420).
F igure  2 /  Predicted erosion scores ve rsus observed erosion scores (N=280)
Erosion score (predicted)
Erosion scores tha t  are predicted by the m ode l in Table 2 are plotted aga inst the observed eros ion scores 



















Based on e a rlie r lite ra tu re , we tested the hypothesis tha t disease severity, de ­
fined by average DAS28 and rad io log ic  jo in t damage, may be in fluenced by the TNFA 
-308G>A genotype. We were able to show  tha t the GG genotype w as associated w ith  a 
w orse rad io log ic  outcom e than the GA + AA group though the rad io log ic  progression 
ove r tim e  was not d iffe ren t between the two genotypes. This association between the 
GG genotype and w orse rad io log ic  jo in t damage could not be explained by d ifferences 
in e ith e r disease activity, levels of TNF expression o r b io log ica l therap ies. Though 
m any s tud ies show  tha t pe rs is ten t disease activ ity  in pa tien ts w ith  RA w ill resu lt in 
w orse rad io log ic  outcom e, o th e r data support an uncoup ling  between disease ac tiv ­
ity and rad io log ic  jo in t damage (21 0 ;211 ;243). The course of the disease activ ity  and 
rad io log ic  progression observed during  the lo n g -te rm  fo llo w -up  in ou r study re flec ts  
daily p ractice  and is s im ila r  to o the r lo n g -te rm  observa tiona l s tud ies  in o the r cohorts  
(13;49;244). N onethe less th is  is fa r from  the present ideas of tig h t and adequate 
disease con tro l (11). Our resu lts  cannot pred ic t w h e th e r the la tte r, can overru le  the 
im pact of th is  and o the r genetic factors.
Several o ther stud ies investigated the -308G>A prom ote r po lym orph ism  and 
its (possible) re lationsh ip  w ith  jo in t damage progression (74;75;77-80;82-85;226), but 
resu lts  are inconsistent. Reasons fo r the con trad ic to ry resu lts  could be d ifferences in 
study design, mean duration of RA, sam ple size and ethnicity. W ith regard to sample 
size, given the genera lly sm a ll effect sizes observed in m u ltifa c to ria l d isorders, this 
facto r is expected to have a large im pact on study resu lts. A m eta-analysis could help 
to c la rify  these contradictive resu lts  whenever s im ila r  disease activity scores and jo in t 
damage scoring m ethods would be used throughout the studies.
Our study shows that the effect of the -308G>A varian t on radiologic jo in t dam ­
age is not explained by d ifferences in a lle le-dependent expression. Many o ther studies 
have investigated alle le  specific expression of the TNFA gene and TNFa production but 
also here resu lts  are inconclusive (229-231;235-239). Again d ifferences in sam ple size, 
power, study design and e thnic ity  m ight be of influence in these discrepancies. Linkage 
d isequ ilib rium  (LD) may be an overa ll facto r w hich can (partly) explain d ifferences in 
results, if we assume that the -308G>A varian t is not functiona l, itself. In fact, LD is 
strong in th is  area of the genome and it is d ifficu lt to study the role of an SNP located 
there in iso lation. The TNFA -308A alle le  is known to be in strong LD w ith  the shared 
epitope (SE) (180). Unfortunate ly, the patients are not genotyped fo r the SE. Therefore 
we could not s tra tify  the patients according to the ir SE genotype. However, the resu lts
of the study of Khanna and co -w orkers indicate an e ffect of the -308G>A polym orphism  
on jo in t damage progression independent of the SE (77).
To conclude, we showed an association of the TNFA -308GG genotype w ith 
increased jo in t damage but no relation w ith  radio log ic progression o r TNF expression. 
The effect of th is  po lym orph ism is probably m odest and the su itab ility  of the po lym or­
phism  as a m arke r fo r disease severity is questionable. We conclude that testing for 
th is  polym orphism  alone is not cost effective.
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Objective. There is a need fo r b iom arkers that are able to predict a n ti-tu m o u r 
necrosis factor (anti-TNF) trea tm ent outcom e in patients w ith  rheum atoid a rth r it is  
(RA). Several studies have suggested that the rare A alle le  of the tu m o u r necrosis factor 
alpha (TNFA) -308G>A po lym orph ism  could be associated w ith  a poorer response to 
anti-TN F therapy. Nevertheless, these resu lts  rem ain controversia l. We perform ed a 
m eta-analysis to determ ine w he ther the TNFA -308G>A po lym orph ism  is associated 
w ith  response to anti-TN F trea tm ent in patients w ith  RA .
Methods. A b ib liograph ic search identified stud ies in w hich the TNFA -308G>A 
gene po lym orph ism  was investigated in RA patients treated w ith  anti-TN F agents. 
C om plem entary data were requested when the DAS28 was not used as the prim ary 
outcom e m easure. Odds ratios (OR) fo r response based on DAS28 and standardized 
mean difference (SMD) fo r mean im provem ent of DAS28 were calcu lated to assess the 
po tentia l association between TNFA -308 genotypes and response to anti-TN F agents.
R esults. The b ib liograph ic search yielded twelve stud ies that m et the inclusion 
crite ria . Those were supplem ented w ith  the data from  a large Dutch cohort (n=426). The 
OR based on twelve stud ies including 1721 patients was 1.24 (95% CI 0.98-1.56) and the 
SMD based on eleven studies includ ing 2576 patients was -0.15 (95% CI -0.38-+0.07). 
Sub-group analysis based on the two classes of anti-TN F agents did not dem onstrate 
any association between TNFA -308 genotypes and anti-TN F trea tm ent outcom e
Conclusion. According to th is m eta-analysis, the TNFA -308 polym orphism  is not 



























Although the pathogenesis of rheum atoid a rth ritis  (RA) is not yet fu lly  understood, 
it is clear that tum our necrosis factor alpha (TNFa) plays a key role in the in flam m atory 
process of this comm on autoim m une-m ediated d isorder (20 ;21). In the last decades, TNF 
has emerged as one of the m ost im portant targets for therapeutic interventions in RA and 
other autoim m une diseases. Three anti-TNF agents are currently used in daily c lin ica l 
practice, etanercept a human, soluble, fusion protein consisting of two p75 TNF recep­
tors linked to an IgG1 Fc part and two m onoclonal antibodies in flix im ab a ch im aeric IgG1 
antibody and the fu lly  humanized IgG1 antibody adalim um ab. A ll three anti-TNF drugs 
bind to TNF w ith  high affin ity leading to inactivation of TNF by preventing binding of TNF 
to its receptor (12;42). Though, TNF neutralization is highly effective and w idely used in 
RA, there is a large heterogeneity in response and approxim ately 30% of patients treated 
w ith  TNF-blocking agents fa il to show clin ica l im provem ent (28). The latter, together w ith 
the potentia l toxicities and the high costs of TNF-blocking agents has driven the search 
for genetic m arkers to predict treatm ent outcome (61 ;66). To date, several variants in 
genes potentia lly involved in the action of anti-TNF therapy and/or in the pathogenesis of 
RA have been analysed (42) but no highly specific and/or sensitive genetic predictors of 
anti-TNF therapy outcome have been identified, yet.
The m ost thorough ly investigated polym orphism  is the -308G>A (rs1800629) 
po lym orph ism  in the p rom oter of the tu m o u r necrosis facto r alpha (TNFA) gene 
w hich codes fo r TNFa (53-55;58-61;245). The relation between the -308G>A prom oter 
po lym orph ism  and anti-TN F response has been investigated by several groups w ith  
inconsistent resu lts  (44;50;52-57;59-63;234;245-247). Two m eta-analyses, perform ed 
by Lee et ai. in 2006 (61) and O Rielly et ai. in 2009 (248), includ ing data of 311 and 692 
patients respectively, suggested that RA patients carrying the rare A alle le had a poor 
response to anti-TN F therapy than those carrying the com m on G alle le. However, these 
m eta-analysis pooled data w ith  varying response crite ria  and curiously, did not include 
stud ies that did not support a s ign ifican t effect of th is  po lym orph ism  on anti-TN F 
response (43;44). Furtherm ore, the m eta-analysis from  O'Reilly e t ai. did not include 
three recently published stud ies accounting fo r 1551 add itiona l RA patients treated w ith  
anti-TN F agents (52;62;63). Therefore we considered that, a new m eta-analysis of a ll 
published data could help to draw  more defin itive conclusions on the role of the -308 
G>A TNFA po lym orph ism  in predicting anti-TN F trea tm ent outcom e in patients w ith  RA. 
The present m eta-analysis included a to ta l of 2576 patients, w hich is 4 tim es more than 
the previous m eta-analysis published in 2009 (248).
CO
CO
> MATERIALS AND METHODS
The m eta-analysis was perform ed according to the recom m endations of the 
Cochrane Collaboration (249).
Search strategy
A b ib liograph ic search was perform ed on the Medline (January 1966 to May 
2009), EMBase and Cochrane database by two investigators (SP and ET) using the 
m edical sub ject heading key words: polym orphism  genetic OR single nucleotide poly­
m orph ism  AND rheum atoid a rth r it is  AND (TNFR-Fc fusion protein OR ada lim um ab 
OR inflix im ab). B ib liographic references contained in the a rtic les  and abstract pub li­
cations from  the Am erican College of Rheumatology (ACR) Annual Scientific Meeting 
(2006-2008) and the European Leaque Against R heum atism  (EULAR) Annual European 
Congress of Rheumatology (2006-2008) were also included. Results from  a ll searches 
were combined and duplicate references excluded. Inclusion and exclusion criteria  
were checked fo r every a rtic le  independently by two reviewers (SP and ET). In case of 
d isagreem ent, a rtic les  were re-exam ined and discussed un til consensus was achieved.
Study selection
In o rder to be included in th is  m eta-analysis, stud ies had to 1) be o r consist of 
c lin ica l tr ia ls  using anti-TN F trea tm ent fo r at least 3 m onths, 2) include RA patients 
according to the ACR crite ria  and 3) investigate the role of the TNFA -308G>A gene 
po lym orphism . Studies on non-Caucasian patients were excluded from  th is  analysis in 
o rder to evaluate a more genetica lly homogenous population.
Data collection
The prim ary outcome measure of the m eta-analysis was the num ber of patients 
achieving clin ica l response to anti-TNF treatm ent defined as was the num ber of patients 
that achieved an improvement of the DAS28 (Disease Activity Score 28) (16) superior 



























response/non-response. The secondary outcome measure was a continuous variable 
consisting of the mean improvement of the DAS28 in the same period of time. We chose to 
focus on DAS28 because it is the main outcome param eter used in daily c lin ica l practice. 
Moreover, it is the outcome variable m ost frequently reported in the selected studies. Upon 
identification of papers fu lfilling  the inclusion and exclusion criteria, com plem entary in fo r­
mation was requested from  the corresponding author if needed. This was the case if the 
num ber of patients that experienced an improvement of the DAS28 equal or superior to 1.2 
was e ither not used as outcome measure o r not reported in the paper. Data collection and 
data extraction were performed by one reviewer (SP) using a predefined form.
Quality assessment
The influence of ind ividual study qua lity  on the resu lts  of m eta-analysis has 
been w e ll described (250). A lthough the use of assessm ent scales are recom m ended 
in system ic reviews and m eta-analysis to undergo som e type of qua lity  review, it has 
been dem onstrated that use of such scoring m ethods may not accurate ly assess the 
qua lity  m easures of in terest (251). Furtherm ore, those scales assess the qua lity  of the 
data reporting, but not tha t of the study, especially in the case of brief reports  o r le t­
ters. According to the recom m endations of the Cochrane co llaboration (252), we used 
study design as qua lity  variable (prospective c lin ica l tr ia ls  versus cohort designs) and 
perform ed subgroup analysis to evaluate its im pact on e ffect measures.
Statistical analysis
The odds ratio (OR) regarding the d ichotom ous outcom e m easure of efficacy 
(num ber of patients achieving an im provem ent of the DAS7I1.2) and the standardized 
means difference (SMD) regarding the continuous outcom e m easure of efficacy (mean 
im provem ent of the DAS28) were the effect m easures of in terest to assess the associa­
tion between the TNFA-308G>A gene p rom oter po lym orph ism  and the response to an ti- 
TNF treatm ent. For the m eta-analysis, sum m ary ORs and sum m ary SMDs were com ­
puted using e ithe r fixed e ffects m odels (for data that did not dem onstrate s ign ificant 
heterogeneity, I2<50%) o r random  effects m odels (for data dem onstrating  s ign ificant 
heterogeneity, I2>50%) (253). To assess po tentia l heterogeneity across studies, we used 
the I2 s ta tis tic  based on Cochran's heterogeneity s ta tis tic  (Q) (254). M eta-analyses were 
computed using RevMan analyses software (Review Manager (RevMan), In. Version 5.0 
ed. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2008).
Sensitivity analysis: Assessment of the effect of TNF agents, of the potential excessive 
influence of varying studies and of potential publication bias
This sensitiv ity analysis was perform ed on the data from  the cu rren t m e ta -ana l­
ysis including twelve studies. The OR and the SMD of the d iffe ren t classes of anti-TN F 
agents (TNF receptor fusion protein and antibodies against TNF) were calcu lated apart 
in order to determ ine w he the r the resu lts  were affected by the agent used. F u rthe r­
more, to assess w he the r a specific study could have exerted excessive influence on 
the fina l results, we repeated analyses a fte r excluding each study and a fte r excluding 
studies of varying designs.
Potentia l publication bias (ie, the association of publication p robability  w ith  the 
s ta tis tica l s ign ificance of study results) was investigated using visual assessm ent of 
the funne l plot calculated by RevMan analyses software. Funnel plots are plots of effect 
estim ates on the horizonta l axis against sam ple size on the vertica l axis and publication 
bias may lead to asym m etrica l funne l plots.
Sensitivity analysis: Assessment of the effect of covariates related to the characteris­
tics of the disease and co-medication
As pa rt of the se n s itiv ity  analysis, we pe rfo rm ed  a separa te  s ta tis tic a l 
ana lys is  on ind iv idua l pa tien ts  data from  two large s tud ies . This ana lysis a im ed to 
investiga te  w h e th e r p o ten tia lly  im p o rta n t covaria tes could in fluence  the associa tion 
between the -308G>A p ro m o te r po lym orph ism  and the response to a n ti-T N F  tre a t­
m ent. These covaria tes consis ted of gender, age, d isease du ra tion , c lasses of an ti- 
TNF m ed ica tion , co -m ed ica tio n  w ith  d isease m od ify ing  a n tirh e u m a tic  d rugs and 
hea lth  assessm ent ques tionna ire  (HAQ) at base line. This ana lys is  w as perfo rm ed  
in a subse t of 814 w e ll-c h a ra c te riz e d  pa tien ts  (426 Dutch pa tien ts  from  the DREAM 
reg is try  and 388 French pa tien ts  from  the la rge in te rn a tio n a l ReAct c lin ic a l tr ia l)
(21, 34). In th is  subse t of pa tients , the TNFA -308G >A po lym orph ism  w as genotyped 
by a lle lic  d isc r im in a tin g  TaqMan PCR by use of the PreDeveloped TaqMan assay kit 
C_7514879 (PE Applied B iosystem s), accord ing to the m a n u fa c tu re r 's  p ro toco l. The 
p rim a ry  c lin ic a l ou tcom e fo r th is  ana lys is  w as the abso lu te  change in DAS28 at 12 
w eeks (+/- 2 w eeks in cases of in flix im a b  trea tm en t). B ivaria te  and lin e a r re g re s ­
sion analyses w ere pe rfo rm ed  to assess associa tion  between DAS28 and TNFA -308 
genotype using R so ftw are  (R -D eve lopem ent-C ore-Team . R: A Language and Envi­
ron m e n t fo r S ta tis tica l C om puting . In. V ienna, A u s tr ia : R Foundation fo r S ta tis tica l 





























The literature search yielded 32 citations (Figure 1). Twelve published studies met 
our inclusion criteria  and could be included in the m eta-analysis a fte r requesting and 
receiving com plem entary resu lts from  five groups who did not use or report the DAS28 in 
detail in the orig ina l publications. The 20 remaining, non-selected papers encompassed 
studies in which the TNFA -308 gene polym orphism  was not investigated, duplicate pub­
lications, review and com m ent articles, and one study on non-Caucasian patients from  
Korea. A sm a ll study w ith only nine patients w ith RA was also excluded (56). In addition to 
the 12 selected studies, data from  a to ta l of 426 Dutch patients were included in th is m e­
ta-analysis. Two studies (43;52) were included in only one of the two analysis (regarding 
the dichotom ous or the continuous variable used as outcome measure) due to the lack of 
accessible data. Detailed in form ation of the included studies is presented in Table 1.
Tab le 1 /  Ch a r a c te r i s t i c s  of s tu d ie s  in cuded in the  m e ta -a n a ly s is  of t he  assoc ia t io n  of TN FA-308  gene p o l y m o rp h is m  w i th  
A u th o r ,  ye a r  (ref.) Pa tien t  se lec t ion  r e q u i re m e n ts  s tu d y  design
Chatz ikyriadou et al, 2007 (43) Re fractory  disease to at least two DMARDs
Cr iswe l l  et a l , 2004 (44) 
Cuchacovich et a l, 2006 (59) 
Fonseca et a l , 2005 (74)
Guis et al, 2007 (245) 
Marotte  et al, 2006 (58) 
M axwel l  et al, 2008 (52)
Active disease, ear ly RA 
Active disease despi te  DMARDs
DAS 28> 3.2 desp ite MTX
DAS 28> 3.2, refractory to previous t reatment by infl iximab 
Refractory  disease to MTX
Retrospect ive cohort 
Prospective, subgroup of a RCT 




Na tiona l Cohort
M ice l i-R ichard  et al, 2008 (62) 
M ugn ie r  et al, 2003 (54) 
Padyukov et al, 2003(53)
Pinto et a l, 2008 (63)
Seitz et al, 2007 (60)
DAS 28> 3.2 desp ite DMARDs
DAS 28> 3.2 desp ite MTX
Refractory  disease to at least one DMARDs
DAS 28> 3.2 desp ite DMARDs
Prospective c l in ica l tr ia l  
Prospective coho rt 
Retroversive cohort 
Prospective coho rt 
Prospective coho rt
Toonen et al, Re fracto ry  disease to at least one DMARDs Prospective  cohort
repor ted in the presen t ar t icle
Total
Mean [range]
DMARD: d isease-mod if y in g  a n t i - rh e u m a t ic  drugs,  MTX: methot rexa te , -: not repor ted
Figure  1 /  Study selection
Medline, EMBase, Cochrane  databases
Keywords  [MeSH]: po lym o rph is m  genetic;  po lym o rph is m  single nuc leot ide; rheum ato id  ar th ri t is ; 
TNFR-Fc fusion protein o r  ada l im u m a b  or  inf l ix imab 
Z 32 potent ia l ly  relevant s tud ies  identi f iec
20 Excluded
TN F-308 gene p o lym o rph is m  not investigated 
7 review, meta -analys is , com m e n ts
2 dup l ica te pub l ica t ions
3 Not about  adu lt  RA patients
1 Non caucasian RA patients
12 potent ia l ly appropria te  s tudies to be included
Z C o m p lem en ta ry  resu lt s  requested to au thors:  5 -  obtained 4 
Z Unpub l ished study  identi f ied : 1
J
13 s tudies included in the meta -ana lysis
12 s tud ies  w ith  the n u m b e r  of responders  to 11 s tud ies  w ith  the mean improvement
t re a tm e n t  according to the DAS28 as outcom e of the DAS28 as outcom e measure
response to an t i-TN F  t rea tm en t  in RA
No. of 
pa t ien ts




% fem a le % RF+ A n t i -T N F  Date of 
m ed ic a t ion  endpoint,  weeks
58 Greece 58 15.4 79 67 inf l ix imab 22
15' USA 50 1.' 74 78 etanercept 52
8' Chile 49 11.5 - 84 ada lim um ab 24
22 Portuga l - 8.8 77 - inf l ix imab 25
86 France 56 11.5 69 67 etanercept 26
198 France 50 10.4 79 79 inf l ix imab 30
1050 UK 57 13.9 77 in f l ix imab(=455] 
ada l im um ab(n  = 142] 
etanercept(n=453]
26
388 France 54 2.7 78 7 1 ada lim um ab 12
59 France 56 13.2 78 - inf l ix imab 22
123 Sw eder 52 14.0 81 94 etanercept 12
113 Spain 52 11.6 78 74 inf l ix imab 30
54 Switzer land 57 14.4 68 100 inf l ix imab(n=33]





The Netherlands 67 9.4 67 81 inf l ix imab(n=231]
ada l im umab(n=159]
etanercept(n=36]
12





























As the TNFA-308 AA genotype is rare, we compared the TNFA -308 GG genotype 
group to the combined AG and AA genotype groups. Considering a ll anti-TNF agents 
together, we did not observe any sign ificant association between the TNFA-308 G>A poly-
Figure  2a /  Meta-analys is of t he TNFA  -308 genotype w i t h response to ant i-T N F t rea tm ent  in r heumatoid  a r t h ri tis for t he outcome:
T N F - 308 geno ty p e GG T N F - 308 geno ty p e GA/AA
St u dy o r  Su bg roup Events Total Events Total W e ig h t
M ugn ie r 33 4' 5 12 1.2%
p a dyukov
L5 77 34 46 5.3%
Cr iswel l 63 89 43 62 11.8%
Fonseca 1' 15 3 7 0.9%
Marotte 93 147 33 5 1 14.3%
Cuchacovich 45 5' '3 19 1.8%
Chatz ikar iak idou 32 43 ' ' 15 3.3%
Guis 6
1^
68 '0 18 2.2%
Seitz 33 37 '4 17 1.7%
Toonen L522 792 98 129 26.4%
Pinto 01^ 86 '6 72 8.1%
Micel l i '9 4 26' 79 106 23.0%
S u bto ta l (95% CI) 1212 509 100.0%
Tot a l Event s 900 953
H eterogeneity: Chi2 = 16.06, d f = 11 (p  = O .H j; i2 = 31% 
Test of  overa ll e ffect; Z  = 1.&0 [p  = 0.07 'j
M - H = M ant e l - Haenszel  ste^s^cal .  m e th o d ; Cl = Conf idence |nt erval
F igure 2b /  Meta-analysis of the TNFA -308 genotype wi th  response to ant i-TNF t rea tm ent  in rheumatoid ar th ri t is  for the outcome
Study  o r  Su bg roup  Weig h t
M ug m e r  5.3%




Mice l l i  5.9%
Toonen 13.6%
M axwel l  15.2%
Tota l (95% CI) 100.0%
Heterogeneity: Tau2 = 0.05, Chi2 = 31.83, d f = 10 [P  = 0.0004); i2 = 69% 
Test o f overa ll e ffec t: Z  = 1.87 [P  = 0.06)
M -H = M ante l-H ae nsze l sta t is t i ca l method; Cl = Confidence Interval
m orphism  and num ber of patients responders to TNF inh ib itors (decrease of DAS28>1.2): 
OR=1.24 (95% confidence interval: 0.98 -  1.56) (Figure 2a). The test fo r heterogeneity was 
I2=31% w ith a p-value=0.07. S im ila r results were observed when comparing the mean 
im provem ent of the DAS28 between genotypes w ith  a non sign ificant effect size of -0.18 
point in favour of TNFA-308 GG genotype (95% CI: -0.36 - 0.01) (Figure 2b).
n u m ber  o f responders  according) to t h e DAS28 (> ^ 2)
Odds rat io
M-H CI%59d,eixFi Year
5.78 [1.45 .03.2 2003
1.91 8.7[0. .74. 2003
7.0 3.5[0.
12” 2004
73. .5[0. 34.2 2005
0.94 8.4[0. 1.83] 2006
-63. 5.9[0.
-O.52. 2006
-6.0 8.2[0. .014. 2007
3.73 2.2 4].4 2007
7.7 5.3[0. 5].98. 2007
0.99 [0. 0] 2008





Odds ra t io 
M - H  Fix ed, 95% CI
genotypes GA/AA genotype GG
mean im provem ent  of the DAS28
Std. Mean Di ffe rence 
IV, Random, 95% CI Year
-0.72 [-1.38 - 0 .0 7 ] 2003
0.12 [-0.22 0.45] 2004
-0.96 [-1.91 -0.01] 2005
-0.53 [-1.07 0.00] 2006
-0.15 [-0.48 0.18] 2006
-0.44 [-0.96 0.08] 2007
-1.04 [-1.64 -0.43] 2007
-0.01 [-0.23 0.22] 2008
-0.04 [-0.25 0.17] 2008
0.11 [-0,32 0.55] 2008
0.13 [ 0.00 0.26] 2008
-1.18 [-0 .36,  0.01]
Std. Mean Di ffe rence 
IV, Ra ndom, 95% CI



























F igure  3a /  M e ta -ana ly s is  of the TNFA -308 genotype w i th  response  to TNF an t ib od ie s  m e d ica t io n s  in rh e u m a to id  a r th r i t i s
TN F-3 08  geno ty pe  GG TN F-3 08  geno type  GA/AA
Study  o r  Su bg roup  Events Total Events Total W eig h t
1.2.1 In f l ix im ab
M ugn ie r  33 4' 5 12 1.4%
Fonseca 11 26 3 10 2.4%
Marotte  93 147 33 5 1 17.2%
Ch atz ikar iak idou 32 43 1' 15 4.0%
Toonen 84 166 35 65 23.8%
Pinto 5C 86 16 27 9.8%
S u b to ta l  (95% CI) 509 180 58.7%
Total Events 3C3 103
Heterogeneity: Chi2 = 6,72, d f = 5 (P = 0.24); I2 = 26%
Test o f overa ll e ffec t: Z  = 0.41 (P = 0.68)
1.2.2 A d a l im u m a b
Cuchacovich 45 5' 13 19 2.1%
Toonen 76 106 32 53 11.6%
Micel i  194 261 79 106 27,6%
S u b to ta l  (95% CI) 418 178 41.3%
Total Events 315 124
Heterogeneity: Chi2 = 3,76, d f = 2 (P = 0.15); I2 = 47%
Test o f overa ll e ffec t: Z  = 1.34 (P = 0.18)
Tota l (95% CI) 927 358 100.0%
Total Events 618 722
Heterogeneity: C h i = 11,06, d f = 8 (P = 0.20); I2 = 28%
Test o f overa ll e ffec t: Z  = 1.19 (P = 0.23)
Test fo r subgroup d ifferences: Not applicable
M -H = M ante l-H ae nsze l sta t is t i ca l method; CI = Confidence Interval
F ig u re  3b /  M e ta -an a ly s is  of t he  TNFA -308 genotype w i th  response to TNF recep to r  agon is t  in rh e u m a to id  a r th r i t i s  fo r the
TN F-3 08  geno ty pe  GG TN F-308  geno type  GA/AA
Study  o r  Su bg roup  Events Total Events Total W e ig h t
1.1.2 R e com b in an t  TN F  recep to r
M ugn ie r  65 77 34 46 23.6%
Cr iswe l l  63 89 43 62 52.7%
Guis 56 68 10 18 9.9%
Toonen 15 25 7 11 13.8%
S u b to ta l  (95% CI) 259 137 100.0%
Total Events 199 94
Heterogeneity: Chi2 = 4,26, d f = 3 (P = 0.23); i2 = 30%
Test o f overa ll e ffec t: Z  = 1.71 (P = 0.09)
M -H = M ante l-H ae nsze l sta t is t i ca l method; CI = Confidence Interval
for the ou tcome: n u m b e r  of responders  according  to the DAS28 (> 1.2)
Odds rat io 
M-H, Fixed, 95% CI
3.47 [0.95, 12.56] 
1.66 [0.83, 3.33] 
0.99 [0.59, 1.66] 
1.31 [0.88, 1.93]
Year
Odds rat io 
M-H, Fixed, 95% CI
5.78 5,.4 3].03.2 2003
1.71 6,.3[0. 5]8, 2005
4.90. 8,.4[0. 1.83] 2006
1.06 8,.2[0. .014. 2007
0.88 9,.4[0. 2.30] 2008








TN F-308 genotype GG
ou tcome: n u m b e r  of responders  according to the  DAS28 (> 1.2).
Odds rat io 
M-H, Fixed, 95% CI
1.91 [0.78, 4.71] 
1.07 [0.53, 2.17] 
3.73 [1.22, 11.44] 







Odds rat io 
M-H, Fixed, 95% CI
Favours -308 GA or  AA Favours -308 GG
Sensitivity analysis
Analysis of a po tentia l effect of the class of anti-TN F agent anti-TNFalpha 
antibodies (in flix im ab and adalim um ab) versus the so luble TNF receptor (etanercept) -  
did not show  any association between the TNFA-308G>A prom oter po lym orph ism  and 
response to trea tm ent (Figures 3a and 3b). To assess the po tentia l in fluence of study 
quality, we repeated the analysis excluding each single study at a tim e. Only exclusion 
of the largest stud ies (52;58;62) w ould have m odified the s ta tis tica l sign ificance of the 
m ains results. To assess the influence of study quality, we repeated the analysis exclud­
ing the studies that were part of random ized c lin ica l tr ia ls  (RCT). This approach was 
considered because inclusion crite ria  in RCT could have selected fo r a more severe RA 
phenotype w ith  a h igher chance to response to anti-TN F treatm ent. Nonetheless, the 
estim ate generated was s im ila r  to the estim ate found in the p rim ary  analysis (OR=1.30, 
95%CI [0.97-1.73]). The analysis of the funne l p lot to check fo r po tentia l publication bias 
suggested a random  d is tribu tion  around an OR of 1, consistent w ith  the lack of associa­
tion between TNFA -30 8 G > A  po lym orph ism  and response to trea tm ent (Figure 4).
The effect of potentia lly  im portan t covariates, on the association between the 
TNFA -308G>A polym orphism  and response to treatm ent, was analysed using individual 
patient data from  subset database including 814 patients from  The N etherlands and 
France. The patients' characte ris tics  are presented in Table 2. The covariates studied 
encompassed class of anti-TN F m edication, concom itant use of disease modifying 
an tirheum atic  drugs, disease duration, HAQ at baseline, rheum atoid factor positivity, 
age and gender
Bivariate and linear regression analysis did not dem onstrate  association 
between the d iffe ren t TNFA -308 genotypes and response to trea tm ent. The mean abso­
lute varia tions of the DAS28 a fte r 12 weeks of trea tm ent were -1.38, -1.76 and -1.76 for 
the TNFA -308 genotypes AA (n=28 (3.5%)), AG (n=207 (26.1%)) and GG (n=559 (70.4%)) 
respectively (p-value=0.33). None of the covariates studied was s ta tis tica lly  associated 
w ith  the TNFA -308 genotypes o r the response to treatm ent.
• o
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F igure  4 /  Funne l plot: assessm ent  of po tentia l  bias of pub l ica t ion  according to the  ORs of associat ion 
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Table 2 /  Chara c te r is t ics  of the coho rts  f rom  The Ne the r lands  and f rom  France
Du tch DREAM reg is t r y React French Database A l l
N u m b e r  of patient 426 388 814
Percen tage of female 67,4 8,7 72,6
Age (mean) 65 54* 59,7
Disease dura tion  (mean) 9,4 2,68* 6,17
RF posit ive (percentage) 81,06 70,54* 76
HAQ basel ine 1,48 1,64* 1,57
ESR basel ine 28,92 31,59* 30,37
CRP basel ine 24,9 27* 26,1
DAS28 basel ine 5,47 5,87* 5,66
MTX (percentage) 60,8 46,9* 53,9
Other DMARD (percentage) 45,6 72,1* 58,6
TNF t rea tm en t adaUmumab:  159 
etanercep t:  36 
in f l ix imab: 231
adaUmumab:  388 adaUmumab:  547 
etanercept : 36 
inf l ix imab:  231
*p<0,001
Acco rd ing to the inclusion c ri ter ia  required fo r the cl in ica l tr ial ,  RA patients  f rom  the React da tabase hac 
a more  act ive disease at base l ine than  the patients of the DREAM registry. RF: rheum ato id  factor, HAQ: 
health assessm ent  questionna ire , ESR: eryth rocy tes send im enta t ion  rate, CRP: C-reactive protein, DAS28 




























This meta-analysis did not show any association between the -308G>A TNFA poly­
morphism  and response to anti-TNF in the largest cohort of RA patients analyzed up t ill 
now. This was s till the case after analysis for im portant covariates such as anti-TNF agents, 
disease duration, DMARDs use. Our results are not in line with the results presented in two 
previous meta-analysis including less patients. The study from Lee et al. and the study from 
O'Reilly et al. included 311 and 692 RA patients from 6 and 9 different studies, respectively. 
They suggested that the TNFA -308 A allele predisposes to a poorer response to TNF-block- 
ing therapy compared to the -308 G allele (61 ;248). Several reasons may explain the observed 
difference between these previous reports and our study. First, one of the obvious differences 
in favour of our study is that sample sizes were very different. Our meta-analysis involved 
between 2.5 to 4 times more patients (depending on the end-point) than the previous ones. 
Moreover, our study of the funnel plot revealed that the largest cohorts did not show any 
association between TNFA -308 GG versus GA/AA genotypes whereas the sm allest studies 
did. Those large studies, published in 2008, were not included in the previous meta-analysis 
(52;62;63). We identified these studies and we requested to authors details on their negative 
results. Secondly, the previous meta-analysis disregarded other studies that showed no sig­
nificant effect of this polymorphism on anti-TNF response which may introduce publication 
bias. Finally, our and previous studies differ in the use of response criteria. We strictly used 
response measurements based on the DAS28 whereas Lee et al. (61) and O'Reilly et al. (248) 
combined two distinct response measurements, the American College of Rheumatology 
(ACR) response criteria (158) and the DAS28 (249) in the ir meta-analysis.
Since the last study included in the meta-analysis of O'Reilly and colleagues, 3 
studies investigating the TNFA -308G>A polymorphism and anti-TNF treatm ent outcome in 
large cohorts of RA patients appeared. A ltogether 6 (53;54;57;59;60;245) out of the 13 stud­
ies reported an association between the polymorphism and treatm ent outcome, whereas 
7 did not (43;44;49;52;58;62;63). These inconsistent results are largely explained by too low 
statistical power and sm all sample sizes. The problem of low power is illustrated even by 
the largest study published up to date (n=1041 RA patients treated w ith anti-TNF agents) 
(52). The authors reported an association only between the very rare homozygous -308AA 
genotype (n = 7) and response to etanercept (n = 444) but not other TNF neutralizing agents. 
Comparison of the GG genotype versus the combined AA and AG groups in this and a ll other 
studies including our meta-analysis (Figure 3b) showed no difference in the response to any 
anti-TNF therapy including etanercept. Combining the AA and AG group is in line w ith  the 
overall hypothesis that the A allele could be associated w ith  anti-TNF non-response (62).
Besides the overa ll m eta-analysis, we also investigated w he ther potentia lly  
im portan t covariates could in fluence the association of the TNFA po lym orph ism  w ith 
trea tm ent outcom e but th is  was not the case. Such type of analysis is c ruc ia l to assess 
possible in te ractions between genes and environm enta l factors.
Our meta-analysis does not support an association between the TNFA -308G>A pro­
m oter polymorphism and response to anti TNF therapy. This does not fu lly rule out that the 
gene encoding for TNF m ight influence anti-TNF treatm ent outcome as we focused on only 
one genetic variant in the gene. In fact, linkage d isequilibrium  (LD) is strong in this area and 
it is d ifficu lt to study the role of a SNP in isolation. Therefore, other SNPs of the TNFA gene, 
not in complete linkage disequilibrium  w ith the -308G>A polymorphism deserve fu rther 
study (87;255). Haplotype analysis of the gene m ight be an alternative approach to investi­
gating anti-TNF treatm ent outcome. An example of such an analysis has been shown in the 
recently published study by our group (62). The la tter showed that neither the num ber of 
HLA-DRB1 shared epitope copies nor the presence of three TNF polymorphisms (-238A>G, 
-308G>A and -857C>T) tested separately was significantly associated w ith response to adal- 
im umab therapy. However, haplotype reconstruction of the TNF locus revealed that the GGC 
haplotype (-238G, -308G, -857C) in a homozygous form  was significantly associated with 
lower ACR50 response to adalimum ab at week 12 (62). Unfortunately the num ber of studies 
on the effect of the extended TNFA haplotypes is too sm all to perform  a meta-analysis.
In conclusion, we observed no effect of the TNFA -308G>A p rom oter po lym or­
phism  on response to anti-TN F trea tm ent in the largest cohort of RA patients analyzed 
so far. We conclude that th is  po lym orph ism  is not a su itab le p red ic to r fo r response to 
anti-TN F in the c lin ica l practice. Nonetheless, the gene encoding fo r TNFB may s t ill be 
an in teresting candidate gene and o ther polym orphism s, haplotypes and in teractions 
w ith  environm enta l factors need to be investigated fo r the ir role in anti-TN F response.
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Over the last years m icroarray technologies have generated new perspectives 
fo r h igh -th roughpu t analysis of b io log ica l systems. Nowadays, it is possible to m on ito r 
thousands of genes in a s ing le experim ent. This m olecu la r p ro filing  technology com ­
bined w ith  standardized and validated c lin ica l m easurem ents can a llow  a more precise 
characteriza tion of a patient's phenotype, and may lead to the design of therapeutic 
protocols and procedures be tter ta ilored to ind ividual patient's needs.
In th is  report we provide an overview of expression p ro filing  stud ies in rheu­
m atoid a rth r it is  (RA). RA is a chronic in flam m ato ry  disease in w hich both genetic and 
environm enta l factors are involved. The precise m o lecu la r m echanism s underlying 
RA are not fu lly  understood. A system atic lite ra tu re  search revealed e ight array-based 
expression pro filing  stud ies in RA patients. Findings from  these studies were compared 
to those of linkage and genom e-w ide association (GWA) studies. A lthough we observed 
many d ifferences in study design, analysis and in te rp re ta tion  of resu lts  between the d if­
ferent studies, we extracted two sets of genes: 1) those d iffe ren tia lly  expressed in more 
than one study and 2) genes d iffe ren tia lly  expressed in at least one of the reviewed 
studies and present in RA linkage o r GWA loci. We suggest that both sets of genes 



















Large-scale analysis of gene expression pa tterns using (m icro-)arrays is spread­
ing over many fields, includ ing that of rheum atology. Nowadays, array-based approach­
es a llow  the analysis of thousands of genes in a single experim ent (256). There has 
been specia l in terest in these technologies to elucidate the genetics of heterogeneous 
auto im m une diseases like rheum atoid a rth r it is  (RA).
Array-based expression analysis is based on the hybrid ization of an ordered set 
of probes attached to a surface w ith  a target consisting of ce ll- /tissue -iso la ted  mRNAs. 
In genera l these are mRNAs isolated under d iffe ren t biologic s itua tions, e.g. health and 
disease, or before and a fte r treatm ent. The hybrid ization pattern reflects  the relative 
abundance of each mRNA and leads to the identifica tion of genes up- o r downregulated 
in the test condition compared to the reference.(256) By grouping sets of d iffe ren tia lly  
expressed genes according to function, in fo rm ation  can be obtained about key pathways 
related to disease or trea tm ent (257).
Expression pro filing  studies in RA can be classified roughly into two categories:
1) those focused on finding (new) candidate genes for disease etio logy and understand­
ing its pathogenesis, and 2) those focused on identify ing expression patterns typical for 
a state of RA (e.g. m ild  versus severe disease or drug-responsive versus non-respon- 
sive patients). In the firs t category expression analysis is often the firs t step in e luc ida t­
ing gene function, in the second it is aimed at reducing phenotypic heterogeneity o r at 
identify ing expression profiles that can serve as diagnostic tools predicting e.g. disease 
outcom e or response to disease m odifying an ti-rh e u m a tic  drugs (e.g. tu m o r necrosis 
facto r (TNF) blocking agents).
The cu rren t study compared the find ings of published reports dealing w ith 
expression p ro filing  in RA w ith  the aim of identify ing genes frequently  up- o r dow nregu­
lated. Furtherm ore, localization of genes was compared to known genetic linkage and 
association regions for RA. Two sets of genes were derived: 1) those d iffe ren tia lly  ex­
pressed in more than one of the reviewed stud ies and 2) genes d iffe ren tia lly  expressed 
in at least one of the reviewed studies and located w ith in  a genetic linkage or associa­
tion region fo r RA. Since the large heterogeneity in study design precluded a m eta ­
analysis, we extracted these gene-sets by s im ple  com parison of the studies and report 
a power estim ate of the reviewed genes. We argue that the selected genes are excellent 
candidates fo r fu rth e r research.
> METHODS
Studies were selected by system atica lly  searching MEDLINE (OVID 1966 to Janu­
ary 2007) using the fo llow ing search te rm s: rheum atoid a rth ritis , expression profiling, 
expression pattern, trea tm ent responsiveness, anti-TN F responsiveness and au to im ­
mune disease. Studies had to deal w ith  expression pro filing  in RA or o ther autoim m une 
diseases, if these also in c lud ed  RA sam ples. A n im a l stud ies and expression profiling 
perform ed using techniques o ther than m icroarray technology were excluded. The 
c rite ria  were checked fo r every a rtic le  independently by two reviewers (ET and MC).
In case of d isagreem ent, a rtic les  were re-exam ined and discussed un til consensus 
was achieved. From each selected artic le, detailed in fo rm ation  was extracted on study 
design, num ber and characte ris tics  of partic ipants, interventions, outcom e m easure­


















Tab le 1 /  Overv iew of s tud ie s ,  co n ce rn in g  pa t ie n t  ch a ra c te r is t ic s ,  used t is su e s  and e x p e r im e n ta l  se tup
N u m b e r  of  p a t ie n ts  (% fema le) Tissue A r r a y
RA: n=29 (75%). Average disease dura t ion :  12 years). 
No in fo rmation  about  ACR cr i te r ia  w as  given.
PBMCs U95Av2 (12626 cDNAs) 
(Af fymetr ix  Inc.,
Santa Clara, CA, USA)
RA: n=8 (63%). Mean age 38.25 year. Mean disease durat ion : 
1.7 years. AH patients we re  DMARD-na ïve at en ro lmen t  
s table  dose of NSAIDs and /o r  predn iso lone w a s  al lowed.
B-ceUs Genome-sca le  ol igonuc leotide  
l ib rary  con ta in ing 21,329 
human genes. (Corning 
UltraGAPS Big Flats, NY, USA)
RA: n = 15 (87%). No in fo rmation  on disease dura t ion  provided. 
14 pat ients received DMARD medication,  4 received predn isone
RA synovial t issue cDNA m ic roa r ray  (24,000 
cDNAs) represent ing  a 
random  set of genes  (custom 
made; not f u r th e r  specif ied)
Early RA: n = 11 (82%). Average disease dura tion  1.1 year. 
Establ ished RA: n=8 (100%). Average disease duration of 10.5 years.
PBMCs Gene Fi l te rs  release 1
(4329 cDNAs) (Research 
Genetics  /  Invitrogen)
RA: n=4 (unrela ted individuals).
Famil ies : 1 parent  w ith  RA, 1 una ffected dau gh te r  (NS)
PBMCs Gene Fi l te rs  GF-211 
(4329 cDNAs), 
(Research Genetics, 
Huntsvi l le, AL, USA)
Early RA: n = 17, Average disease dura tion  1,1 year. 
Establ ished RA: n=9. Average disease dura t ion  of 10,5 years 
No in fo rmation  about  gender  w as  provided
PBMCs Gene Fi l te rs  GF-211 
(4133 cDNAs) 
(Genet ics/Invi troger  
Carlsbad, CA USA)
RA :n=33 (76%) DAS28 >5.1. Average disease duration: 11 to 12 years. 
Pa tients  we re  res istance to at least one DMARD (MTX included) 
Inf l ix imab adm in is t ra t io n :  basel ine, w e eks  2 and 6, 
and every 8th week thereafter. Change of DAS28 = 1.2 after 3 months 
w as  considered as responder  (EULAR cri ter ia  (16))
PBMCs (col lectec 
at base l ine anc 
a fte r 3 m onths  
of trea tm ent)
cDNA m ic roa r ray  with 
12,000 cDNA probes 
for 10,000 non-redundan t  
genes (cus tom made)
RA: n = 10 (80%), med ian age: 54 years. A l l  pa t ients we re  trea ted 
w i th  MTX, 5 patients received predn iso lone.
Infl ix imab administrat ion: baseline, 2 and 6 weeks. Disease activi ty 
assessment  (DAS28): at baseline and after 12 weeks of t reatment 
EULAR cri ter ia  we re  used to de te rm ine  response (16).
RA synovial t issue  HUM 30k cDNA 
(taken before and ar ray containing 
a fte r a med ian of 9 30,000 spots 
w eeks  of t rea tm ent .  (custom made) 
Biops ies we re  taker  
f rom  the site of in f l amm at io n )
AH patients  met the Am er ic an  College of Rheum ato logy  (ACR) c ri ter ia  unless  indicated o therw ise  (9). RA: rheum ato ic  
ar th ri t is , NS: not specif ied, LPS: Lipopolysacchar ide,  PMA: Phorb o l mystra te  acetate, IL-1: In te r leuk in  1, DMARD: 
d isease-modif y ing  a n t i rheu m a t ic  drugs,  ACR: Am er ic an  College of Rheumato logy,  SLE: sys temic  lupus ery thematosus ,  
PBMC:  per ip hera l blood m ononu c lea r  cel ls, IDDM: insul in dependent  diabe tes mel l i tus,  MS m u lt ip le  scleros is , MTX: 
m ethotrexate  SAM: Signi f icance Analys is  of Microar rays , SD: standard  deviat ion, DAS28: Disease Act ivi ty Score 28, 
NSAID: non -s te ro id a l a n t i - in f la m m a to ry  drugs
Forty-six stud ies were identified by the lite ra tu re  search, e ight m et the selection 
c rite ria  and were included in th is  study. Two stud ies (258;259) dea lt w ith  autoim m une 
diseases in general. Six studies discussed expression profiles of RA patients, specifi-
Spec if ics  of  ana lysis P o w er  es t im at io n Reference
3 cri ter ia  fo r defin i t ion of d if fe rentia l ly expressed genes  m 
com par is on  of RA patients  and cont ro ls : (1) P <0.001 by an unpairec 
S tudent 's  t - test ,  (2) di f fe rence in express ion of 100 s ig na l units 
or  greater  wh en com par in g  the means of two groups, (3) g rea te r  than 
1.4-fold change  in mean gene expression between the two groups
264 patients and 264 con trols 
are needed to detect 
di f fe rences  (1.4 fold change) 
w ith  a power  of 90%
Batl iwa l la  et al., 
(262)
Genes s igna l in tensi t ies  >10 SD above mean of the d is tr ibu t ion  of 
random  negative cont ro ls , and induced or  repressed 3.0- fold or  greater  
in RA vs. cont ro ls  we re  catalogued and used fo r f u r th e r  analysis.
12 patients  and 12 con trols 
are needed to detect 
d if ferences (3.0 fold change) 
with  a power  of 90%
Szodoray et al.
(263)
T ranscr ip ts  var ied in abundance  at least two - fo ld  f rom  the ir  median 
level in at least four  t issue samples .  Co mparison of sta t is t ical  
d i f fe rences  in gene expression we re  genera ted by SAM 
q-va lu es  <5 we re  considered  sign if ican t
44 patients and 44 con trols 
are needed to detect 
di f fe rences  (2.0 fold change) 
w ith  a power  of 90%
Van der  Pouw 
Kraan et al.
(260)
Gene expression data we re  f i l te red to inc lude  only genes  that  showed 
s igni f icant var iab i l i ty  (3 standard  deviat ions) in the c lu s te r in g  analyses
N u m b e r  of analyzed pat ients 
is su f f i c ien t  to detect 
d if ferences w ith  90% power
Olsen et al. 
(261)
Difference in expression in tensity between two groups de term ined 
by Chen test (264): s ta t is t i ca l ana lysis on the basis of a specif ied 
con fidence  in tervals  (99% for al l  tests)
Using the n u m b e r  of sa m p le s  
that were analyzed, the min imal  
fold change in express ion that 
could be detected wi th  a power 
of 90% is 4.2
Maas et al., 
(258)
M ic roar ray  data we re  s ta t ist ica l ly analyzed using the SAM a lgor i thm  
(265). SAM uses the SD of repeated gene express ion m easu rem en ts  
to assign a score to each gene
Using the n u m b e r  of sa m p le s  
that were analyzed, the min imal  
fold change in express ion that 
could be detected wi th  a power 
of 90% is 2.0
Liu et al., 
(259)
A  tran sc r ip t  w as  considered  to be expressed if at least twc 
hybrid izat ions provided a posit ive signa l
No rm a li zed  values w ith  abundance d i f fe rences  in two  o r  more 
com par is on s  between two samples, using a funne l -shaped  
con fidence  in terval  (p < 0.05)
Using the n u m b e r  of sa m p le s  
that  we re  analyzed, the 
di f fe rences  in expression as 
defined in the study  cou ld be 
detected w i th  a power  of 90%
Lequerre  et al. 
(189)
Modera te  t -tes t  w as  used to identi fy d if f e rentia l ly  expressed genes. 
Probabi l i ty  of falsely identi fying  d if feren tia l ly  expressed genes  was 
cont rol led using a false discovery rate app roach with  q-value 
(ana logous to a p-value) ass igned to each gene
Cutoff was  set at q=0.025: expected propor t ion of false posit ives genes. 
shou ld  be less than  0.025% among d i f fe rent ia l ly  expressed
Using the n u m b e r  of sa m p le s  
that  we re  analyzed, the 
di f fe rences  in expression 
as def ined in the study 
could be detected 
with  a power  of 90%
Lindberg  et al., 
(190)
caLLy (189;190;260-263). Of these, fou r (260-263) focused on expression patterns typical 
of a specific disease state, and two stud ies (189;190) examined expression patterns 
predictive of anti-TN F respondership. Table 1 sum m arizes in fo rm ation  about patient 


















In Table 2 we compiled genes found to be regulated in more than one study, i r ­
respective of the above defined categories, but includ ing at least one study comparing 
expression profiles from  RA sam ples w ith  those of healthy controls.
Tab le 2 /  Genes tha t show  a d i f feren tial  expression in more than one study
Gene sym b o l Gene nam e Chromosomal
locat ion
Up -  o r  d o w n re g u la te d  in RA 
com pared  to  con t ro ls  
(or  o th e rw is e  spec if ied )
Re ference
CSTF2 Cleavage s t im ula t io n
factor, 3' pre-RNA, 
subun it  2




Solute ca r r ie r  family 7A7: 14q11.2 
25A4: 4q35
Upregulated (260), (266)
CSF3R Colony st im u la t in g  
fac tor  3 recep tor




Troponin 1, Tropon in 2, 






ASL Arg in in osuccma te  lyase 7cen-q11.2 Downregu la ted (258), (259)
TP53 T um or  protein p53 17p13.1 Downregu la ted (258), (259)
TXK TXK ty rosine  kinase 4p12 Downregu la ted (258), (259)
LAMR1 Ribosom al protein SA 3p21.3 Downregu la ted (261), (189)
BMP8 Bone m orphogene ti c  
protein 8
1p35-p32 Downregu la ted (258), (259)
CYP3A4 cytochrome P450 
family  3, sub fam il y  A
7q21.1 Ref .(261): up regu la ted 
Ref. (189): dow nregu la ted  m 
in f l ix imab responders  vs 
non -responders
(261), (189)
KNG1 Kin inogen 1 3q27 Ref. (258) and ref. (259): 
downregu la ted  . Ref. (189): 







S100 ca lc ium 
binding protein
1q21 Ref. (261): downregu la ted 
Ref. (262): upregu la ted
(261), (262)
PPP2R3 Protein phosphatase  2 
( fo rmerl y  2A), regu la to ry  
subun it  B' ',  alpha
3q22.1 Ref. (258) and ref. (259): 
downregu la ted .  Ref. (260): 
H igher  expressed in RA-I 
group com pared to RA-I group
(258), (259), 
(260)
M MP-3 Matrix metal loproteinase 3 11q22.3 Ref. (260): H igher  expressed m 
RA-I g roup  com pared to RA-II 
group. Ref. (190): Upregulated  
in in f l ix imab responders
(260), (190)
Studies focused on finding (new) candidate genes for disease and understanding its 
pathogenesis
Batliwalla and coworkers (262) performed gene expression profiling using peripher­
al blood mononuclear cells (PBMCs) from  29 patients w ith RA and 21 healthy controls (Ta­
ble 1). Out of the 4500 investigated genes, they identified 81 genes w ith significantly different 
expression levels between RA and control; 29 genes were downregulated and 52 genes 
were upregulated in the RA group. Glutaminyl cyclase (glutam inyl-peptide cyclotransferase; 
QPCT), IL1 receptor antagonist (IL1 RA), S100 calcium binding protein A12 (S100A12) and 
GRB2-associated binding protein 2 (GAB2) were among the top of overexpressed genes; 
whereas CD72 and CD79b were most significantly downregulated. Strikingly, many of the 
overexpressed genes were monocyte-specific. This may have been related to the fact that 
the RA patients had an active disease and were included before therapy initiation (262).
Szodoray et al. (263) used a genom e-scale m icroarray representing 21,329 genes 
to identify d iffe ren tia lly  regulated genes in periphera l blood B -ce lls  from  eight patients 
w ith  early RA compared to e ight healthy con tro ls  (Table 1). Three hundred and five 
genes were overexpressed in RA-derived B -ce lls  and 231 genes were repressed when 
compared to contro ls. C lusters of functiona lly  associated netw orks of the d iffe ren tia lly  
expressed genes were constructed into w hich 51 of the 536 genes fitted. Five functiona l 
classes were defined: ce ll activation, pro life ra tion  and apoptosis (31 genes); au to im ­
m unity  (five genes); cytokines, cytok ine-receptors and cytokine-m edia ted processes 
(eight genes); neuro-im m une regulation (two genes); and angiogenesis (five genes). 
Quantitative-PCR (q-PCR) confirm ed the upregulation of 13 random ly chosen genes in 
B -ce lls  from  RA patients (Supplem entary Table 1) (263).
Studies on gene expression patterns typical of a specific state of disease
Studies in th is  category were aimed at identify ing profiles predictive of a disease 
state, predom inantly, but often also included a case-con tro l comparison.Van der Pouw 
Kraan et al. (260) used a custom  m icroarray containing approxim ately 24,000 cDNA 
probes to subclassify RA patients (n=15) (Table 1). H ierarch ica l c luste ring  of gene 
expression in synovial tissue identified two main patients groups. These groups were 
indicated as RA-I (n=10) and RA-II (n=5). Gene expression in the RA-I group was ind ica­
tive of an adaptive im m une response, whereas genes identified in the RA-II group were 
involved in fib rob last dedifferentiation.(260) The RA-I group overexpressed 121 genes 
compared to RA-II; 39 genes were overexpressed in the RA-II group compared to RA-I 




















O lsen e t al. (261) a im ed at iden tify ing  a gene expression p a tte rn  spec ific  for 
ea rly  RA w h ich  could be used as a d iagnostic  m a rke r and lead to ea rly  therapy and 
b e tte r prognosis. PBMCs from  RA pa tien ts  w ere analyzed using m ic ro a rra ys  co n ­
ta in ing  4329 cDNAs (Table 1). Eleven pa tien ts  who had RA fo r less then two years 
w ere com pared w ith  e igh t pa tien ts  w ith  longstand ing  RA (>10 years). The c lu s te r 
ana lys is  indeed a llow ed them  to d isce rn  pa tien ts  w ith  ea rly  RA from  those w ith  
longstand ing  disease (261). No c le a r rank ing  w as provided fo r genes m ost s ig n if i­
can tly  over- o r underexpressed, but genes tha t w ere upregu la ted  m ore than th re e ­
fold in ea rly  RA inc luded tropon in  I (TNNI2), tropon in  T2 (TNNT2), cytochrom e P450, 
fa m ily  3, su b fam ily  A, po lypeptide 4 (CYP3A4), cleavage s tim u la tio n  fa c to r (CSTF2) 
and CSF 3 recep to r (CSF3R). Genes dow nregu la ted  in early  RA inc luded S100A10 
and r ib oso m a l p ro te in  SA (RPSA; LAMR1).
In ano ther study, the sam e group hypothesized that patients w ith  autoim m une 
d isorders (including RA) exhibit highly reproducible PBMC gene expression profiles re ­
su lting  from  chronic in flam m ation , o ther disease m anifestations, o r from  fam ily resem - 
blance.(258) To test the la tte r hypothesis, PBMC gene expression profiles of individuals 
w ith  RA (n=4) and SLE (n=4) and th e ir  unaffected firs t-deg ree  relatives were compared 
(see Table 1). Genes were classified into three m ajor categories: overexpressed genes 
(n=94), underexpressed genes (n=111) and non-au to im m un ity  genes (n=3924). Expres­
sion profiles in unaffected firs t-deg ree  relatives resem bled those of ind ividuals w ith  
auto im m une diseases. Interestingly, th is  was also true  for many of the autoim m une 
genes. Supplem entary Table 3 lis ts  the top 5 under- and overexpressed au to im m unity  
genes displaying the highest corre la tion  coeffic ients in re lative-pa irs. Though the main 
goal of th is  study was to identify gene expression signa tures across autoim m une d iso r­
ders and not the identifica tion  of RA candidate genes, we added a ll genes tha t replicate 
resu lts  from  o ther stud ies to Table 2.
Another study of th is  group was aimed at identify ing the proportion of a gene 
expression profile tha t was independen t of fa m ilia l resem blance and determ in ing 
w he the r th is  was a product of disease duration, disease onset o r o ther disease-re lated 
factors (259). The study included patients w ith  SLE (n=19) longstanding and early RA 
(n=9 and 17, respectively), insu lin -dependent d iabetes m e llitu s  (IDDM; n=5), m ultip le  
sclerosis (MS; n=4), healthy con tro ls  (n=8) and firs t-deg ree  unaffected fam ily  m em bers 
of individuals w ith  SLE and RA, (n=8) (Table 1). One hundred genes w ith  shared expres­
sion levels between ind ividuals w ith  auto im m une diseases but not unaffected fam ily 
m em bers o r con tro ls  were identified (259).
A recen t pha rm acogene tic  s tudy by Lequerre  e t a l. (189) se t out to iden tify  
genes p red ic tive  of responsiveness to in flix im a b  (R em icade® ), a TNF b locking 
agent, in PBMCs. T h ir ty -th re e  pa tien ts  w ith  h igh ly  active d isease re fra c to ry  to
m etho trexa te  (MTX) tre a tm e n t w ere inc luded (see Table 1); 16 pa tien ts  w ere c la s s i­
fied as responders  to in flix im ab , 17 as non-responde rs . U nsupervised h ie ra rch ica l 
c lu s te rin g  of 41 m RNAs d iffe re n tia lly  expressed in PBMCs p rio r  to tre a tm e n t p e r­
fec tly  d isc r im in a te d  responders  from  non -responde rs . These tra n s c r ip ts  inc luded 
CYP3A4, LAMR1 and KNG1, genes th a t w ere also d iffe re n tia lly  expressed in severa l 
o th e r s tud ies  and re lated to disease severity  (Table 2). Twenty of the 41 tra n s c r ip ts  
w ere assessed by q-PCR in a second se t of 10 responders  and 10 n on -responde rs  
to va lida te  th e ir  p red ic tive  value. This se t of tra n s c r ip ts  provided 90% se n s itiv ity  and 
70% sp e c ific ity  fo r the c lass ifica tio n  of responders  and n o n -responde rs  (S upple­
m en ta ry  Table 4) (189).
Also Lindberg and cow orkers (190) examined gene expression profiles in in flix i­
m ab-treated RA patients (n=10). They included three responders to therapy, five m oder­
ate responders and two non-responders (Table 1). Two hundred seventy-nine s ign ificant 
d ifferences in gene expression of synovial (inflamed) tissue were observed between the 
three good responders and the two non-responders (190). Several of the d iffe ren tia lly  
expressed genes were also observed in p a tien t-con tro l com parisons (Table 2).
Power estimation of expression profiling studies
Several param eters  are needed fo r pow er analysis of expression pro filing  
stud ies, such as sam ple  size and standard deviation (SD). SD was not m entioned in 
m ost of the stud ies. Therefore th is  pa ram e te r w as estim ated using a free ly  accessible 
RA expression dataset (Gene Expression Omnibus, GSE 1911; h ttp ://w w w .n cb i.n lm . 
nih.gov/geo/). Using th is  dataset, we ca lcu la ted the SD fo r the RA group (0,936) and 
fo r the con tro l group (0,670) and used these to de te rm ine  the m in im a l fold change 
in gene expression a study w as able to detect w ith  a s ta tis tica l pow er of 90%. A ll s tu d ­
ies were included (Table 1). In the study of B a tliw a lla  e t a l. (262) a 1.4 fold change in 
gene expression w as considered as th resho ld  fo r d iffe re n tia l expression of genes. We 
ca lcu la ted tha t 264 RA sam ples and 264 con tro ls  w ou ld  be needed fo r 90% pow er to 
detect a 1.4-fo ld  change; 29 were analyzed (Table 1). Szodoray and cow orkers (263) 
used a 3 -fo ld  change as c u t-o ff fo r d iffe re n tia l expression. We ca lcu la ted tha t 12 
sam ples in both groups w ould  be needed; e igh t were analyzed. Van der Pouw Kraan 
and cow orkers (260) used a 2.0 fold change c u t-o ff and there fore  44 sam ples in each 
group w ould  have been needed to reach 90% s ta tis tica l power; 15 were analyzed. The 
study of Olsen e t al. (261) considered a d iffe rence of 3 SD as th resho ld  fo r d iffe ren tia l 
expression. The to ta l group of pa tients  analyzed in th is  study (n=19) w as su ffic ie n t to 


















For the studies of Maas e t a l. (258) and Liu et al. (259) no in fo rm ation  about fold 
change, effect size o r False Discovery Rate (FDR) was provided. Assum ing a FDR of 5% 
fo r both studies and taking into account the num ber of sam ples in the studies, we e s ti­
mated that Maas and co -w orkers w ould have been able to re liably detect a fold change 
of 4.2 and higher, whereas Liu e t al. could detect a fold change of 02.0. Also Lequerre et 
al. (189) and Lindberg e t al. (190) did not report the fold change cu t-o ff used. Using the ir 
published effect sizes (1.9 fo r Lequerre et al., 2.9 for Lindberg et al.) we calcu lated the 
m in im a l fold change. Based on the num ber of sam ples analyzed, indeed, both studies 
appeared su ffic ien tly  powered to detect these effects.
Linkage and genome-wide association studies
Add itiona l inpu t fo r the iden tifica tion  of candidate genes fo r RA disease su s ­
ce p tib ility  can be obtained by com bin ing resu lts  of d iffe ren t experim en ta l approaches, 
like expression s tud ies and genetic linkage o r association s tud ies (267). Genes that 
are found d iffe re n tia lly  expressed in p a tie n t-co n tro l com parisons and tha t are located 
under linkage peaks fo r RA can be viewed as strong candidates fo r RA. Several 
w ho le -genom e scans fo r RA have been perfo rm ed (268-273). Recently, a lso two 
genom e-w ide  association s tud ies (GWAS) have been published.(187;274) In th is  study 
we com pared data from  linkage m eta-ana lyses (275;276) and the GWAS (187;274) w ith  
the resu lts  of the expression p ro filing  s tud ies described above. Several d iffe ren tia lly  
expressed genes were located in RA linkage regions (Table 3). As fo r overlap w ith  the 
GWAS, tu m o r necrosis  factor, a lpha-induced prote in 2 (TNFAIP2), w h ich was d iffe r­
en tia lly  expressed in the study of Maas and cow orkers (258), was also associated w ith  
RA in one of the GWAS (187).
Table 3 /  Overview of candidate  
one or  m ore  RA expression stud 
stud ies  (189;258;259;261)
genes located in RA suscep tib i l i t y  loci and d i f fe rent ia l ly  expressed in 
es w i th  highest  pr io r i ty  given to those  genes  found in proper ly  powered
Gene ID Gene loca tion Gene nam e Locus ident i f ied by RA References
l i nkage meta-analysis
KNGi 3q27 Kininogen 1 3q2 7.3 -q ter (189;258;259)
CSF3R 1p35-p34.3 Colony st imulat ing  factor 3 receptor 1p35.3-p32.2 (258;259;261)
TNNT2 1q32 Troponin T type 2 1q32-q42.3 (261)
PSMB9 6p21.3 Proteasome subunit ß type 9 (LPM2) .321p6 (189)
EPS15 1p32 EGF receptor pathway subst ra te  15 1p35.3-p32.2 (189)
MCP 1q32 M embrane  cofactor  protein (CD46) 1q32-q42.3 (189)
EPB72 9q34.1 Stom at in 9q33.3-qter (258)
IRF-4 6p25-p23 In terferon regu la to ry  fac tor  4 .32.2-pp6 (258)
NCF4 22q13.1 neu troph i l  cy tosol ic  fac tor  4 22q13 (26C)
IL-8 4q13-q21 In te r leuk in  8 4q13.3-q24 (26C)
GM-CSF (CSF2) 22q13.1 colony s t im u la t in g  fac to r  2 22q13 (26C)
STMN1 1p36.1 s ta thm in  1/oncopro te in  18 1p36 (26C)
PTPRK 6q22.2-23.1 protein tyrosine  phosphatase, 6q23 (26C)
receptor  type, K
AA59884C 1p34.3 - 1p35-p32.2 (26C)
AA48759C 13q12-q13 - 13q12 (26C)


















> DISCUSSION AND CONCLUSION
The advent of expression pro filing  in RA research has served several im portan t 
purposes: (1) long assumed concepts of RA got add itiona l support on the m olecu lar 
level. For example the study of van der Pouw Kraan and co -w orkers confirm ed the 
heterogeneous nature of RA and gave ins ight in the d is tinc t pathogenic m echanism s 
con tribu ting  to the disease (260). (2) C lin ica l b iom arkers to aid disease diagnosis, prog­
nosis and trea tm ent outcom e can be extracted from  the genes d iffe ren tia lly  expressed 
between RA patients and con tro ls  (277;278). The prognostic potentia l of gene expres­
sion profiles has been e legantly shown in cancer (279-283) and is a lready used in the 
c lin ic. Studies dealing w ith  various types of cancer show how gene expression p ro fil­
ing can help to predict trea tm ent outcom e in ind ividual patients (284-286). For RA two 
recent papers suggest feasib ility  of predicting trea tm ent response by pharm acogenom - 
ics, potentia lly  leading to more individualized trea tm ent s trateg ies (189;190). Especially 
Lequerre and co -w orkers (189) -by m easuring tran sc rip t levels at baseline in a w e ll 
accessible tissue (blood) su itab le for im plem enta tion  into c lin ica l p ractice- showed that 
a sm a ll subset of d iscrim ina tive  transcrip ts  can provide a tool to predict in flix im ab e ffi­
cacy in RA. The genes identified in the trea tm ent response studies were also found d if­
fe ren tia lly  expressed in s tudies related to disease severity, s trengthen ing the view that 
the same genes and genetic m echanism s may underlie  disease severity and response 
to anti-TN F trea tm ent (53).
In th is  s tudy we pe rfo rm ed  a sys tem a tic  lite ra tu re  search  to iden tify  a rray- 
based expression p ro filing  s tud ies  in RA. Our hypo thesis  w as th a t genes id e n ti­
fied in severa l o f the s tud ies  are b e tte r cand idates fo r fu r th e r  research in to RA 
s u sc e p tib ility  and p rogression  than those iden tified  only once. C om bina tion  of data 
from  severa l sou rces may also help in ta rge t id e n tifica tion  (267), the re fo re  we also 
inc luded in fo rm a tio n  from  RA linkage m eta -a n a lys is  and the two f irs t GWAS. We 
describe  the s im ila r it ie s  and d iffe rences  of the reviewed s tud ies  based on the data 
presented in the s tud ies , and ex trac t severa l genes tha t seem  s trong  cand idates 
fo r fu r th e r  s tudy (Table 2 and 3). The overlap between the GWAS and the exp res­
s ion p ro filing  s tud ies  w as som ew hat d isappo in ting , but m igh t be re lated to the low 
pow er of the s tud ies  pe rfo rm ed  so fa r w h ich  w il l  ce rta in ly  im prove. A b e tte r w ay to 
se lec t in te res ting  genes from  a ll s tud ies  w ou ld  be a m eta -ana lys is . However, due to 
the la rge he te rogene ity  between the s tud ies  th is  is im possib le . The gene expression 
data are obta ined from  s tud ies  w ith  d iffe re n t designs (case -con tro l, RA only) using 
very diverse p la tfo rm s  and probe se ts  and d iffe re n t sou rces of pa tien t m a te ria l or 
p a rtly  overlapp ing  pa tien t sam p les  (Table 1).
The d iffe rences in study design also ham per com parisons of the s ta tis tica l 
pow er between stud ies. However, using a s im u la tion  s tra tegy we were able to e s ti­
mate the s ta tis tica l power of ind iv idua l stud ies. Many of them  appeared underpow ­
ered. N evertheless a num ber good candidates fo r fu rth e r study were defined (Table 
3). Based on the power analysis the s trongest candidate genes w ould  be KNG1 and 
CSF3R. Both genes were found d iffe re n tia lly  expressed in th ree s tud ies w ith  su ffic ien t 
pow er (KNG1: (189;258;259), CSF3R: (258;259;261)) and are located in a known RA 
linkage region (276).
Based on the above it seem s very im p o rta n t to reduce he te rogene ity  between 
s tud ies  and increase pow er in fu tu re  s tud ies . One way to achieve a reduction  of h e t­
e rogene ity  is to m ake use of s tandard ized  p ro toco ls  fo r the desc rip tio n  of m ic ro a r­
ray experim en ts . MIAME is such a p ro toco l and describes the M in im u m  in fo rm a tio n  
About a M ic ro a rra y  E xp e rim e n t tha t is needed to enable unam b iguous in te rp re ta ­
tion  of the s tudy re su lts  and rep roduc tion  of the e xpe rim en t (h ttp ://w w w .m g e d .o rg / 
W orkgro u p s /M IA M E /m ia m e.h tm l). Of the described  s tud ies , only Lequerre  et. al. 
(189) s ta ted th a t th e ir  c lin ic a l and e xp e rim e n ta l data com p lies  w ith  the MIAME rec ­
om m enda tions . Besides the use of standard ized  p ro toco ls, w hen studying  com plex 
d iseases like  RA, the like lih o o d  of iden tify ing  im p o rta n t genetic  d isease d e te rm i­
nan ts  can be increased if pa tien ts  are w e ll cha rac te rized  and phenotypes are very 
n a rrow ly  defined (287).
In ou r study we combined expression profiling, linkage and genom e-w ide as­
sociation data to predict candidate genes for fu rth e r research. One m ight also consider 
taking add itiona l evidence into account, like proteom ics stud ies that identify proteins 
d iffe ren tia lly  expressed between patients and con tro ls  or between responders and non­
responders to trea tm ent (198;288).
To perm it the in tegra tion of data from  d iffe ren t sources, like expression p ro fil­
ing (in hum ans and m odel organism s), linkage, association and proteom ics studies, 
softw are too ls are cu rren tly  being developed (289) and som e are already in use, like the 
program s P rio ritize r' and Endeavour' (290;291). These perform  searches of existing 
lite ra tu re  as w e ll as of databases containing e.g. gene expression profiles to identify 
(new) candidate genes for various diseases.
In conclusion, expression pro filing  opens up a new era in diagnosis, prognosis 
and trea tm ent of RA and helps to elucidate many of the pathophysiological processes 
involved in th is  disease. Com bining in fo rm ation  from  d iffe rent stud ies and different 
sources can aid to find the r igh t genes to study in the maze of d iffe ren t reports. We have 
identified genes reproducib ly regulated in expression pro filing  stud ies of RA and/or 
present in RA linkage and association regions fo r RA and suggest tha t these are excel­
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> SUPPLEMENARY TABLES
S u p p le m e n ta r y  Table 1 /  Genes tha t we re  upregu la ted in RA B -ce l ls  com pared  to cont ro l B -ce l ls  and 
w e re  chosen fo r re -ana lysis  in the s tudy  of Szodoray and co -w o rke rs  (263).
Gene ID Gene nam e C h ro m o s o m a l  loca tion
CNNM 4 Cyclin M4 2p12-p11.2
BARD' BRCA1 associa ted RING domain  1 2q34-q35
U5-116KD U5 snR N P-spec i f ic  protein 116 kDa 17q21.31
TLR9 Tol l- l ike receptor  9, t ran sc r ip t  var ian t A 3p21.3
IL-5RA Inter leuk in  5 receptor, alpha 3p26-p24
IL-10 In ter leuk in  10 1q31-q32
IL-12A In ter leuk in  12A (natura l k i l le r  cel l  s t im u la to ry  fac tor  1, 
cytotoxic lymphocyte m atu ra t io n  fac to r  1, p35)
3p12-q13.2
PTX3 Pentax in- re la ted gene 3q25
CRLF ' Cytokine recep to r - l ik e  fac to r  1 19p12
C H R N B ' Chol inergic  receptor, nicot inic, beta polypeptide 1 17p13.1
DRD2 Dopamine receptor  D2, t ran sc r ip t  var ian t 1 11q23
MMP28 Matr ix  meta l lop ro te inase  28 17q11-q21.1


















S u p p le m e n ta r y  Tab le  2 /  Top 5 of h igher  expressed genes in RA-I vs RA-II g roup  and RA-II vs RA-I group 
in the study of van der  Pouw Kraan and co -w o rke rs  (260).
Gene ID Gene nam e Fold change q I%1 C h ro m o s o m a l
loca tion
Top 5 o f genes expressed af h ighe r level in RA -l group com pared fo R,A-H group
Im m u n o g lo b u l in s  (n = 10) - 20.90 0.91 -
NCF' N e u t roph i l  cy tosol ic  fac tor  1 20.25 0.91 7q11.23
MMP3 Matr ix  m eta l lopro te inase 3 12.67 2.03 11q22.3
AA59884C - 11.49 0.91 1p34.3
CX CL'0  (IP-10] Chemok ine (C-X-C motif)  l igand 10 7.80 0.91 4q21
Top 5 o f genes expressed af h ighe r levels in R A -ll group com pared fo RA -l group
T N N I ' Troponin I type 1 9.98 2.03 1q31.3
AA196465 - 8.43 2.90 -
KRT17 Keratin  17 6.91 1.87 17q12-q13.2
COL11A' Collagen type XI 6.74 0.91 1p21
TNNT3 Troponin T type 3 6.02 2.90 11p15.5
Compari son of sta t is t i ca l d i f fe rences  in gene express ion between the RA-I vs RA-II we re  genera ted by 
Signi f icance Analys is  of M ic roarrays  (SAM). q-va lues <5 we re  considered sign if ican t
S u p p le m e n ta r y  Tab le  3 /  Top-5 of und e r-  and overexpressed a u to im m u n e  genes  disp laying the highest
co r re la t ion  coef f icient  in pa ren t -o ff sp r in g  pai rs in the study  of Maas et al (258)
Gene ID Gene nam e Rs* P-va lue* Chro m osom a l
loca tion
Underexpressec EPB72 Stomat in 0,98 5
CDE8.4 9q34.1
genes KNG1 Kininogen 1 0,98 5
CDE8.4 3q27
ASL Arg in in osucc in a te  lyase 0,98 1.48E -05 7cen-q11.2
TNFAIP2 Tum or  necros is  factor, 
a lp ha- in duced  protein 2
0,98 5-0E8.4 14q32
MADCAM1 Mucosa l addressin cel l 
adhesion molecu le-1
0,96 1.18E -04 19p13.3
Overexpressec APEX APEX nuc lease (mul t i  func tional 0,98 5-0E8.4 14q11.2-q12
genes DNA repa ir  enzyme)
DGKA Diacy lglycerol kinase, alpha 0.98 1.48E -05 12q13.3
CHGB Chrom ogran in  B 0.95 3.89E -04 20pter -p12
GPR30 G pro te in -coup led receptor  30 0,95 3.89E -04 7p22.3
NFIL3 Nuclear factor, interleukin 3 regulated 0.95 3.89E -04 9q22
*The corresponding Spearman correlat ion (Rs) and signif icance (P-value, Student's f-test) for each gene are show r
Supp le m en ta ry  Table 4. Transc r ip t levels as pred ic to rs  of in f l i x imab respons iveness according  the s tudy  of 
Lequerre  ef al (189)
Gene ID Gene nam e SAM* t  test  
|p-va lue)*
C h ro m o s o m a l
loca tion
AKAP9 A kinase (PRKAl anchor  protein 9 -2.83 0.002 7q21-q22
LA M R ' R ibosom al protein SA (37LRP) -2.43 0.007 3p21.3
FBXO5 F-box protein 5 -2.42 0.006 6q25-q26
RASGRP3 RAS guany l releasing protein 3 
(calc ium and DAG-regulated)
-2.41 0.004 2p25.1-p24.1
PFKB4 6-Phosphofructo-2-kinase /fruc tose-2,6-biphosphatase 4 -2.33 0.003 3p22-p21
H L A -D P B ' M ajo r  HLA, c lass II DP beta 1 -2.32 <10-4 6p21.3
RPL35 R ibosom al protein L3E -2.2E NS 9q34.1
RPS16 R ibosom al protein S16 -2.24 NS 19q13.1
RPS28 Sim i la r  to 40S r ib oso m a l protein S28 -2.23 NS 19p13.2
PSMB9 Proteasom e subun it  ß type 9 (LPM2) -2.17 0.006 6p21.3
SCAM-1 Vinexinß (SH3-con ta in ing adapto r  molecu le-1 -2.1E NS 8p21.3
EPS15 EGF receptor  pathw ay  subst ra te  1E -2.12 0.003 1p32
TBL2 Transducin  (beta)- l ike 2 -2.12 NS 7q11.23
PTPN12 Protein ty rosine  phosphatase, n on -recep to r  type 12 -2.09 NS 7q11.23
MTCBP-1 M em b ran e - type  1 m atr ix  m eta l lo p ro te i r  
c y top la smat ic  ta i l  binding protein 1
-2.04 0.005 2p25.2
QIL1 QIL1 protein NS 0.009 19p13.3
COX7A2L Cytochrome c oxidase subun it  Vi la polypept ide 2 like NS 0.007 2p21
ELMOD2 ELMO domain  con ta in ing 2 + 1.85 NS 4q31.21
MRPL22 M itochond r ia l r ib oso m a l protein L22 + 1.99 0.009 5q33.1-q33.3
MCP M em b ran e  co facto r  protein (CD46) +2.30 0.005 1q32
*S ign if icance Ana lys is  of M ic roarrays  (SAM) value as an in dicator  of s igni f icance of t ran sc r ip t  variat ion 
in responders  versus  non -responders .  A positive or  negative value ind icates an over- or  undere xpres­
sion at base l ine in responders  ve rsus  non-responders ,  respectively. P-value of a f test as an in dicator  of 
s ign if ican t  t ran sc r ip t  varia t ion in responders  versus  non -respond e rs  (p < 0.05 is considered signif icant)  
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Objective: So far, there are no means of identify ing rheum atoid a rth r it is  (RA) 
patients who w ill fa il to respond to tu m o u r necrosis facto r blocking agents (anti-TNF), 
p rio r to trea tm ent. We used genom e-w ide gene expression pro filing  to identify gene 
expression signatures predicting therapy outcom e. We firs t tested the va lid ity of three 
published expression signa tures in ou r patient cohort. Second, we identified a new pre­
dictive gene expression signature. Third, we explored potentia l m echanism s underlying 
anti-TN F (non-)response.
Methods: Genome-wide expression p ro filing  using A ffym etrix  GeneChip Exon
1.0 ST arrays was perform ed on RNA isolated from  w hite  blood ce lls of 42 RA patients 
s ta rting  trea tm ent w ith  in flix im ab or adalim um ab. C lin ica l response according to EU- 
LAR crite ria  was determ ined at week 14 of therapy.
Results: Hypothesis-driven analysis of the dataset using two existing gene sets 
predictive of anti-TN F trea tm ent outcom e revealed a sensitiv ity of 71% and a spec ifi­
c ity of 61 and 28%, respectively, fo r classifying the patients in the cu rren t study. Our 
exploratory analysis identified a set of 113 genes whose expression predicted therapy 
response w ith  a sensitiv ity of 79% and a specific ity  of 84%. Genes involved in guanylate 
binding, apoptosis, transcrip tion , im m une response, in flam m ation  and ce llu la r p ro lif­
eration were enriched in the set.
Conclusions: We successfu lly validated one of three previously reported pred ic­
tive expression profile and identified a new one. The 113 genes associated w ith  an ti- 
TNF trea tm ent response point out specific pathways fo r fu rth e r study into m echanism s 
of anti-TN F action. Our resu lts  confirm  that gene expression p ro filing  p rio r to trea tm ent 































Rheumatoid a rth r it is  (RA) is a chronic in flam m ato ry  disease, w hich predom i­
nantly involves synovial jo in ts  and a ffects up to 1% of the w o rld 's  population (20). Tu­
m our necrosis factor (TNF) neutra liza tion  is one of the m ost effective therapeutic s tra t­
egies in RA. Nonetheless, th is  approach is not universally effective and approxim ately 
30% of patients treated w ith  TNF b locking agents fa il to achieve or m ainta in c lin ica l 
im provem ent (28). The com bination of prolonged high disease activity, high costs and 
risk  fo r adverse e ffects in these non-responding patients has driven the search for 
predictive m arkers  -  including genetic m arkers - that are able to predict trea tm ent 
outcom e. Insight into the genetics of anti-TN F therapy may fac ilita te  the choice fo r the 
m ost su itab le therapy fo r an individual patient regarding efficacy and safety, thus lead­
ing to more individualized trea tm ent in daily c lin ica l practice (42).
In recent years, genom e-w ide gene expression analysis using m icroarrays has 
become a key component in unravelling the underlying transcriptional regulation of various 
complex diseases (292-295). Gene expression profiling studies in patients w ith RA have not 
only revealed genes associated w ith the disease itself but also identified molecularly distinct 
subgroups of RA patients (67;296-298). Gene expression m icroarray technology has also 
shown to be able to assist in identifying genes which are involved in treatm ent response or 
adverse events associated w ith a therapy (299-303). To date, five studies used genome-wide 
gene expression analysis to identify gene expression signatures predicting the response to 
anti-TNF treatm ent in patients w ith RA (67 ;73; 189;191 ;192;304). Lequerre and co-workers 
perform ed a whole genom e m icroarray analysis in periphera l blood m ononuclear ce ll 
(PBMC) derived RNA from 13 RA patients treated w ith inflixim ab. Expression levels p rior 
to treatm ent in itiation of 41 mRNAs were identified that perfectly separated subsequent 
responders (n=6) from subsequent non-responders (n=7) to infliximab. Validation in 20 other 
patients reduced the set to 20 transcrip ts which classify anti-TNF responders and non-re­
sponders with a sensitivity of 90% and a specificity of 70%. Further reduction of the transcript 
set to only 8 transcripts changed sensitivity to 80% and specificity to 100% (189). Lindberg et. 
al (190) examined gene expression profiles in arthroscopic biopsies from  10 RA patients be­
fore and after infliximab treatment. Their data revealed 279 genes significantly differentially 
expressed in responders and non-responders to infliximab (190). More recently, Koczan and 
co-workers analyzed RNA extracted from PBMCs of 19 RA patients treated w ith etanercept. 
Forty-two differentially expressed genes were examined for the ir ability to discrim inate 
between anti-TNF responders and non-responders, reaching prediction accuracies of 95% 
for given combinations of genes at day 3 of treatm ent, but not p rio r to treatm ent (192).
Two o ther stud ies by Sekiguchi and co -w orkers and van der Pouw Kraan e t al. 
used expression p ro filing  to get more ins ight into the m echanism s underlying the ac­
tion of anti-TNF. They did not report predictive values fo r expression profiles, but the ir 
s tudies suggest tha t responders to trea tm ent are characterized by a h igher level ex­
pression of in flam m ato ry  genes in synovial tissue (73) and that the increased expression 
of in flam m ato ry  genes in responders norm alizes faste r than in non-responders (191).
Despite these prom ising results, the genes identified in each study show little  
overlap. This can partly  caused by the high false positive rate associated w ith  m u lti­
ple testing in a lim ited sample, thus necessitating va lidation in separate cohorts. In 
th is  report we used gene expression pro filing  on w hite  blood ce lls  (WBC) from  42 RA 
patients treated w ith  the m onoclona l anti-TN F antibodies in flix im ab and ada lim um ab 
to validate previously reported gene expression s ignatures (189;191) fo r th e ir predictive 
value in our independent anti-TN F patient cohort. Only patients treated w ith  anti-TN F 
antibodies (in flix im ab and adalim um ab) and not w ith  a so luble receptor (etanercept) 
were included in th is  study to guarantee homogeneity. The expression levels were su b ­
sequently used to identify a new gene expression signature  predicting therapy outcome. 
As a last goal, the genes in th is  newly identified expression signature  were analyzed to 
unravel the underlying b io logica l pathways and m echanism s that m ight be involved in 






























> MATERIAL AND METHODS
Patients
AH pa tie n ts  had RA accord ing  to the 1987 revised A m erican  College of 
R heum ato logy (ACR) c r ite r ia  (9) and a ttended the D epa rtm e n ts  of R heum ato logy 
of the Radboud U n ive rs ity  N ijm egen  M ed ica l Centre o r the St. M a a rte n sk lin ie k  in 
N ijm egen. The pa tie n ts  se lec ted  fo r the c u rre n t s tudy  a ll p a rtic ip a te  in the Dutch 
R heum ato id  A r th r it is  M on ito ring  (DREAM) reg is try . The la tte r  c o lle c ts  deta iled  
c lin ic a l in fo rm a tio n  and tre a tm e n t ou tcom e of pa tie n ts  who s ta r t  th e ir  f ir s t  course 
of a T N F-b lo ck in g  agent accord ing  to the Dutch reco m m en d a tio n s  (D isease A c tiv ­
ity Score 28 (DAS28) > 3.2 and previous fa ilu re  on at least two d isease -m o d ify ing  
a n tirh e u m a tic  d rugs  (DMARDs), one of w h ich  has to be m etho trexa te  (MTX)) (219). 
Response to TNF n e u tra liza tio n  w as assessed at w eek 14 accord ing  to the EULAR 
c r ite r ia  (16). Consecutive  pa tie n ts  en ro lle d  in the DREAM s tudy between 2004 
and 2008 w ere inc luded  in th is  study. Only good responde rs  and non -re sp on d e rs  
at 14 w eeks based on the EULAR response c r ite r ia  w ere se lec ted  fo r exp res­
s ion  analyses. P a tien ts  w ith  a m odera te  response w ere  excluded. This resu lte d  in 
fo rty -tw o  pa tie n ts  (1 8 good responders  and 24 non -responde rs ) th a t w ere inc luded 
in the s tudy (Table 1), rep resen ting  the ex trem es of a to ta l o f 92 pa tien ts . Power 
c a lcu la tio n s  showed th a t th is  sam p le  of 42 pa tien ts  had a pow er of 80% to detect 
a m in im a l fo ld  change of two w ith  an alpha of 0.0000027. R esponders and no n ­
responde rs  w ere  frequ e n cy -m a tch e d  fo r gender, age, R F -pos itiv ity  and use of 
MTX. B lood w as sam p led  p r io r  to tre a tm e n t s ta r t  ( in flix im a b  o r ada lim um ab). The 
reg io n a l e th ics  review  board had approved the s tudy and a ll pa tie n ts  had provided 
w r itte n  in fo rm ed  consent.
Molecular analyses
A ll m o le c u la r  ana lyses w ere p e rfo rm ed  in a CCKL (C oörd ina tie  C o m m is ­
sie te r bevordering  van de K w a lite itsb e h e e rs in g  van het Labora to riu m o n de rzo e k ] 
-accred ited  la b o ra to ry  at the  D epa rtm en t of Hum an G enetics at the Radboud 
U n ive rs ity  N ijm egen  M ed ica l Centre in N ijm egen. RNA w as iso la ted  w ith in  0.5 
hours  a fte r  venapunc tu re , using the RNeasy m id i k it accord ing  to the m a n u fa c ­
tu re r 's  p ro to co l (Qiagen Bene lux B.V. Venlo, The N e the rlands). To rem ove res idu a l
Table 1 /  B ase l ine  charac ter is t ics ,  disease activi ty at base l ine and DAS28 im provem ent  for responders 
and non -respond e rs  to an t i-TN F  t rea tm ent
Responders N o n - re sp o n d e rs
N (basel ine and 14 weeks  fol low-up) 18 (43%) 24 (57%)
Female gender 16 (89%) 14 (58%)
Age (mean ± SD) 58 ±14.2 57 ±13.6
RF posit ivi ty 13 (72%) 19 (79%)
Ad a l im u m a b 4 (27%) 11 (52%)
Inf l ix imab 14 (73%) 13 (48%)
M TX-com ed ica tio r 18 (43%) 24 (57%)
DAS28 base l ine (mean ± SD) 5.3 ±1.0 4.8 ±1.5
DAS28 decrease a fte r  14 w e eks  of an t i-TN F  therapy  (mean ± SD) 2.0 ±0.8 0.1 ±1.0
Percentage  DAS28 change  14 w eeks  of an t i-TNF therapy 37 ±10 -1 ±25
Resu lts are n u m b e r  (percentage) or  mean (SD). Percentages are expressed in relat ion to the to ta l num ber  
of pat ients for each response group (except for the to ta l n u m b e r  of patients)
traces  of genom ic  DNA, the RNA w as trea ted  w ith  DNase I (Inv itrogen, Leek, The 
N e the rlands) w h ile  bound to the RNeasy co lum n . Q uality  and q u a n tity  o f the p u r i­
fied RNA w as co n tro lle d  using a N anoD rop sp e c tro p h o to m e te r (N anodrop te c h ­
no log ies, M ontchan in , DE, USA). RNA in te g rity  w as investiga ted  by using the 2100 
B ioana lyse r (A g ilen t techno log ies , P h ilade lph ia , PA, USA). RNA w as exam ined fo r 
possib le  deg rada tion  using agarose ge l e le c tro p h o re s is . Gene expression  p ro filing  
w as p e rfo rm ed  using A ffy m e trix  1.0 Hum an Exon ST arrays, rep resen ting  a ll known 
genes (17881) (A ffym e trix  Inc., Santa C lara, CA, USA) accord ing  to the m a n u fa c tu r­
e r's  in s tru c tio n s . The A ffym e trix  GeneChip W hole T ra n sc rip t Sense Target Labeling 
Assay w as used to genera te  a m p lifie d  and b io tiny la ted  se n se -s tra n d s  DNA ta rge ts  
from  the e n tire  expressed genom e (2.0 pg of to ta l RNA). A rrays  w ere hybrid ized  by 
ro ta tin g  them  at 60 rpm  in the A ffym e trix  GeneChip hyb rid iza tion  oven at 45 °C for 
1 7 hours. A fte r hyb rid iza tion , the a rrays  w ere  w ashed in the A ffy m e trix  GeneChip 
F lu id ics  s ta tio n  FS 450. A rrays  w ere scanned using the A ffym e trix  GeneChip sc a n ­






























Data extraction and statistical analyses
For quality control, the Affym etrix CEL-files were firs t imported into Affymetrix 
Expression Console version 1.1 where control probes were extracted and normalized us­
ing the default RMA algorithm . The Area Under the Curve (AUC) of the Receiver Operator 
Characteristic was calculated using the positive and negative control probes. A ll arrays 
had an AUC score above the em pirica lly defined threshold of 0.85 indicating a good sepa­
ration of the positive controls from  the negative controls. Pearson correlation between 
arrays showed no outliers. Subsequently, the CEL-files were imported into Partek®  
(Partek®  Genomic Suite software, version 6.4 Copyright ©2008 Partek Inc., St. Louis, MO, 
USA) where only core probe sets were extracted and normalized using the RMA algorithm  
w ith GC background correction. Core transcrip t sum m aries were calculated using the 
mean intensities of the corresponding probe sets, representing the quantitative expression 
levels of a ll genes. We performed a mixed m odel analysis of variance (ANOVA) on the log2 
probe intensities (representing the gene expression intensities) based upon the EULAR re­
sponse criteria after 3 m onths of treatm ent. Variance components indicated that the scan 
date of the samples influenced the expression profiles and this was included in the model 
as a covariate. A p-value of <0.01 was considered as a sta tistica lly significant difference in 
gene expression levels. No correction for m ultip le  testing was applied.
Validation of previously reported expression signatures
We used the tran sc rip t sets from  the study of Lequerre and cow orkers (189] 
and the study of Sekiguchi e t al. (191) fo r va lidation in ou r patient cohort because they 
m atched our experim enta l set up in the fo llow ing aspects: 1) both studies present tra n ­
sc rip t sets that are able to d istingu ish between responders and non-responders based 
upon analyses at baseline (before trea tm ent start) and 2) both stud ies used blood cells 
as s ta rting  m a te ria l (Lequerre used PBMCs, Sekiguchi used whole blood). The pub­
lished tran sc rip t sets were linked to the corresponding expression values obtained in 
ou r analyses. K -m eans partition  c luste ring  was perform ed using Pearson d iss im ila rity  
as a distance m easure. The num ber of partition  c lus te rs  was set to two (non-responder 
and responder). The true positive and true  negative responses values were calculated. 
Sensitiv ity was calculated by the fo llow ing fo rm u la : true  positives (true anti-TN F non­
responders identified as non-responders) /  true  positives + false negatives (true non­
responders identified as responders). Specific ity was calcu lated by the fo rm u la : true 
negatives (true responders identified as responders) /  true negatives + false positives 
(true responders identified as non-responders).
Identification of a new gene expression signature
Gene expression signa tures were identified using K-m eans partition  c luste ring . 
Only genes w hich showed a s ign ifican t difference (p<0.01, no m u ltip le  testing co rrec­
tion) a fte r ANOVA were included. The true positive and true  negative response values 
and the sensitiv ity and specific ity  were calculated.
Analysis of biological pathways and transcription factor binding sites
A hypothetic gene regu la tory netw ork was created from  the lis t of s ign ifican tly  
d iffe ren tia lly  expressed genes using Pathway Studio softw are version 6.0 (Ariadne 
Software, Rockville, MD, USA), w hich contains a large database of lite ra tu re -m ined  and 
curated protein in teractions. The Database fo r Annotation, V isualization and in tegra ted 
Discovery (DAVID) 2008 web-accessib le  functiona l annotation tool was used to identity 
b io log ica l processes enriched in the lis t of d iffe ren tia lly  expressed genes (h ttp ://dav id . 
abcc.ncifcrf.gov/hom e.jsp; accessed in December 2008) (305). The com puta tiona l tool 
rVISTA (h ttp ://genom e.lb l.gov/v is ta ; accessed in December 2008) was used to search for 
transcrip tion  facto r b inding sites (TFBS) over-represented (p-value < 0.006) in the 300 
base pairs upstream  regions of the genes expressed at d iffe ren t levels in responders 































Table 1 shows patients' characte ris tics, mean disease activity (DAS28) at base­
line and DAS28 im provem ent 14 weeks a fte r trea tm ent sta rt. In to ta l 42 RA patients 
treated w ith  anti-TN F were included in the study. According to the EULAR defin ition of 
response (16), 18 patients in our sam ple responded w e ll to anti-TN F trea tm ent and 24 
patients showed no response to the treatm ent. Twenty-seven patients were treated w ith 
in flix im ab, 15 were treated w ith  adalim um ab. No d ifferences between WBC concentra ­
tions (lymphocyts, neutrophils, eosinophils, basophils and monocytes) were observed 
between the responders and non-responder group.
F irst, we attem pted to validate two previously published expression s ignatures 
predicting response to anti-TN F by extracting the expression levels observed fo r the 
genes reported by them  from  our dataset. The tran sc rip t sets from  the study of Leq- 
uerre and cow orkers (189) and the tran sc rip t set from  the study of Sekiguchi et al. (191] 
were linked to the expression values of our 42 RA patients. For the study of Lequerre et 
al., the tran sc rip t set of 20 genes was able to c lassify our patients as anti-TN F respond­
ers and non-responders w ith  a sensitiv ity  of 71% and a specific ity  of 61%, a transcrip t 
set of 8 genes reported by them  classified the patients w ith  a sensitiv ity  of 71% and 
a specific ity  of 28% (Figure 1A and 1B). The tran sc rip t set reported in the study of 
Sekiguchi and cow orkers was able to classify our patient w ith  a sensitiv ity  of 71% and 
specific ity  of 28% (Figure 1C).
Subsequently, we perform ed an exploratory genom e-w ide analysis of the data 
and identified 113 genes that, at baseline, were s ign ifican tly  d iffe ren tia lly  expressed 
in responders and non-responders to TNF blockade by m onoclona l antibodies (Sup­
p lem entary Table 1). The K-m eans c lu s te r analysis on these genes divided the patients 
into two c lus te rs  w hich were identified as a responder and a non-responder c lus te r 
(Figure 2), w ith  a sensitiv ity  of 79% and a specific ity  of 84%.
As shown in Supplem entary Table 2, several b io logica l processes were found to 
be enriched among the 113 d iffe ren tia lly  expressed genes, includ ing guanylate binding 
(represented by a num ber of im m une response related genes), apoptosis, transcrip tion  
and in flam m ation /im m une  response. Im portantly, m ost of the genes fitting  into these 
categories were upregulated in responders compared to non-responders to anti-TN F 
trea tm ent. To get c loser to the potentia l underlying m echanism s regulating response to 
anti-TN F therapy we perform ed gene netw ork analysis and searched fo r transcrip tion  
facto r binding sites enriched in the d iffe ren tia lly  expressed genes. The la tte r revealed 
that 21 genes showed d irect in te ractions w ith  at least one o ther gene from  the list. A
Figure 1 /  Clus ter analysis for the transc rip t sets reported in the studies of Lequerre (189) and Sekiguchi (191)
R esponders
N o n - re s p o n d e rs
K -m e a n s  c lu s te r  ana lysis based upon the t ran sc r ip t  sets  repor ted by A) Lequerre  (20 genes), B) Lequerre  
(8 genes) and C) Sekiguch i (18 genes). The previously  pub l ished  t ran sc r ip t  sets  we re  l inked to the expres ­
sion va lues  of 42 RA patients trea ted w i th  ant i-TNF in our  study. The two c lu s te rs  we re  identi f ied as the 






























group of 17 genes form ed the la rgest netw ork (Figure 3). The genes EGF (epiderm al 
grow th factor), STAT (Signal transducer and activa tor of transcrip tion) 1 and STAT2 have 
a cen tra l place in th is  netw ork and are im portan t fo r ce llu la r p ro life ra tion . The search 
fo r enriched TFBS was focused on the 61 genes w hich were upregulated in responders, 
and the 52 genes w hich were downregulated in the responders compared to the non 
responders. The search yielded 9 transcrip tion  factors overexpressed in the respond­
ers, w ith  ATF1 being m ost s ign ifican tly  overrepresented (p=1.8-10-12), and only one 
transcrip tion  factor, NANOG downregulated in responders (Supplem entary Table 3).
Figure 2 /  Cluster analysis
( ^ )  Responders  
( ^ )  N o n - re s p o n d e rs
Based upon the expression in tensi t ies  of these  113 d if fe rentia l ly  expressed genes  the K -m e a n s  c luster  
analysis divided the data in two clusters . The two c lu s te rs  we re  identi f ied as the non -respond e r  (1) anc 
responder  (2) c lu s te rs































Three main objectives were investigated in th is  study. F irst we analyzed cand i­
date profiles described in e a rlie r pharm acogenom ics stud ies of anti-TN F trea tm ent 
in RA. To our knowledge, th is  is the firs t study in w hich previously reported expression 
s ignatures fo r anti-TN F response are re-investigated in an independent patient cohort. 
Subsequently, we perform ed a genom e-w ide analysis to derive a new gene expression 
signature  able to predict outcom e at 14 weeks in RA patients treated w ith  TNF blocking 
agents. Both these analyses were based on whole transcrip tom e pro filing  p rio r to the 
firs t anti-TN F adm in is tra tion . As an add itiona l goal of the study we aimed at p inpointing 
the m echanism s that m ight explain the m echanism s underlying anti-TN F action and 
the in te r-ind iv idua l variation in response to treatm ent.
The expression profiles identified in d ifferent studies are often not consistent w ith 
each other and d iffe rent gene sets have been reported to distinguish between respond­
ers and non-responders (73; 189-192). One reason for the differences between studies 
m ight be the lim ited sample sizes. Other reasons for inconsistent resu lts  m ight be d if­
ferences in tissues used for analysis (synovial biopsies, PBMCs, whole blood), RNA iso la ­
tion and analyses at d ifferent tim e points, d ifferences in types and doses of anti-TNF 
medication, d ifferences in response criteria  (ACR, EULAR or DAS28 change), differences 
in techniques (array p la tform s, q-PCR methods) and differences in patient e thnicity 
(Caucasian, Asian). Despite the differences observed between the studies it tu rns out 
to be possible to obtain a reasonably good classification of anti-TN F responders and 
non-responders using one of the three previously described candidate profiles (189;191). 
One transcrip t set (20 genes) from  the study of Lequerre e t al. (189) was validated w ith 
a sensitiv ity of 71% and specific ity of 61 %. The validation of th is 20 genes profile results 
in a relatively good sensitiv ity and specificity, even in a d ifferent type of m ate ria l (whole 
blood versus PBMCs). However, we failed to validate two other previously described 
transcrip t sets. Possible explanations for th is m ight be caused by the high false positive 
rate associated w ith  m u ltip le  testing in a lim ited sample, heterogeneous patient cohorts 
and differences in study design or array p la tfo rm s between studies.
Our new exploratory expression s ignature  was able to divide the patients in 
responders and non-responders w ith  a sensitiv ity  of 79% and a specific ity  of 84%. This 
con firm s that ou r resu lts  for the expression pro filing  show potentia l, however, a c ritica l 
rem ark is in place. Our investigated cohort of 42 patients consisted of good responders 
and non-responders according to the EULAR crite ria . No m oderate responders were 
included in th is  cohort. Before such an expression pro filing  test can be im plem ented in
the c lin ic, va lidation of th is  expression s ignature  in a la rge r cohort, consisting of good, 
moderate and non-responders, is needed. Furtherm ore, the sensitiv ity and specific ity 
of the tests m ight be fu rth e r enhanced by includ ing into the equation o ther types of 
b iom arkers, like genetic po lym orphism s, and /o r c lin ica l characteristics.
The th ird  goal of th is  study was to gain more insight in the m echanism s underly­
ing therapy outcome. We found that many of the d iffe ren tia lly  expressed genes are part 
of b io logical processes relevant to the disease activity and potentia lly  the etio logy of 
RA, like im m une response /in flam m ation, apoptosis and transcrip tion  (Supplementary 
Table 2). Interestingly, m ost genes involved in the im m une response were upregulated 
in responders compared to non-responders. These find ings in WBC, together w ith  
s im ila r  resu lts  reported by van der Pouw Kraan et al. in synovial tissue (73) do suggest 
tha t an overa ll enhanced baseline expression of in flam m ato ry  genes is associated w ith 
response to TNF neutra liza tion. Interestingly, ou r study showed that guanylate binding 
protein (GBP) 1, 5 and 7, three genes from  the same fam ily, were a ll upregulated in 
responders when compared to non-responders. GBPs are induced by in terferon gamma 
(IFN-y) and are involved in pro life ra tion  and regu la tion  of ce ll growth (307). This fam ily 
of prote ins has an proven role in im m un ity  (307), though it has not been linked to an ti- 
TNF response, before. These resu lts  suggest tha t the underlying cause of RA m ight be 
d iffe ren t in patients w ith  increased expression of in flam m ato ry  genes, i.e. the anti-TN F 
responders, than in anti-TN F non-responders. Our study identified an add itiona l im ­
m une related gene, EGF, w hich was upregulated in responders. This gene may be an 
in teresting candidate fo r fu rth e r study since also Fabre and co -w orkers showed w ith 
protein biochip array technology that high serum  levels of EGF, especia lly if combined 
w ith  high CRP levels, were associated w ith  a good response to etanercept trea tm ent at 
3 m onths (sensitivity: 87.5% and specific ity: 75%) (308).
Also the genes involved in apoptosis are in teresting candidates in the context of 
the efficacy of TN F-blocking therapy. Most genes involved in apoptosis identified in our 
study were upregulated in responders compared to non-responders. Hlavaty and co­
w orkers  investigated the role of genes involved in apoptosis in in flix im ab trea tm ent in 
patients su ffe ring  from  Crohn's disease (CD). They observed that CD patients w ith  a low 
apoptotic response to in flix im ab had a h igher chance of becoming a non-responders 
to in flix im ab trea tm ent compared to patients w ith  a high apoptotic response (309;310). 
Catrina and co -w orkers reported a grea te r increase in apoptosis levels in those RA 
patients that responded w e ll to trea tm ent w ith  in flix im ab o r etanercept compared to 
non-responders, but the difference did not reach s ta tis tica l s ignificance (164). In con­
clusion, the resu lts  of our study and the resu lts  reported by Hlavaty e t a l. (309;310) and 
Catrina et al. (164) suggest tha t apoptotic genes m ight be useful m arkers  d isc r im in a t­






























The category of genes related to transcrip tiona l b io logical processes contained 
a num ber of im m une related genes, as w e ll. Notably, STAT2 m ight be a prom ising 
candidate gene given its involvement in in terferon (IFN) receptor mediated signaling
(311). Also Sekiguchi and co -w orkers reported IFN related genes to be d iffe ren tia lly  
expressed between in flix im ab responders and non-responders. Their top ten m ost 
d iffe ren tia lly  expressed genes were a ll IFN related (191). In line w ith  th is, as m entioned 
above, our study showed the GBP genes to be d iffe ren tia lly  expressed in responders and 
non-responders to anti-TNF. Also these genes are involved in IFN-Y signaling, em pha­
sizing a potentia lly  im portan t role fo r IFN -y  related pathways in anti-TN F response.
A fam ily  m em ber of the STAT2 gene, STAT1, revealed a cen tra l role in the recon­
s tructed  dynam ic netw ork and showed a d irect in teraction  w ith  PTGS2 (or COX2, the 
target of selective inh ib ito rs used fo r pain and in flam m ation  m anagem ent in a rth ritis
(312)). STAT1 and STAT2 are m em bers of the STAT protein family. In response to cy­
tokines and growth factors, STAT fam ily  m em bers are capable of inducing a w ide range 
of genes, includ ing the in flam m ato ry  genes IFN -gam m a, IL10, IL12 and IL13 (313). 
Po lym orphism s in several m em bers of the STAT fam ily  of genes have been found to be 
associated w ith  RA and o ther au to-im m une diseases (314-321). Our own find ings now 
also im plicate the STAT genes in anti-TN F response.
The search fo r com m on TFBS overrepresented in genes d iffe re n tia lly  ex­
pressed in responders and non-responders  identified  h igh ly  s ign ifican t overrepresen­
ta tion  of binding s ites fo r severa l im m une -re la ted  tran sc rip tio n  factors. This analysis 
m igh t add genes to the lis t of p rom is ing  candidates fo r fu rth e r study regard ing the 
m echan ism s of an ti-TN F  response.
The cu rren t analysis should be viewed in the lig h t of some s treng ths and 
lim ita tions . A relative s treng th  of ou r study is the sam ple size. Our study investigated 
a to ta l of 42 w e ll characterized patients. To ou r knowledge, th is  is the la rgest sam ple 
investigated fo r expression pro filing  to d is tingu ish between an ti-TN F responders and 
non-responders. Ano ther s treng th  of th is  study is that, fo r the firs t tim e, va lidations 
of o ther expression s igna tures are incorporated. This leads to a more evidence-based 
and be tte r argued conclusion in favor of expression pro filing  as a too l fo r predicting 
an ti-TN F response then the resu lts  from  only one single experim ent. A lim ita tio n  of 
the study is given by the fact tha t RA is a very heterogeneous disease, w h ich makes 
it very d iff icu lt to se lect two hom ogeneous groups (responders and non-responders) 
fo r the study. Patients were m atched fo r gender, RF positivity, MTX usage and age and 
divided into responders and non-responders based upon the EULAR response c rite ria . 
Nonetheless, ind iv idua l patient cha rac te ris tics  like DAS28, CRP, diseased duration, 
disease onset, age, co-m edication , jo in t erosions, sm oking and Health Assessm ent 
Questionnaire (HAQ) w ith in  the two groups were s lig h tly  d ifferent. This m ight have
lim ited  ou r power to detect gene expression d ifferences in the com parison be tw een  the 
two groups. In addition, only two genes w ith  a fold change of >2 were detected (MOP1 
and G0S2). Therefore the pa tient population investigated should be increased to have 
su ffic ien t power (80%) to detect fold changes <2. Another possible lim ita tion  of our 
study arises from  the fact tha t we used RNA isolated from  periphe ra l blood. Synovial 
biopsy sam ples are like ly to re flec t the consequences of in flam m ation  at a specific 
jo in t and the therapeutic  response to an ti-TN F  more d irec tly  (190;260), however, 
obtaining such sam ples is d ifficu lt. Especially, th is  w ou ld  lim it th e ir  use fo r diagnostic 
testing, fo r w h ich easy accessib ility  of m a te ria l is an im portan t aspect. In addition, we 
analyzed the two an ti-TN F  agents together, and it is possible tha t genetic m arkers 
associated w ith  response d iffe r between these agents. The last lim ita tion  is tha t we 
did not correc t fo r m u ltip le  testing, and th is  increases the chances of false positive 
find ings. However th is  study should be viewed as a hypothesis generating study, in 
o rder to investigate if ou r identified expression profile is rea lly able to separate the 
responders from  the non-responders, we suggest to validate th is  expression profile in 
an independent and lager patient cohort.
To conclude, th is  study successfu lly validated an e a rlie r reported gene expres­
sion profile predictive of anti-TN F trea tm ent outcom e and indentified a new phar- 
m acogenom ic expression profile of 113 genes suitab le for prediction of response to 
anti-TN F therapy. Our find ings con firm  e a rlie r find ings suggesting that responders to 
trea tm ent show a h igher level of in flam m ation  compared to anti-TN F non-responders, 
indicating potentia lly  d iffe ren t m echanism s con tribu ting  to disease in the la tte r group.
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Supp le m en ta ry  Table 1 /  Genes that are dif ferential ly expressed between ant i-TNF responders and non -responders (113 genes)
Gene sy m b o l  Gene n a m e  C h ro m o s o m a l  locat ion
MOP-1 MOP-1 4q21.22
G0S2 G0/G1switch 2 1q32.2-q41
PTGS2 P ros tag land in -endoperox ide synthase 2 1q25.2-q25.3
GBP1 Guanylate binding protein 1, in te r fe ro n-induc ib le  1p22.2
EGR3 Early growth  response 3 8p23-p21
NR4A2 Nuc le ar  receptor  sub fam il y  4, group A, m e m b e r  2 2q22-q2
PMAIP1 P h o rb o l-12 -m y r is ta te -13 -ace ta te - in duced  protein 1 18q2
EGR2 Early growth  response 2 10q21.1
GBP5 Guanylate binding protein 5 (GBP5), m R N A  1p22.2
MGLL Monog lycer ide l ipase 3q21.3
PDE3A Phosphod ies terase 3A, cGMP-inh ib ited  12p12
EGF Ep id erm a l growth  fac tor 4q25
AXUD1 AXIN1 up- regu la ted  1 3p22
RAPGEF1 Rap guanine  nucleot ide exchange fac tor (GEF) 1 9q34.3
HSPC159 Galect in -re la ted protein 2p14
GPD2 G lycero l-3-phosphate  dehydrogenase  2 (m itochondr ia l)  2q24.1
STAT2 Signa l t ra n sd u ce r  and act ivator  of t ransc r ip t i on  2 12q13.2
PCSK6 Proprotein  convertase subt i l is in /kex in  type 6 15q26.3
PSTPIP2 P ro l in e -se r in e - th reon ine  phosphatase  in te ract ing  protein 18q12
C7orf41 C h rom osom e 7 open reading f ram e  41 7p15.1
PPP1R15A Protein phosphatase  1, regu la to ry  ( inhibitor) su bun it  1 19q13.2
PCGF5 Po lycomb group  r ing f in ge r  5 10q23.32
GMPR Guanos ine monophospha te  reduc tase 6p23
TPM1 Tropomyosin 1 (alpha) 15q22.1
SESTD1 SEC14 and spect r in  dom a ins  1 2q31.2
TMOD2 T ropom odu lin  2 (neuronal) 15q21.1-q21.2
NB N  Nibr in  8q21
PKHD1L1 Polycystic kidney and hepatic disease 1 8q23.1-q23.2
NEXN  Nexi lin (F act in binding protein) 1p31.1
DUSP1 Dual speci f ic i ty  phosphatase  1 5q34
GRAMD1B GRAM domain  con ta in ing 1B 11q24.1
STAT1 Signa l t ra n sd u ce r  and act ivator  of t ransc r ip t i on  1 2q32.2
M PP7  M em brane  protein, pa lm ito yla ted 7 10p11.23
YPEL5 Y ippee-l ike 5 (Drosophila) 2p23.1
Biological process P-value Fold change
U n know r
Regula t ion of progress ion th ro ugh  cel l  cycle
Fatty acid biosynthet ic  process, p rostagland in  biosynthesis, in f l amm at io n  
Im m une  response 
Transcr ip t ion,  apoptos is 
Transcrip t ion
Cytochrome c f rom  mitochondria  
Regula t ion of transcrip t i on ,  apoptosis  
Im m une  response 
Lipid m etabo l ic  process 
Lipid m etabo l ic  process
Act iva t ion of MAPKK activi ty, im m u n e  response 
Apoptos is,  regulat ion of t ranscrip t i on  
Signa l t ransduction ,  apoptos is 
Unknown
Glucose catabo l ic process




Apoptos is,  cel l  cycle ar rest, regulat ion of t ranscrip t i on
Transcrip t ion
Metabo l ic  process
Cell  moti l i ty
Unknown
Nervous sys tem  deve lopment
DNA dam age checkpoint ,  cel l  prol i fe rat ion
Unknown
Regula t ion of cel l  migra t ion
Protein am ino acid d e p h o s p h o r y la t o
Unknown








































































Supp le m en ta ry  Table 1 /  Genes that are dif ferential ly expressed between ant i-TNF responders and non -responders (113 genes)
Gene sym b o l Gene nam e C h ro m o s o m a l  locat ion
C9orf91 Ch rom osom e 9 open reading f ram e  91 9q32
GCH1 GTP cyc lohydrolase 1 (dopa-respons ive dystonia) 14q22.1-q22.2
NT5C3 5'-Nuc leot idase,  cytoso l ic III 7p14.3
GBP7 Guanylate binding protein 7 1p22.2
RNF11 Ring f inger  protein 11 1pter-p22.1
XRN1 5'-3'  Exoribonuc lease 1 3q23
TAP2 Transpo r te r  2, ATP-b ind ing cassette, sub - fa m i ly  B (MDR/TAP) 6p21.3
VEPH1 Ve n tr ic u la r  zone expressed PH dom ain  homolog 1 (zebrafish) 3q24-q25
GCNT2 Glucosaminy l (N-acetyl) trans fe rase  2, I -b ranch in g  enzyme 6p24.2
FRMD3 FERM dom ain  con ta in ing 3 9q21.32
TNFAP3 Tum or  necros is  factor, a lp ha- in duced  protein 3 6q23
GTPBP2 GTP binding protein 2 6p21-p12
GTF2F2 General t ran sc r ip t ion  fac to r  IIF, polypeptide 2 13q14
PPCDC Phosphopanto thenoy lcys te ine decarboxylase 15q24.2
APP Amylo id  beta (A4) p recu rso r  protein 21q21.3
PDE4B Phosphod ies terase 4B, cAM P-spec i f i c  (phosph od iesterase E4B) 1p31
SLK STE20-l i ke kinase (yeast) 10q25.1
TAS2R50 Taste receptor, type 2, m e m b e r  50 12p13.2
UVRAG UV radia t ion res istance associa ted gene 11q13.5
C M P C -M af- induc in g  protein 16q23
MED12L M edia to r  complex  subun it  12-like 3q25.1
CD97 CD97 molecu le 19p13
MAP4K2 Mitogen-activa ted protein kinase kinase kinase kinase 2 11q13
HERPUD2 HERPUD fami ly  m e m b e r  2 7p14.2
SQSTM1 Sequestosome 1 5q35
C5 Co m plem ent  com ponent  5 9q33-q34
RANBP17 RAN binding protein 17 5q34
PH 1D 2 PIH1 domain  con ta in ing 2 11q23.1
LRRC44 Leucine r ich repeat con ta in ing 44 1p31.1
KCNJ13 Potassium inward ly - rec t i fy ing  channel,  sub fam il y  J, m e m b e r  13 2q37
BAT1 HLA-B associa ted t ran sc r ip t  1 6p21.3
PXT1 Perox isomal,  test is  speci f ic  1 6p21.31
ARL6 AD P-ribosy la t ion  fac to r - l i ke  6 3q11.2
ZNF425 Zinc f in ge r  protein 425 7q36.1
C7orf46 Ch rom osom e 7 open reading f ram e  46 7p15.3
ELOVL4 Elongat ion of very  long chain fatty acids 6q14
FLJ30672 Hypothet ical  protein FLJ30672 Xq26.3
HSCB HscB ir o n -su l fu r  c lu s te r  co -chape rone homolog  (E. coll) 22q12.1
OGG1 8-Oxoguan ine DNA glycosylase 3p26.2
LOC652968 Unknown 22q12
(continued)
B io lo g ic a l process P-va lue Fold change
Unknown 0.00989524 1.255524342
L-pheny la lan in e  catabol ic process, im m u n e  response 0.00939347 1.245159019
Pyr im id ine nucleos ide metabo l ic  process 0.00637296 1.243804723
Im m une  response 0.00297358 1.241479122
Protein ubiqui t inat ion 0.00651408 1.235923973
Cell  cycle 0.00686137 1.234562607
Protein complex  assembly,  im m u n e  response, ant igen presentat ion 0.00666743 1.226570365
Unknown 0.0029713 1.22616234
Glycosaminoglycan biosynthet ic  process 0.00610597 1.218156929
Cytoskele ta l protein binding 0.00814001 1.216056281
Ubiquit in  cycle, apoptosis, im m u n e  response 0.00567462 1.214910469
Sm a l l  GTPase med ia ted s ig na l transduction 0.00176723 1.212235502
Transcrip t ion 0.00962998 1.200678584
Coenzyme A biosyn thet ic  process 0.00998291 1.199871 576
C e llu la r  copper  ion hom eostas is 0.00853138 1.198657926
Signal t ransduction 0.00716894 1.190716533
Nucleotide-exc is ion  repair 0.00655314 1.181099084
Signal t ransduction 0.00698444 1.166818366
DNA repair 0.0088686 1.161871082
Unknown 0.00458458 1.161806656
Transcr ip t ion,  prol i fe rat ion 0.00341 71 1 1.13723468
Cell  moti l i ty, im m u n e  response, in f la m m a to ry  response 0.00791707 1.133512264
Protein am ino acid phosphory la t ion , im m u n e  response 0.00937475 1.1 1359142
Protein modi f ica t ion  process 0.00129877 1.107402743
Ub iqu i t i n -dependen t  protein catabo l ic process, apoptos is 0.00269138 1.10629796
Act iva t ion of MAPK activi ty, in f lam m at io n 0.00930742 1.102867902
Protein im por t  into nucleus, docking 0.00101 526 1.063382036
Unknown 0.00548372 -1.02431 539
Unknown 0.00825136 -1.03227689
Ion t ranspor t 0.00460367 -1.05643939
N uc le ar  m R N A  spl icing,  via sp l iceosome 0.00418843 -1.05720855
Unknown 0.00854238 -1.06394236
Sm a l l  GTPase med ia ted s ig na l transduction 0.00712878 -1.07250918
Transcrip t ion 0.0094925 -1.07424272
Unknown 0.0031 5607 -1.07509936
Fatty acid biosynthet ic  process 0.00474756 -1.07516643
Unknown 0.0012008 -1.07788256
Protein folding 0.009621 5 -1.0823221 7































Supp le m en ta ry  Table 1 /  Genes that are dif ferential ly expressed between ant i-TNF responders and non -responders (113 genes)
Gene sy m b o l  Gene n a m e  C h ro m o s o m a l  locat ion
SLC7A6OS So lute ca r r ie r  family 7, m e m b e r  6 opposi te  st rand 16q22.1
ATPBD1B  ATP binding domain  1 family, m e m b e r  B 1p36.11
HIRIP3  HIRA in te ract ing  protein 3 16p11.2
GLT25D2 Glycosyl trans ferase 25 dom a in  containing  2 1q25
FAIM  Fas apoptot ic in hibi to ry  molecu le  3q22.3
OR6C74 Olfactory  receptor, family  6, sub fam il y  C, m e m b e r  74 12q13.13
CATSPER3 Cation channel,  sp e rm  associa ted 3 5q31.1
BEX2 Brain expressed X- l inked  2 Xq22
ZN F2  Zinc f in ge r  protein 2 2q11.2
FSCN1 Fascin homolog 1, a c tm -bun d ling  protein 7p22
EDC3 Enhancer  of m R N A  decapp ing 3 homolog  (S. cerevisiae) 15q24.1
ATP6V0E2 ATPase, H+ t ran spo r t ing  V0 subun it  e2 7q36.1
GPR175 G p ro te in -coup led receptor  1 75 3q21.2
AK123815 Unknown 13q1'
C15orf40 C h rom osom e 15 open reading f ram e  40 15q25.2
PIGV Phosphat idy l inos ito l glycan anch o r  biosynthesis,  class V 1p36.11
GSX1 GS homeobox 1 13q12.2
EIF4E2 Eukaryotic t rans la t io n  l r l t l a t l o r  fac tor 4E fam i ly  m e m b e r  2q37.1
TUSC4 T um or  supp resso r  candidate 4 3p21.3
ADAMTS1 ADAM meta l lopept idase with  th ro m b o s p o r C l r  type 1 moti f ,  1 21q21.2
PGK1 Phosphog lycerate kinase 1 Xq13
RAD23A RAD23 homolog  A (S. cerevisiae) 19p13.2
HOP H o m eo dom a in -on ly  protein 4q11-q12
AY358807 Unknown 6p25.1
RAMP3 Receptor  (G pro te in-coupled) act ivi ty mod ifying protein 3 7p13-p12
AY358772 3q13.2
ZBTB6 Zinc f in ge r  and BTB domain  con ta in ing 6 9q33.2
FBXO10 F-box protein 10 9p13.2
OR2L3 Olfactory  receptor, family 2, sub fam il y  L, m e m b e r  3 1q44
SH2D2A SH2 domain  protein 2A 1q21
TMEM186 T ransm em bra ne  protein 186 16p13
PTGDS P ros taglandin D2 synthase 21kDa (brain) 9q34.2-q34.3
CLIC3 Chlor ide in t race l lu la r  channe l 3 9q34.3
ATP6V0A2 ATPase, H+ transpor t i ng ,  lysosomal V0 subun it  a2 12q24.31
KIAA1274 KIAA1274 10q22.1
UQCRFS1 U b iq u ino l -cy tochrom e c reductase, Rieske ir o n -su l fu r  polypeptide 1 19q12-q13.1
DND1 Dead end hom olog 1 (zebrafish) 5q31.3
OSM Oncostat in M 22q12.2
IL8  In te r leuk in  8 4q13-q21
ued)
B io lo g ic a l p rocess P-va lue Fold change
Unknown
Unknown
Chrom at in  assem bly  o r  d isassembly
L ipopolysacchar ide biosynthet ic  process
Apoptosis
Signa l t ransduction
Ion t ranspor t,  cel l  di f ferent iat ion
Unknown
Transcrip t ion
Cell  prol i fe rat ion
Unknown
Ion t ranspor t
Lipid m etabo l ic  process
Unknown
Unknown
GPI anch or  biosynthe tic  process 
Regula t ion of transcrip t i on ,  DNA-dependent  
T rans la t i ona l ini t iat ion 
Cell  cycle
Proteolysis, regulat ion of cel l  prol i fe rat ion 
Glycolysis
Nucleotide-exc is ion  repair 
Regula t ion of transcrip t i on  
Unknown




Signa l t ransduction
Angiogenes is , ce l l  di f ferent ia t ion,  s igna l t ransduction  
Unknown
Prostaglandin biosynthet ic  process 
Ion t ranspor t
Ion t ranspor t,  im m u n e  response
Unknown
Electron t ranspor t
M u l t ice l lu la r  o rgan ism a l deve lopment 
Regula t ion of cel l  growth , im m u n e  response 













































































































S u p p le m e n ta r y  Tab le  2 /  En riched biologica processes am ong the ident i f ied d if fe rentia l ly  expressed genes
Biologica l process p -va lu e Gene s ym bo l Gene nam e U p - /d  own regu la ted*
G uanylate b inding 5.9-10-® GBP7 Guanylate binding protein 7 Upregu lated
GBP1 Guanylate binding protein 1, in te r fe ron-induc ib le Upregu lated
GBP5 Guanylate binding protein 5 (GBP5), m RN A Upregu lated
A poptosis 5.3-10-3 PPP1R15A Protein phosphatase  1, regu la to ry  ( inhibitor) subun it  1 Upregu lated
RAPGEF1 Rap guanine  nucleo tide exchange fac to r  (GEF) 1 Upregu lated
AXUD1 AXIN1 up- regu la ted  1 Upregu lated
EGR2 Early grow th  response 2 Upregu lated
EGR3 Early grow th  response 3 Upregu lated
SQSTM1 Sequestosome 1 Upregu lated
OSM Oncostat in M Downregu la ted
FAIM Fas apoptot ic in hibi to ry  molecu le Downregu la ted
Transcrip tion 2.0-10-2 MED12L M edia to r  complex  subun it  12-like Upregu lated
PCGF5 Polycomb group r ing f inger  5 Upregu lated
PPP1R15A Protein phosphatase  1, regu la to ry  ( inhibitor) subun it  1 Upregu lated
AXUD1 AXIN1 up- regu la ted  1 Upregu lated
GR2 Early grow th  response 2 Upregu lated
EGR3 Early grow th  response 3 Upregu lated
GTF2F2 General t ransc r ip t i on  fac tor  IIF, polypept ide 2 Upregu lated
STAT1 Signal  t ran sduce r  and act ivator  of t ran sc r ip t ion  1 Upregu lated
NR4A2 N u c le a r  receptor  sub fam il y  4, group A, m e m b e r  2 Upregu lated
STAT2 Signal t ran sduce r  and act ivator  of t ran sc r ip t ion  2 Upregu lated
ZNF2 Zinc f inger  protein 2 Downregu la ted
HOP H o m eo dom a in -on ly  pro te ir Downregu la ted
ZNF425 Zinc f inger  protein 425 Downregu la ted
GSX1 GS homeobox  1 Downregu la ted
ZBTB6 Zinc f inger  and BTB dom ain  con ta in ing 6 Downregu la ted
Im m une response 4.4-10-2 PTGS2 Pros tag land in -endoperox ide synthase 2 Upregu lated
and in flam m ation TNFAIP3 Tum or  necrosis factor, a lp ha- in duced  protein 3 Upregu lated
MGLL M onog lycer ide l ipase Upregu lated
STAT1 Signal t ran sduce r  and act ivator  of t ran sc r ip t ion  1 Upregu lated
EGF Ep id erma l growth  factor Upregu lated
TAP2 Transporter 2, ATP-binding cassette, sub- fami ly  B (MDR/TAP) Upregu lated
CD97 CD97 molecu le Upregu lated
C5 Co m p lem en t  5 Upregu lated
MAP4K2 Mitogen-activated protein kinase kinase kinase kinase 2 Upregu lated
GCH1 GTP cyclohydrolase 1 (dopa- respons ive dystonia) Upregu lated
STAT2 Signal t ran sduce r  and act ivator  of t ran sc r ip t ion  2 Upregu lated
IL8 In te r leukin  8 Downregu la ted
ATP6V0A2 ATPase, H+ transpor t i ng ,  lysosomal V0 subun it  a2 Downregu la ted
RAMP3 Receptor (G protein-coupled) act ivi ty modifying protein 3 Downregu la ted
OSM Oncostat in M Downregu la ted
* Up- o r  downregu la ted  in anti -TNF responders  com pared to non-responders
S u p p le m e n ta r y  Table 3 /  T ransc r ip t ion fac to r  binding sites  (TFBS) overrepresen ted in genes dif feren tial ly  
expressed in responders and non-responders
Transc r ip t ion fac to r  p-va lue O vere xpre ssed  genes in w h ic h  TFBS a re  found
TFBS enriched in genes upregu la ted in trea tm ent responders
ATF1 1.810-12 EGR2, EGR3, NR4A2, GTF2F2, PPP1R15A, DUSP1, C7orf41, RNF1,1 AXUD1
CREBP1 2.410-7 EGR2, EGR3, NR4A2, GTF2F2, PPP1R15A, DUSP1, C7orf41
CREBATF 5.610-7 EGR2, EGR3, NR4A2, GTF2F2, PPP1R15A, DUSP1, C7orf41, RNF11, AXUD1,
TPM1, FRMD3, YPEL5, SESTD1, GTPBP2, NT5C3, HERPUD2, C9orf91
E4F1 6.910-5 EGR2, EGR3, NR4A2, PPP1R15A, DUSP1, C7orf41
TAXCREB 1.410-4 NR4A2, PPP1R15A, DUSP1, C7orf41, RNF11, AXUD1, HERPUD2
ATF4 1.2-10-3 EGR2, EGR3, NR4A2, GTF2F2, PPP1R15A, DUSP1, C7orf41, RNF11, AXUD1,
TPM1, FRMD3, YPEL5, SESTD1, GTPBP2, NT5C3, HERPUD2, XRN1, TNFAIP3
MINI20 2.8-10-3 EGR3, NR4A2, GTF2F2, PPP1R15A, DUSP1, C7orf41, RNF11, AXUD1, TPM1,
FRMD3, YPEL5, GTPBP2, TNFAIP3, MED12L, TMOD2, CMIP, STAT1, APP,
MGLL, VEPH1, UVRAG, GCNT2,
BARBIE 3.7-10-3 EGR2, EGR3, NR4A2, PPP1R15A, GTPBP2, MED12L, PTGS2, PCGF5, SLK,
MAP4K2, GCH1, EGF, GCNT2, TAP2, , NEXN, RAPGEF1
ZNF219 4.3-10-3 EGR3, DUSP1, FRMD3, YPEL5, SESTD1, CMIP, MGLL, VEPH1,
TFBS enriched in genes dow nregulated in trea tm ent responders
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Objective. The purpose of th is  study was to investigate w he the r anti-TN F tre a t­
m ent outcom e was associated w ith  d ifferences in RNA expression at the exon level 
using a gene expression m icroarray covering the human genome.
Methods. RNA expression analysis in 42 rheum atoid a rth r it is  (RA) patients 
before the s ta rt of anti-TN F trea tm ent was used to identify a lte rnative ly  spliced genes. 
Quantitative PCR was used to validate (n=42) and replicate (n=34) the resu lts  obtained 
by m icroarray analysis. In order to investigate two partly  overlapping deletions in the 
SIRPB1 gene we perform ed m u ltip lex  ligation probe analysis (MLPA) in a cohort of 523 
RA patients treated w ith  anti-TNF.
R esults. Expression analysis of 42 RA patients revealed reduced expression of 
two adjacent exons in the SIRPB1 gene in anti-TN F non-responders when compared to 
responders (p=0.033). This gene encodes s igna l-regu la to ry  protein B1, a receptor-type 
transm em brane glycoprotein known to be involved in the positive regu la tion  of receptor 
tyrosine kinase-coupled s ignaling processes. A fte r validation, com bination w ith  an ad­
ditional, independent sam ple showed an association between the RNA expression levels 
of exon 5 and 6 of SIRPB1 and anti-TN F trea tm ent response in 76 patients (p=0.011), 
w ith  good responders show ing h igher expression. The decrease in expression of the 
two exons is a d irect resu lt of two partly  overlapping deletions in the SIRPB1 gene. We 
observed no association of the deletions at the DNA level w ith  response to trea tm ent in 
a cohort of 523 RA patients treated w ith  anti-TN F medication.
Conclusion. The RNA expression levels of exon 5 and 6 in the SIRPB1 gene 
showed an association w ith  anti-TN F trea tm ent response in RA patients in a sam ple 
of 76 patients. However, at the DNA level no relation between the deletions in the gene 
and anti-TN F response was found in a la rger sam ple of 523 patients. Further study is 




















Rheumatoid a rth r it is  (RA) is a com m on m u ltifa c to ria l auto im m une disease, 
characterized by a chronic in flam m ation  of the synovial jo in ts  w ith  a prevalence of ap­
proxim ate ly 1 percent w orldw ide  (1).
Tum or necrosis facto r alpha (TNFa) is a key in flam m ato ry  m ed ia to r in RA (20). 
This cytokine binds to two receptors, the type 1 TNF receptor (p55) and the type 2 TNF 
receptor (p75) (49). Evidence fo r the essentia l role of TNFB in the pathogenesis of RA 
has resulted in the developm ent of therapeutic in terventions targeting th is  cytokine 
(25;322). Currently, three TNF antagonists, In flix im ab (Remicade®), Adalum im ab 
(H um ira® ) and Etanercept (Enbre l® ) are com m erc ia lly  available and two new anti-TN F 
agents, go lim um ab (CNTO 148) and certo lizum ab pegol (C imzia®), w ill m ost like ly be 
approved in 2009. The m o lecu la r m echanism s fo r these TNF inh ib ito rs  are s im ila r: 
they block the binding of TNFa to its ce ll-su rface  receptors and thereby lim iting  the 
s igna ling of TNFa induced pathways. In flix im ab is a ch im eric  m ouse-hum an antibody, 
w h ile  Ada lim um ab is a fu lly  humanized antibody. Etanercept is a d im eric  TNF receptor- 
IgG fusion protein and m im ics  the inh ib ition  effects of so luble TNF receptor by binding 
to TNFa (66). The new anti-TN F agents go lim um ab and certo lizum ab pegol are a fu lly  
human m onoclona l anti-TN F antibody and a humanized m onoclona l anti-TN F antibody, 
respectively (26). A lthough the therapeutic effect of TNF neutra liza tion  is w e ll estab­
lished, patients show substan tia l heterogeneity in th e ir response. Approxim ate ly 30 pe r­
cent of the patients treated w ith  TNF blocking agents do not show  c lin ica l im provem ent 
(28). Non-response, but also adverse events and the high costs of anti-TN F blocking 
agents, have motivated the search fo r genetic m arkers  to predict trea tm ent outcome. 
Insight into the genetics of anti-TN F therapy may fac ilita te  the choice fo r the m ost ap­
propria te therapy for an ind ividual patient (42;213).
In the last few years, genom e-w ide gene expression analysis using m icroarrays 
has become a useful too l to help unravel disease etio logy of various complex diseases 
and tra its  (292-295;323). Gene expression p ro filing  of patients w ith  RA has yielded 
specific sets of genes (genetic m arkers) associated w ith  disease and has dem onstrated 
m olecu la rly  d is tinc t subgroups of RA patients (67;296-298). In addition, gene expres­
sion m icroarray technology can help to identify genes involved in trea tm ent response or 
adverse events associated w ith  a certa in therapy (299-303;324;325).
Gene expression analysis of RA patients treated w ith  anti-TN F has led to the 
identifica tion  of gene expression signa tures w hich may discern responders from  non­
responders to trea tm ent (67;73;189-192), a lthough these stud ies were lim ited by sm a ll
sam ple sizes, so far. Nowadays it is also possible to m on ito r expression of individual 
exons in genom e-w ide expression studies. D iffe ren tia l expression of certa in  exons or 
exon c lus te rs  points to the presence of a lternative spliced variants. Dysregulation of 
sp lice varian ts of specific genes m ight fo rm  a m arke r fo r therapy outcom e (326).
In th is  study we used the GeneChip Human Exon 1.0 ST array to analyze 
expression levels of individual exons in w h ite  blood ce ll (WBC) derived RNA from  42 
RA patients treated w ith  the m onoclona l anti-TN F antibodies in flix im ab o r ada lim u- 
mab, selected fo r e ithe r a good trea tm ent response (n=18) or non-response (n=24) at 
14 weeks of therapy. This analysis led to the identifica tion of a d iffe ren tia lly  expressed 
exon c lus te r in the s igna l-regu la to ry  protein B1 (SIRPB1) gene associated w ith  anti-TN F 
trea tm ent response. Quantitative PCR at the RNA level and m u ltip lex  liga tion-depend­
ent probe am plifica tion  (MLPA) analysis at the DNA level were used to fu rth e r investi­



















> MATERIAL AND METHODS
Patients
Patients included in the study are a ll part of the Dutch Rheumatoid A rth ritis  
M onitoring (DREAM) registry (w w w .dream -reg istry .n l) and attended the D epartm ent of 
Rheumatology of the Radboud University N ijmegen Medical Centre or the St. M aarten- 
shosp ita l in N ijmegen. The regional ethics review board had approved the study and all 
patients had given w ritten  inform ed consent. The DREAM reg istry co llects detailed c lin i­
cal in form ation and regu lar m easurem ents of trea tm ent outcome in patients who s ta rt 
the ir firs t course of a TNF-blocking agent according to the indications in The N ether­
lands. These encompass a Disease Activity Score 28 (DAS28) > 3.2 at baseline and failure 
on at least two d isease-m odifying an tirheum atic  drugs (DMARDs), one of which has to 
be m ethotrexate (MTX)) (219). A ll patients in th is  study fu lfilled  the Am erican College of 
Rheumatology (ACR) crite ria  (9). In the curren t RNA expression study, we included 18 
good responders and 24 non-responders a fte r 14 weeks of anti-TN F therapy (In flix i­
mab o r Adalim um ab) according to the EULAR criteria  (16). The patients were matched 
fo r age, sex, and MTX. These had been selected from  a to ta l sam ple of 100 patients for 
whom  RNA had been collected ju s t before anti-TN F trea tm ent s ta rt and a fte r 14 weeks 
of treatm ent. The replication sam ple consisted of 34 RA patients from  the Autoim m une 
B iom arkers Collaborative N etw ork (ABCoN) cohort w hich is previously described (66).
A fter finding an association between SIRPB1 deletions and anti-TNF response at the 
RNA level, a total of 523 patients were genotyped using MLPA analysis at the DNA level.
Molecular analyses
All m olecular analyses were performed in a CCKL (Coördinatie Commissie ter bevor­
dering van de Kwaliteitsbeheersing van het Laboratoriumonderzoek) -accredited laboratory 
at the Department of Human Genetics at the Radboud University Nijmegen Medical Centre. 
RNA was isolated w ithin 0.5 hours after blood extraction using the RNeasy midi kit accord­
ing to the manufacturer's protocol (Qiagen Benelux B.V. Venlo, The Netherlands). To remove 
residual traces of genomic DNA, the RNA was treated w ith DNase I (Invitrogen, Leek, The 
Netherlands) while bound to the RNeasy column. Quality and quantity of the purified RNA 
was controlled using a NanoDrop spectrophotometer (Nanodrop Technologies, Montchanin, 
DE, USA). RNA integrity was investigated by using the 2100 Bioanalyser (Agilent technolo­
gies, Philadelphia, PA, USA). RNA was examined for possible degradation using agarose gel 
electrophoresis. DNA isolation was performed as described by M iller et al. (206).
(A) Gene expression profiling
Gene expression profiling was performed using A ffym etrix 1.0 Human Exon ST 
arrays, representing a ll known exon clusters. RNA isolated from  blood taken before anti- 
TNF treatm ent s ta rt was analyzed. Performance was according to the m anufacturer's in­
s tructions (Affymetrix Inc., Santa Clara, CA, USA). Briefly, the A ffym etrix GeneChip Whole 
Transcript Sense Target Labeling Assay was used to generate am plified and biotinylated 
sense-strand DNA targets from  the expressed genome (2.0 pg of to ta l RNA). Arrays were 
hybridized by rotating them  at 60 rpm in the A ffym etrix GeneChip hybridization oven at 45 
°C for 17 hours. A fter hybridization and washing in the A ffym etrix GeneChip F luidics s ta ­
tion FS 450, arrays were scanned using the A ffym etrix GeneChip scanner 3000 7G system.
(B) Synthesis of cDNA and quantitative PCR
Total RNA (1 pg) was reverse transcribed using a commercially available cDNA 
synthesis kit (iScript, BioRad Laboratories, Hercules, CA, USA). Primers were developed 
for SIRPB1 exon 1 -2/1 -7, exon 5-6 and exon 10-11 using Primer3 software (http://b iotools. 
umassmed.edu/bioapps/primer3_www.cgi) (Table 1, Figure 1). A ll p rim er pairs spanned 
an exon-intron boundary, to ensure amplification of RNA exclusively. The firs t p rim er pair, 
annealing to either exon 1 and 2 or exon 1 and 7 (Figure 1), was able to detect a ll three 
SIRPB1 splice variants. Primers for SIRPB1 exon 1-2/1-7 and exon 10-11 were used as posi­
tive controls to detect expression of the specific splice variants (Figure 1) (327). The general 
housekeeping gene GUSB (glucuronidase beta) showing a stable expression in leukocytes 
was used as endogenous control (328). A ll PCR products were selected to be between 80 and 
120 bp long. Quantitative PCR (q-PCR) was performed by SYBR Green-based quantification 
according to the manufacturer's protocol (Applied Biosystems, Foster City, CA, USA). The ex­
pression levels of specific SIRPB1 exons were analyzed using the 7500 Fast Real-Time PCR 
System (Applied Biosystems, Foster city, Ca, USA) according to the following protocol: 3 min. 
denaturation at 95°C, and 40 cycles of 30 sec. denaturation at 95°C, 30 sec. annealing and 
extension at 60°C. A ll p rim er pairs were validated in triplicate using serial cDNA dilutions 
that resulted in a final concentration of the equivalent of 800, 400, 200, 100 and 50 pg/pl input 
of total RNA in the firs t strand synthesis. Prim er pairs that were 100010% efficient (which 






















Table 1 /  P r i  m e r  s e q u e n c e s  SIRPB1  u s ed  f o r  qPC R
Reverse se quence
GAGTGGCCGACTCTCCAG 
ATTT CCTGGGAGGCT GTT G 
TCGCCAGCTCCTTCTCTC
Loca tion Size (bp) Fo rw a rd  sequence
Exon 1-2 /1 -7 114 TCCTGCTGATGACGCTACTG
Exon 5-6 104 TGT CAT CTATGTCTACTGGAAGCAG
Exon 10-11 103 CT CT GCCAT CTACAT CTGCTG
Figure 1 /  Schematic overview of SIRPB1 as indicated in the UCSC Genome Browser  (http:/ /genome.ucsc.edu /)
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Exon organizat ion is as w e l l  as the GeneChip Human Exon 1.0 ST ar ray probese ts  layout in SIRPB1 are 
dep icted in the f igure. Three t ran sc r ip ts  of the gene are known, al l  w ith  dif feren t exon organizat ions.  Also 
two overlapp ing de le t ions  as described  in l i te ra ture  are depictec
Table 2 /  Pr  m er  sequences SIRPB1 used fo r MLPA
Location Size
(bp)
5' p robe  ( 5 ' ^ 3 ' j 3' p robe  ( 5 ' ^ 3 ' j
Exon 1 10C CAG CACAGACGTTTGGACAGAG CAGGCTC CTAAGGTCTCCAGAATGCCCGTGCCAGCC
Exon 2 and 7 112 GAG CAGAG CT G CAT CAT CT CAGAAT GTCCCT CACCT CAG GA AAGAG GTCCCACAAGT GGGT GACTTAG G G
Exon 4 96 GACCACGCCCCCAGGTGACCATGAGTG GTCAAAGCAAGGGCCTCCTTTGGGTCC
Exon 5 108 G CAGAAG GCCTGACTGTAAGTGTGGGGGA TG GATGCCTGAC CAAGGGCTGCTC CAAAAG GGCAGGG
Exon 6 88 ATGGCCCCTTCCTCCCACAGCAA CTTCCCTCCT GGGACAT CATGGC
Exon 7a 92 CCCTGATCCCTGTGGGGCCCATCAT GTGGTTTAGAG GAGCTGGAG CAG G C
Exon 7b 92 GGAGAGTCGGCCACTCTGCGCTGTG CTATGACGTCCCTGATCCCTGTGGG
Exon 9 104 GGATGCCTTCTGTGACGTGCTGCATCAGTGG CATGGGAGCCTAGTGAGAGACTGTGCCCTAG
Exon 10 and 11 124 CCCAGG GAGTGTGCAG GAGTTGG GATG GTCAAG G GTATTAC AGGAGGTGG GAT G CTT CAAG GGG GTT CAAAGTT GTCCCCAG
(C) M ultip lex  ligation probe analysis IMLPA]
Probes were designed w ith in or in close proximity of the exons of the SIRPB1 gene 
(Table 2). Quality control and reference probes were selected outside the region. To ensure 
specific hybridization, the BLAT program from the UCSC website (http://genome.ucsc. 
edu) was used to exclude the presence of repetitive sequences (329). Due to high sequence 
s im ila rity  of exons 2 and 7 as w e ll as exons 10 and 11 of the SIRPB1 gene it was not possible 
to develop specific probes for these exons (Table 2). The hybridizing regions of the probes 
had a Tm of at least 67.5oC and GC content between 40 and 60 percent. Both aspects were 
defined by the use of MELTingeny 1.0 software (Ingeny International, Goes, The Nether­
lands). Each end of the designed probes contained universal p rim er sequences, which have 
been described before (330), allowing simultaneous probe amplification w ith one pair of 
primers. Probes w ith in each set were designed to produce PCR products ranging in size 
from 88 bp to 136 bp w ith a size separation of at least 4 bp. Probes were designed using the 
MELTingeny 1.0 software and ordered from Biolegio (Nijmegen, The Netherlands). MLPA 
reaction reagents were ordered from MRC-Holland (Amsterdam, The Netherlands). For each 
reaction, 200 ng of genomic DNA was heated to 98°C for 5 minutes. The DNA was cooled 
down to room temperature and subsequently 1.5 |_il probe mix (4 fm ol/p l for each probe 
set) and SALSA hybridization buffer were added to each sample. The mix was denaturated 
at 97°C for 1 minute, followed by hybridization for at least 16 hours at 60°C. Next, ligation 



















PCR amplification was carried out for 30 cycles and 1 |_il of product from each PCR reaction 
was mixed with 8.5 |_il formamide and 0.5 |_il LIZ500 as a size standard (Applied Biosystems). 
Product separation was performed using capillary electrophoresis on an ABI 3730 sequencer 
(Applied Biosystems). For analysis, data were retrieved using Genemapper software follow­
ing the manufacturer's protocol (Applied Biosystems). These data were exported to an Excel 
worksheet for fu rther analysis (331).
Statistical analysis
(A) Data extraction and statistical analysis of expression arrays
For quality control, the Affymetrix CEL-files produced by the Affymetrix station were 
firs t imported into Affymetrix Expression Console version 1.1 where control probes were 
extracted and normalized using the default Robust Multichip Average (RMA). The Area Under 
the Curve (AUC) of the Receiver Operator Characteristic (ROC) was calculated using the posi­
tive and negative control probes present on the Affymetrix expression array. A ll arrays had 
an AUC score above the empirically defined threshold of 0.85, indicating a good separation of 
the positive controls from the negative controls. Furthermore spike-in control probes and in­
tensity histograms for a ll arrays were checked. Pearson correlation between arrays showed 
no outliers. Subsequently, the CEL-files were imported into Partek® (Partek® Genomic 
Suite software, version 6.4 Copyright ©  2008 Partek Inc., St. Louis, MO, USA), where only 
core probesets were extracted and normalized using the RMA algorithm  w ith GC background 
correction. GC RMA is an extension of the RMA algorithm  that incorporates some m is­
matched probe information by using physical models of nonspecific hybridization based on 
the GC-content of the probes. Core transcrip t summ aries were calculated using the mean 
intensities of the corresponding probesets, representing the quantitative expression levels 
of a ll genes. We performed a mixed model analysis of variance (ANOVA) on the log2 probe 
intensities (representing the exon expression intensities) using the EULAR response criteria 
after 3 months of treatment. Variance components indicated that the scan date of the sam ­
ples influenced the expression profiles and this was included in the model as a covariate. A 
p-value of <0.01 was considered as a statistically significant difference in probe expression 
level. Alternative splicing (AS) analysis was performed using the RMA normalized intensity 
values of the core probesets. For each transcrip t we used the mean of the corresponding 
probeset intensities. Transcripts w ith mean expression across the different groups lower 
than 70 were removed. To decrease the number of false positives, probesets with Detection 
Above Background (DABG) p-value above 0.01 were removed as were probesets of which the 
expression showed a five-fold difference compared to the expression of the corresponding
transcript. After filtering we calculated for each probeset a normalized value by dividing its 
intensity through the intensity of the transcript. For both sample groups (anti-TNF respond­
ers and anti-TNF non-responders) we compared the mean normalized probeset intensities 
using an ANOVA and corrected the resulting p-values using Benjamini-Hochberg correction 
for multiple testing (332). In addition we calculated for each combination of groups the sp lic­
ing index (SI) of the probeset which is defined as the log2 of the ratio of normalized probeset 
intensities. The maximum splicing index was used as selection criterion for the sample 
group that contains alternatively spliced probesets. Only probesets w ith a maximum SI above
1.0 and a corrected ANOVA p-value below 0.0001 were considered as candidate genes show­
ing alternative splicing. Finally, candidate probesets were grouped by their corresponding 
transcript and for each transcript we calculated the number of candidate probesets showing 
alternative splicing, the average maximum SI, the average corrected ANOVA p-value, and the 
most occurring group w ith the maximum SI.
(B) Analysis of quantitative PCR
Threshold cycle num bers (referred to as Ct) were obtained using the 7500 Sys­
tem  SDS software version 1.4 (Applied Biosystems). A ll sam ples were measured twice 
and duplicate sam ples w ith  a standard deviation (SD) la rge r than 0.5 were excluded 
from  the analysis. The relative quantity (RQ) of the gene-specific  mRNA was calculated 
from  the average value of the ACt (target gene Ct -  endogenous con tro l gene Ct) fo r 
each of the analyzed sam ples. D ifferences in expression between two sam ples were 
calcu lated by the 2AACt m ethod (241;333) and tested fo r association w ith  anti-TN F tre a t­
m ent outcom e using the independent S tudent's t-tes t. A p-value of <0.05 was consid­
ered s ta tis tica lly  s ign ificant. Analyses were perform ed using SPSS fo r W indows, version
14.0 (SPSS, Chicago, IL, USA).
(C) Analysis of MLPA analysis
To assess the effect of the deletions on anti-TN F response, a tw o-ta iled  Fisher's 
exact test was perform ed (SPSS for Windows, version 14.0). The patients were su b ­
divided into two groups based on the ir genotype. The groups consisted of (1) patients 
show ing deletions of exon 5 and 6 on both a lle les (n=309) and (2) patients e ithe r hetero­




















RNA taken before trea tm ent s ta rt (=baseline) of a to ta l of 42 RA patients treated 
w ith  anti-TN F (in flix im ab or adalim um ab) (18 good responders and 24 non-responders 
at 14 weeks of treatm ent) were analyzed on GeneChip Human Exon 1.0 ST arrays to 
obtain genom e-w ide exon expression profiles. Table 3 shows patient cha racte ris tics  at 
baseline and a fte r 14 weeks of treatm ent.
Tab le 3 /  B ase l ine  charac ter is t ics ,  disease activi ty at base l ine and DAS28 im provem ent  for responders 
and non -respond e rs  (based on the EULAR cri ter ia ] to an t i-TN F  t rea tm en t
Responders No n - re sp o n d e rs
N (basel ine and 14 w eeks  fol low-up) 18 (43%) 24 (57%)
Female gender 16 (89%) 14 (58%)
Age 58 ±14.2 57 ±13.6
RF posit ivi ty 13 (72%) 19 (79%)
A d a l im u m a b 4 (27%) 11 (52%)
Inf l ix imab 14 (73%) 13 (48%)
MTX as c o -m e d ic a t io r 18 (43%) 24 (57%)
DAS28 basel ine 5.3 ±1.0 4.8 ±1.5
DAS28 decrease a fte r  14 w e eks  of an t i-TN F  therapy 2.0 ±0.8 0.1 ±1.0
Percentage  DAS28 change  14 w eeks  of an t i-TN F  therapy 37 ±10 -1 ±25
Resul ts  are n u m b e r  (percentage) o r  mean ± s tandard  deviat ion (SD). Pe rcen tages are expressed in re la ­
t ion to the to ta l n u m b e r  of pa tients  fo r each response group (except for the to ta l n u m b e r  of pa tients  (N 
base l ine and 14 w eeks  fo l low-up)).
Expression array analysis
Individual probeset analysis revealed several genes that showed indications of 
alternative splicing based on the splicing index and the ANOVA. The gene w ith the highest 
splicing index (SI= 6.53) and most significant p-value (p= 0.000483371) was the SIRPB1 gene 
(signal-regulatory protein beta 1 ; located on chromosome 20p13). SIRPB1 is a m em ber
of the s ignal-regulatory protein (SIRP) fam ily and encompasses 11 exons (http ://genom e. 
ucsc.edu/). Figure 1 shows a schematic outline of the gene. Exon organization is illustrated 
as w e ll as the GeneChip Human Exon 1.0 ST array probesets layout in SIRPB1. Three tran ­
scrip ts of the gene are known, a ll w ith  different exon organizations. Transcript 1 consists of 
exon 1, 7, 8, 9, 10 and 11; transcrip t 2 consists of exon 1, 7, 10 and 11; transcrip t 3 consists 
of exon 1, 2, 3, 4, 5 and 6 (Figure 1). Five consecutive probesets located in exons 5 and 6 
of SIRPB1 (3894744, 3894745, 3894746, 3894747, 3894748) showed a decrease in mean 
expression in the array analysis in non-responders compared to responders (Figure 2).
C loser exam ination showed that o ther find ings w ith  high sp lic ing  indices and 
low p-values were e ithe r due to an exceptionally high sp lic ing  index in only one o r two 
patients, or to highly variable expression levels between patients. These find ings were 
not selected fo r fo llow -up.
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SIR.PB1 is covered by 15 probesets of the GeneChip Human Exon 1.0 ST array (for local ization see Figure 1). 
Each probeset is indicated by specif ic color  bar  wh ich  cor responds  to its unique probenumber  out l ined in the 
legend. Norm alized mean expression values of each probeset is shown for 4 groups (ant i-TNF responders 
and non-responders  at basel ine and after 14 weeks  of treatment ). Five consecutive probesets  showed a 



















Quantitative PCR analysis of exon 5 and 6 of the SIRPB1 gene
Quantitative PCR (qPCR) was used to validate the low er expression of exon 5 and 
6 of the SIRPB1 gene observed on the array in anti-TN F non-responders. The qPCR 
analysis was firs t perform ed in the sam e 42 patients used fo r the in itia l a rray analy­
sis, con firm ing  the association found on the array (p=0.033, Table 4) and second in an 
independent sam ple of 34 patients. A combined analysis in a ll 76 patients also dem on­
strated an association between anti-TN F trea tm ent response and the expression levels 
of exon 5 and 6 of SIRPB1 (p= 0.011; Table 5), w ith  those patients expressing the exons 
more like ly to be good responders to anti-TN F therapy.
Tab le 4 /  SIRPB1 exon 5 and 6 expression d is tr ibu t ion  according to the EULAR response cr i te r ia;  va l id a ­
t ion of the ar ray resu lt s  in 42 pat ients
Expression o f  exon 5  an d  6 
No express ion o f  exon 5  an d  6 
Total
------------------------------ Response to an t i -T N F  t r e a t m e n t ------------------------
Good re sp o n se  N o n - re s p o n s e  Total
10 (63%) 6 (37%) 16 (100%)
8 (31%) 18 (69%) 26 (100%)
18 (43%) 24 (57%) 42 (100%)
In the table  the n u m b e r  of pat ients and percen tage  are presented.  The Fisher  exact test show ed an as ­
soc ia t ion between the express ion of exon 5 and 6 and an t i-TN F  t rea tm en t  response (p=0.033).
Investigating the deletion in SIRPB1 at the DNA level using Multiplex ligation probe 
analysis (MLPA)
The com p le te  absence of exon 5 and 6 expression detected by qPCR in 58% 
of the pa tien ts  (Table 5) suggested  a possib le  de le tion  at the DNA level. A recent 
p ub lica tion  (334) and in fo rm a tio n  on copy nu m b e r va ria tio n  from  the UCSC Genome 
B row ser (h ttp ://g e n o m e .u csc .e d u /) showed the existence of two p a rtia lly  ove rla p ­
ping de le tions in SIRPB1 (Figure 2). Hence, we investiga ted  by MLPA if the reported 
DNA de le tions w ere respons ib le  fo r the absence of expression of SIRPB1  exons 5 
and 6 in ou r pa tients . MLPA ana lys is  in the in it ia l coho rt of 42 pa tien ts  showed that 
a ll 26 pa tien ts  w ith o u t expression of exon 5 and 6 at the RNA level indeed had a
hom ozygous de le tion  inc lud ing  exon 5 and 6 at the DNA level w hereas a ll pa tients  
show ing  expression of exons 5 and 6 of the gene had at least one non-de le ted  a lle le . 
In the la tte r  group the nu m b e r of non -de le ted  a lle le s  did not seem  to in fluence  the 
extent to w h ich  the exons w ere expressed. The MLPA re su lts  also con firm ed  the ex­
istence of two p a rtly  overlapp ing  de le tions  located in the SIRPB1  reg ion as reported 
by Kidd and co -w o rke rs  (334) (Figure 3).
In a sam ple  of 523 RA pa tien ts  we subsequen tly  investiga ted by MLPA 
w h e th e r the de le tion  of exon 5 and 6 of SIRPB1  w as indeed associated w ith  non ­
response to TNF n e u tra liza tio n  (Table 6). The genotype d is tr ib u tio n  in th is  coho rt is 
ou tlined  in Table 7.
For th is  association analysis we categorized the patients into two genotype 
groups (Table 8); one including patients w ith  exons 5 and 6 present (genotypes: 
homozygous for no deletions o r heterozygous fo r e ithe r no de le tion/de le tion 1 or no 
de le tion/de le tion  2) and one w ith  patients carrying homozygous deletions of exon 5 
and 6 (genotypes: homozygous for deletion 1 o r deletion 2 or com pound-heterozygous 
fo r deletion 1/deletion 2). When evaluating the course of DAS28 change compared to 
baseline over the firs t year of anti-TN F trea tm ent in the patient groups, we found that 
patients homozygous fo r the deletions showed a sm a lle r change in DAS28 (expressed 
as percentage) 12 m onths a fte r trea tm ent in itia tion  compared to patients that were 
e ithe r heterozygous did not show  deletions (Figure 3). However, the observed difference 
was not s ta tis tica lly  s ign ifican t (p=0.329).
Table 5 /  SIRPB1 exon 5 and 6 expression d is tr ibu t ion  according to the EULAR response  c r i ter ia  in the 
co m b in ed  cohort  of 76 patients.
Good response
Expression o f  exon 5  a n d  6 21 [66%:
No expression o f  exon 5 an d  6 16 (36%)
Total 37 (43%)




























Tab le 6 /  Base l ine  character is t ics , disease activi ty at base l ine and DAS28 im provem ent  fo r responders  
and non -respond e rs  to an t i-TN F t re a tm e n t  (based on the EULAR cr i ter ia) included in the MLPA analysis.
Responders N o n - re s p o n d e rs
N (basel ine and 14 w eeks  fol low-up) 371 (71%) 1 52 (29%)
Female gender 257 (69%) 92 (61%)
Age 56 ±12.2 58 ±14.1
RF posit ivi ty 304 (82%) 123 (81%)
A d a lim um ab 167 (45%) 44 (29%)
Inf l ix imab 145 (39%) 90 (59%)
Etanercept 59 (16%) 18 (12%)
MTX as co-medicat ion 258 (70%) 97 (64%)
DAS28 basel ine 5.6 ±1.13 5.1 ±1.54
DAS28 decrease a fte r  14 w e eks  of an t i-TN F  therapy 2.0 ±0.88 -0.1 ±0.8
Percentage  DAS28 change  14 w eeks  of an t i-TN F  therapy 37 ±14.5 -4.6% ±22
Resul ts  are n u m b e r  (percentage) o r  mean ± s tandard  deviat ion (SD). Pe rcen tages are expressed in re la ­
t ion to the to ta l n u m b e r  of pa tients  fo r each response group (except for the to ta l n i m be r  of pa tients (N
base l ine and 14 w eeks  fo l low-up)).
Tab le 7 /  Genotype percen tages of the two de let ions  in SIRPB1
Genotype SIRPB1 Percen tage
N o rm a l / N o rm a l 8%
N o rm a l /D e l  1 7%
N o rm a l /D e l  2 26%
Del 1/Del ' 2%
Del 2 /De l 1 17%
Del 2 /De l 2 40%
Total 100%
Table 8 /  Associa t ion  ana lys is of the SIRPB1 gene and an t i-TN F  t re a tm e n t  outcome
Response to an t i -T N F  tr e a tm e n t
Genotype SIRPB1 Response N o n - re sp o n se Total
N o rm a l / N o rm a l 22 (56%) 18 (44%) 40 (100%)
N o rm a l /D e l  1 24 (68%) 11 (32%) 35 (100%)
N o rm a l /D e l  2 98 (71%) 40 (29%) 138 (100%)
Del 1/Del ' 8 (78%) 2 (22%) 10 (100%)
Del 2 /De l 1 62 (70%) 27 (30%) 89 (100%)
Del 2 /De l 2 1 56 (74%) 55 (26%) 211 (100%)
Total 371 (71%) 1 52 (29%) 523 (100%)
A Fisher  exact tes t dem ons t ra ted  no assoc ia t ion between the SIRPB1 genotype and an t i-TN F t rea tm ent  
response (P=0.395). In the table  the n u m b e r  of pa tients  and percentage fo r each genotype group are 
dep icted fo r the responders  and non -respond e rs  to ant i-TNF t rea tm ent .
F igu re  3 /  Course of percen tage  DAS change  compared to base l ine in al l  pat ients  (n = 523)
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delet ior
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Percentage decrease in DAS28 at three, six, nine, and twelve m onths  a fte r  t rea tm ent  start  fo r the patients 





















In th is  study we aimed at identifying a lte rna tive ly  spliced genes w ith  an effect on 
the response to TNF neutra liza tion  therapy in rheum atoid a rth ritis . In a genom e-w ide 
analysis, one gene showed p a rticu la rly  strong effects, w ith  two exons being frequently 
repressed in a sam ple of 42 patients. Association testing revealed an association of 
the dow nregulation of these exons w ith  non-response to anti-TNF. Combined analysis 
w ith  an add itiona l 34 patients from  an independent cohort confirm ed th is  association. 
D ownregulation was subsequently identified as being due to two overlapping deletions 
located in the SIRPB1 gene, there was a perfect corre la tion  between the presence of 
(homozygous or compound heterozygous) deletions and absence of transcrip tion  of the 
exons. MLPA analysis in much la rge r cohort of 523 anti-TN F treated patients fo r whom  
DNA and trea tm ent response data were available revealed no s ign ifican t associa­
tion between (e ither of) the two deletions and anti-TN F response, though a trend for 
reduced response at prolonged trea tm ent was observed in deletion carriers.
In addition to SIRPB1 , two o ther m em bers, SIRPA and SIRPG, have been 
characterized in hum ans (335;336). S im ila r to S IR PB1 , SIRPA and SIRPG  have three Ig- 
like dom ains in th e ir ex trace llu la r regions. The s truc tu res  of th e ir  cytoplasm ic regions 
however, are quite d ifferent. SIRPB1 has a very sho rt cytoplasm ic region and lacks 
s igna ling m otifs. The protein associates w ith  DAP12 (which is a dem eric adaptor protein 
containing an im m unoreceptor tyrosine-based activation m otif (ITAM)), through a basic 
am ino acid residue in the transm em brane region. SIRPA has a longer cytoplasm ic 
region w hich consists of several putative tyrosine phosphorylation sites. Also SIRPG has 
a sho rt cytoplasm ic region, but it lacks a charged am ino acid residue in its tran sm e m ­
brane region and therefore does not associated w ith  DAP12 (336). The SIRP  fam ily 
m ight be an in teresting candidate fam ily  fo r fu rth e r study in RA and o ther autoim m une 
related disorders. Both SIRPA and SIRPG are expressed by T -ce lls  and binds CD47 m o l­
ecules. CD47 m olecules are known to be involved w ith  several auto im m une associated 
ce ll functions such as in tegration, m igra tion , phagocytosis, T ce ll activation, anergy and 
appotosis (337). Olsson and co -w orkers suggested that the CD47-SIRPA interaction 
is im portan t in the induction of autoim m une d isorders such as auto im m une hem o­
lytic anemia (AIHA) (338). Furtherm ore, in the study of Kawasaki e t a l. it is stated that 
CD47-SIRPG induced T -ce ll s igna ling is increased during the active stages of system ic 
lupus erythem atosus (SLE), indicating that th is  s igna ling pathway is involved in SLE 
(339). However, the ligand fo r SIRPB1 is (still) unknown, m aking it d ifficu lt to unravel its 
precise functions.
Based upon ou r in itia l resu lts  tha t SIRPB1 is involved in anti-TN F response 
and on lite ra tu re  concerning the SIRP  fam ily, SIRPB1 is an in teresting candidate gene 
fo r fu rth e r study. Unfortunate ly, we were not able to con firm  our in itia l resu lts  w ith 
MLPA in a cohort of 523 RA patients. Possible explanations for not con firm ing  SIRPB1 
as a m arke r fo r anti-TN F response m ight be heterogeneity in both the disease itse lf 
and its response to therapy. Therefore, SIRPB1 m ight be responsible fo r anti-TN F non­
response in a subset of patients. For example, the patients tha t were investigated at 
the level of RNA was only a sm a ll subgroup of the patient cohort tha t was investigated 
at the DNA level. Subtle d ifferences in disease characte ris tics  (CRP, anti-CCP, DAS28, 
jo in t damage) or co-m edication  between the sm a ll RNA cohort and the la rger DNA 
cohort m ight be responsible fo r not con firm ing  SIRPB1 as a marker. Investigation of the 
deletions located in the SIRPB1 gene in larger, w e ll characterized RA patient cohorts 
w ith  longer fo llow -up  is needed to unravel the precise role of SIRPB1 in anti-TN F re ­
sponse. Since we were able to show a trend towards lower anti-TN F response rates in 
patients w ith  a deletion a fte r a longer tim e of trea tm ent (12 months), it is possible that 
SIRPB1 is a m arke r fo r response a fte r a longer period of treatm ent.
Given the equivocal find ings of ou r association stud ies and the potentia l 
functiona l im p lica tions of the deletion fo r SIRPB1 protein function, la rge r association 
studies should be perform ed before the SIRPB1 de letions are discarded as candidate 






























The main goal of the stud ies presented in th is  thesis was the identifica tion of 
genetic m arkers w hich are able to predict response to a n ti-tu m o u r necrosis factor 
(anti-TNF) trea tm ent in patients w ith  rheum atoid a rth r it is  (RA). To do so, we used both 
a hypothesis-driven and a non-hypothesis driven approach. The hypothesis-driven 
approach is presented in the firs t part of th is  thesis. Here, we investigated w hether 
several po lym orph ism s located in candidate genes are involved e ithe r in the response 
to anti-TN F therapy (TNFRSF1B  and TNFA) and /o r in RA disease severity (HMOX1, 
TNFRSF1B, and TNFA) We investigated both trea tm ent outcom e and disease severity 
as the anti-TN F therapy target TNF plays a pivotal role in the pathogenesis of RA and 
it is expected that the same genes m ight be involved in both processes (42;53). The 
resu lts  of the non-hypothesis-driven approach are shown in the second part of th is 
thesis. Whole genome gene expression pro filing  of RA patients was perform ed p rio r to 
th e ir  firs t an ti-TN F adm in is tra tion  in o rder to identify new genes/expression profiles 
involved in anti-TN F response. Both the hypothesis and non-hypothesis approach w ill 
be discussed in th is  chapte r
Our aim s directed to identify genetic m arkers predictive fo r anti-TN F response 
are hampered by several d ifficu lties. RA disease severity and response to anti-TN F 
trea tm ent m ight, like RA itse lf, be m u ltifa c to ria l events. In such case, the genetic d is ­
section of a complex phenotype is as d ifficu lt as defin ing the genetic background of 
complex diseases. Studies directed to the identifica tion of genetic factors associated 
w ith  a complex tra it often have a low power as the tra it is influenced by several genetic 
and non-genetic (environmental) factors, w ith  each of those having probably sm a ll 
ind ividual effects. In addition, disease severity and trea tm ent response can be defined 
at several tim e-po in ts  using diverse outcom e m easures m aking com parisons between 
studies d ifficu lt. Therefore, com parison between stud ies is often hampered by d iffe r­
ences in e thnic ity  (differences between genetic backgrounds) between the investigated 
patient cohorts. These d ifficu ltie s  may lead to con trad ic to ry resu lts  between studies 
resu lting  in fa ilu re  to validate previous resu lts  in independent patient cohorts. These 








> CANDIDATE GENE STUDIES 
(HYPOTHESIS-DRIVEN 
APPROACH)
The focus of previous anti-TN F pharm acogenetic studies has been m ainly 
on (functional) po lym orph ism s located in candidate genes (43-45;49;50;52- 
54;56;57;59;60;114;156;159;160;234;245). The la tte r encompass genes involved in the 
pathogenesis of RA, im plicated in the m echanism s of action of TNFa or involved in the 
breakdown and clearance of anti-TN F agents. Such stud ies have not resulted in the 
identifica tion  of genetic m arke rs  tha t can predict anti-TN F trea tm ent outcom e w ith  
high sensitiv ity and specificity. As shown in chapter 2, the lite ra tu re  on these candidate 
gene stud ies is plagued by con trad ic to ry resu lts  (42). This can be related to the use of 
d iffe ren t e thnic groups or d iffe ren t outcom e defin itions, but m ost often seem s due to 
power problem s since the patient cohorts studied are genera lly  very sm a ll (44;50;53- 
57;59-63;234;245;247;340). O ne way to draw  more defin ite  conclusions concerning 
the association of a genetic variant w ith  anti-TN F response is com bining studies in a 
m eta-analysis, as shown in chap te r 6 of th is  thesis. The po lym orph ism s investigated in 
th is  thesis, have a (possible) effect on receptor shedding (TNFRSFIb) and the degree of 
gene expression (TNFA, HMOX1). In case that a (supposed) functiona l po lym orph ism  is 
associated w ith  outcom e, in our case the TNFA and HMOX1 genes in re lation to disease 
severity, it is s t ill possible that the e ffect is not caused by the po lym orph ism  itse lf but 
by a n o th e r  po lym orph ism  w hich is in linkage d isequ ilib rium  (LD) w ith  the form er. LD 
describes a s itua tion  in w hich some com binations of a lle les o r genetic m arkers occur 
more or less frequently  in a population than w ould be expected from  a random  fo rm a ­
tion of haplotypes from  alle les based on the ir frequencies. The causal polym orphism  
co-segregates w ith  the genotyped po lym orph ism  located in the same haplotype. LD 
a llow s the identifica tion  of genetic variation w ithou t genotyping every s ingle SNP in 
a chrom osom al region (341). These representative SNPs in a region w ith  high LD are 
often referred to as tag SNPs' (342;343). Even though LD based analysis in a certa in 
candidate region has long served as a too l fo r human genetic research it became 
more genera lly applied in the analysis of complex tra its  a fte r the e lucidation of the LD 
s truc tu re  of the human genome by the HapMap consortium  (341). The last few years LD 
based analysis is also increasingly applied in pharm acogenetic research (344).
A lthough the hypothesis-based candidate gene approach is appealing, it does 
not account fo r the po tentia l role of genes o ther than the obvious candidates, inc lud ­
ing the genes of unknown function. Therefore, a candidate driven approach is lim ited 
by the existing knowledge about disease aetio logy and modes of action of the th e ra ­
peutic agent under study. An approach to (partia lly) solve th is  problem is the so called 
candidate pathway' approach. This m ethod takes into account com plete downstream  
and in teracting  s igna lling  pathways of a candidate gene. Pathways of genes ha rbou r­
ing a lle lic  variants may have more im pact on drug response than one po lym orph ism  in 
an individual gene, as several po lym orph ism s in netw orks of genes may in teract. One 
study investigated genes located in the w ith in  the TNF receptor superfam ily  m em ber 
1B s igna lling  pathway. They identified two SNPs located in the genes MAP3K1 and 








> GENOME WIDE ASSOCIATION 
STUDIES (NON-HYPOTHESIS 
DRIVEN APPROACH)
Since the present knowledge on the aetiology and course of RA and on the modes 
of action of new therapeutics like anti-TNF is s till lim ited, more non-hypothesis-driven 
approaches (‘fishing expeditions') seem also warranted. The best example of the la tte r are 
studies aimed to search for genes involved in complex tra its  in a genome-wide fashion, like 
a genome-wide association study (GWAS) (187). This technique makes it feasible to analyse 
hundreds of thousands of SNPs in one single experiment (39;64;65). Association is detect­
ed via a surrogate m arker (tag SNP) in linkage d isequilibrium  w ith the true causal variant 
(which can be a SNP, copy num ber variant (CNV) or repeat-type polymorphism). A GWAS 
has the advantage of investigating many genes at the same time including those genes 
whose function in relation to the studied tra it is not yet fu lly  understood or recognized 
(346). The results of our expression profiling study in chapter 9 of this thesis suggest that 
such genes are im portant in anti-TNF response since the most significant finding is for an 
unknown gene. The fact that a GWAS can identify genes w ith an indirect or unknown link to 
a tra it or disease is also illustrated by the recent study of The Wellcome Trust Case Control 
Consortium  (187). These authors identified common genetic variants located in or nearby 
the genes MMEL1, ANAPC4, CRYL1 and the unknown gene AK_094492 to be associated 
w ith  RA susceptibility (187). L im itations of the GWAS are the (still) relatively high costs and 
the large samples required to account fo r m ultiple testing in combination w ith sm all effect 
sizes of individual variants (347;348). A less expensive way to increase power is a meta- 
analyis in which relevant studies are combined as shown in the study of Raychaudhuri 
et ai. (349). So far, one GWAS for identifying genetic m arkers for anti-TNF response was 
performed and a SNP located in interleukin 10 (IL10) was identified as a (weak) m arker for 
anti-TNF response (66). However, the num ber of patients analyzed is sm all.
As already m entioned, many genetic varian ts are like ly to have a role in therapy 
response and the con tribu tion  of each single po lym orph ism  is probably m odest and 
therefore d ifficu lt to identify. For these reasons, it is of u tm ost im portance for cand i­
date gene based as w e ll as GWAS to investigate very large sam ple sizes and that those 
patient cohorts are w e ll-cha racte rized  fo r dem ographics, disease characte ris tics  and 
therapy response at baseline and during fo llow  up. Large sam ples increase the study 
power and a thorough patient characteriza tion a llow s be tter patient s tra tifica tion , 
increasing the chance of identify ing true  associations (350).
Nonetheless, the candidate gene as w e ll as the GWAS are only the firs t steps 
in identifying genetic m arkers/genes for anti-TN F response. Especially resu lts  from  
GWAS, studies need not only to be replicated in additional, independent patient sam ples 
to guarantee th e ir  va lid ity  and genera lizab ility  (351) but also followed up by more fo­
cused studies searching for the causal va rian ts in the region of in terest. The iden tifica ­
tion of causal variants is of p a rticu la r in terest to gain more ins ight in the m echanism s 








> GENE EXPRESS I ON S T U D I E S  
AND COMBINATION WITH OTHER 
‘ OMICS'  S T R A T E G I E S  (NON­
HYPOTHESIS DRIVEN APPROACH)
Another non-hypothesis driven approach to search fo r genes involved in anti- 
TNF trea tm ent outcom e is the use of genom e-w ide gene expression studies. During the 
last decade, gene expression p ro filing  has emerged as a key too l in the study of various 
complex diseases and tra its  (292-295;323). Several stud ies focusing on RA identified 
gene expression signatures predicting the response to anti-TN F trea tm ent in patients 
w ith  RA (73;189-192). Quite a few of the identified genes did not only have a (potential) 
role in anti-TN F response but are also candidate genes fo r RA severity, backing up the 
hypothesis that (a subset of) the same genes are involved in both disease severity and 
anti-TN F treatm ent. U nfortunate ly there is litt le  overlap between the expression s ig ­
natures reported in d iffe rent studies, as yet, probably fo r the same reasons discussed 
above for the gene polym orphism  analyses.
Especially in m icroarray experim ents there is an increased chance for false posi­
tives because of the m u ltip lic ity  problem: thousands of hypotheses (in th is case genes] 
are tested s im ultaneously for the ir association w ith  anti-TNF response. Therefore there is 
a need to correct for m ultip le  testing when assessing the s ta tis tica l significance of find ­
ings. Due to the high costs and the tim e consuming procedure to co llect su ffic ien t sam ­
ples in a standardized manner, m icroarray experim ents are often underpowered. When 
m ultip le  testing correction is applied in these underpowered studies, not a single gene or 
polym orphism  w ill be identified as true positive. Yet, th is w ill not autom atica lly mean that 
the results obtained in these studies are not inform ative and there is reason for debate. 
The biological functions and m echanism s underlying the identified genes and polym or­
phism s are often involved in the m echanism s underlying the investigated complex tra it 
(67;192;256). Therefore, the last few years a sh ift is observed in the interpretation of 
m icroarray experim ent results. The focus is no longer on m ultip le  testing correction but 
on validation of the exploratory resu lts in independent patient cohorts. In chapter 8 we 
show that some of the previously reported expression signatures are able to provide a 
reasonable classification of anti-TNF responders and non-responders in an independent 
patient cohort. This clearly shows that validation of exploratory expression signatures is 
possible and that these signatures are useful to predict anti-TNF treatm ent outcome.
In addition to gene expression profiling, stud ies on protein p ro files -so -ca lled  
p ro teom ics- are also of in terest (193-198;352;353). For example, a sustained increase 
of so luble CD30 levels has been recently reported to be associated w ith  non-response 
to anti-TN F therapy (353). In tegration of the resu lts  of the above described techniques 
(candidate gene analysis, GWAS, expression profiling) w ith  those of an analysis at the 
level of the proteom e (two d im ensiona l gel e lectrophoresis, surface-enhanced laser 
deso rp tion /ion iza tion -tim e  of flig h t (SELDI-TOF), c lin ica l m arke rs  (rheum atoid factor 
positivity, C-reactive protein, anti-CCP) and im portan t environm enta l factors is probably 








> STRENGTHS AND L I M I T A T I O N S  
OF THE S T U D I E S  PRESENTED 
IN T H I S  T H E S I S
In ligh t of our results, we have to conclude that since the s ta rt of our pharm a- 
cogenom ic research five years ago, we were not able to identify a genetic m arke r for 
anti-TN F response w ith  high sensitiv ity  and specific ity  so far. To identify such m arkers, 
both a hypothesis as non-hypothesis driven stra tegy was used. One could argue w h e th ­
e r the r igh t patient cohorts and s trateg ies were used in these stud ies and if the righ t 
hypotheses were made. To draw  sensible conclusions from  an association study, it is of 
u tm ost im portance that the investigated patient cohort is w e ll characterized regarding 
disease activity/severity, response anti-TN F medication, response to co-m edication  and 
c lin ica l m arkers such as rheum atoid facto r positivity, anti-CCP and C-reactive protein. 
A w e ll-cha racte rized  cohort makes it possible to correc t fo r non genetic confounders 
in the analysis. The patient cohort used fo r our pharm acogenom ic stud ies was derived 
from  the DREAM reg istry (w w w .dream reg istry .n l), in w hich many disease cha rac te r­
is tics are m onitored. In ou r analysis also these c lin ica l param eters were integrated, 
however they did not have any effect on the results.
One of the two s tra te g ie s  we used to iden tify  genetic  va rian ts  associated 
w ith  an ti-T N F  outcom e w as a hypothesis  driven cand idate  gene strategy. Based 
upon the pha rm acogenom ic  know ledge from  five years ago, th is  s tra te g y  w as a 
good and a ffo rdab le  m ethod to investiga ted (possible) assoc ia tions between genetic 
va rian ts  and response to m ed ica tion . For exam ple, one of the e a rlie s t c lin ica lly  
accepted pha rm acogene tic  tes t ava ilab le  is used to de te rm ine  d iffe re n t a lle le s  of 
the gene coding fo r the enzyme th io p u rin e  S -m e th y ltra n s fe ra se  (TPMT), w h ich  has 
a im p o rta n t role in m e tabo liz ing  th io p u rin e  drugs. A lso the cytochrom e P-450 drug 
m etabo liz ing  enzyme cy tochrom e P-450 2DS (CYP2D6) rep resen ts  an exam ple of a 
su ccess fu l pha rm acogenom ic  cand idate  gene study. P o lym orph ism s in th is  gene 
showed a d irec t associa tion  w ith  the a b ility  of pa tien ts  to oxidize o r m etabo lize  
ce rta in  d rugs. Both the TPMT  and the CYP2D6 genes w ere obvious cand idate  genes, 
seen th e ir  d irec t in te ra c tio n s  w ith  the investigated d rugs. Both pharm acogenom ics 
tes ts  are s t i l l  used in a daily c lin ic a l se tting .
Seen these resu lts  in pharm acogenom ic research in w hich the hypothesis-d riv­
en candidate gene strategy was applied, it was com m on sense to se lect th is  approach 
as one of the s trateg ies to investigate the pharm acogenom ics of anti-TN F treatm ent.
U nfortunate ly we have not been able to identify genetic varian ts in the genes inves­
tigated. It m ight be possible that o ther varian ts in the investigated genes explain the 
d ifferences in response to anti-TN F m edication o r we s im p ly  investigated the wrong 
candidate genes. A genom e-w ide association study a llow ing the investigation of the 
com plete genome in a non-biased m anner would be the best approach to c ircum vent 
the candidate gene selection.
In ou r non-hypothesis  (genom e-w ide) approach d irected to the iden tifica tion  
of d iffe rences in gene expression levels between responders and non-responders  
to an ti-TN F  trea tm e n t we only identified  genes w ith  sm a ll d iffe rences in expression 
between the two groups (fold changes <2). R eplication stud ies inc lud ing  su ffic ien t 
pa tients are needed to be able to d raw  defin ite  conclus ions concern ing the associa ­
tion of these genes w ith  an ti-TN F  outcom e. However we have been able to validate 
existing gene expression pro files w ith  a re la tive ly  good negative and positive p red ic­
tive value suggesting tha t the m ethod we used is su itab le  to iden tify  b iom arke rs  
p red ic ting  an ti-T N F  trea tm e n t outcom e. In the study of Acharya and co -w orke rs  it 
is dem onstra ted  tha t the genom e-w ide approach is able to successfu l identify ing 
genetic m arke rs  w h ich can be used fo r op tim iz ing  ind iv idua l the rapeu tic  s tra teg ies  
(354). This study uses genom e-w ide expression p ro filing  to dem onstra te  the value of 
in teg ra ting  genom ic in fo rm ation  w ith  c lin ica l and pa tho log ica l r isk  factors, to refine 
prognosis, and to im prove the rapeu tic  s tra teg ies  fo r early  stage breast cancer. They 
conclude tha t inco rpo ra tion  of gene expression s igna tu res into c lin ica l r isk  s tra tif ic a ­
tion can refine prognosis and therapeu tic  s tra teg ies  (354).
A ll data generated so fa r suggests that anti-TN F (non-)response is a more 
complex phenom enon as was anticipated five years ago. It is expected that the genetic 
varian ts involved in non-response to anti-TN F therapy have sm a ll e ffect sizes instead of 
the effect sizes seen in the pharm acogenetic tests that are used in daily practice nowa­
days. Drugs can be m etabolized by a d iffe rent sets of enzymes, transported  by d ifferent 
types of protein ca rrie rs  and in te ract w ith  one or m ultip le  targets. Most drug effects 
are polygenic, meaning that the drug processing pathway (m etabolism , transporta tion, 
ta rget in teraction) d isplays genetic variation between patients. C lear-cu t frequency 
d is tribu tions as observed for tests used in daily practice would be replaced by m ultip le  
overlapping d is tribu tions, thereby obscuring the re lationsh ip  between drug and target. 
To identify these genetic variants it is of u tm ost im portance to investigate large p re fe r­
ably homogeneous patient cohorts. Our patient population m ight have been under­
powered to detect these sm a ll e ffects in the genes we investigated. As a result, it is far 
m ore d ifficu lt to identify genes w hich are associated w ith  anti-TN F therapy response 
and consortium s w ith  access to large w e ll characterized populations are needed to 








To conclude, the investigated patient population is very w e ll characterized and 
therefore it is (probably) not the reason for not identifying genetic m arke r fo r anti-TN F 
(non-)response. It is more like ly that the effect sizes fo r the investigated SNPs are very 
sm a ll and that the patient cohort has insu ffic ien t power to detect them . It is also pos­
sib le that the w rong candidate genes are investigated. Ways to improve power are: 1| 
includ ing more patients and 2) improve fo llow -up  w hich w ill generate possib ilities to do 
extensive long itud ina l analyses.
> TOWARDS PERSONAL I ZED 
ME DI C I NE ?
As mentioned above, it is un like ly that a single genetic varian t w ill predict 
anti-TN F trea tm ent outcom e w ith  su ffic ien t sensitiv ity  and specificity. It seem s more 
like ly that a set of genes and genetic variants w ill together predict anti-TN F trea tm ent 
response. In th is  respect it is im portan t to take additive e ffects as w e ll as in te rac­
tions between genetic po lym orph ism s into consideration in pharm acogenetic s tud ­
ies. Besides these gene-gene in teractions, ind ividual disease course and trea tm ent 
response is also influenced by gene-environm ent in teractions. For example, a p rom i­
nent gene-environm ent in teraction  was identified between sm oking and the HLA-DRB1 
shared epitope (SE) a lle les (355-357). Kallberg and co -w orkers investigated in a recent 
study the in teraction between the HLA-DRB1  a lle les and another environm enta l factor: 
a lcohol consum ption. They reported that alcohol consum ption was dose-dependently 
associated w ith  reduced risk of RA in the investigated patient cohorts. The absolute 
risk  reduction associated w ith  alcohol consum ption was more pronounced among 
sm okers carry ing one or two of the HLA-D RB1  SE a lle les (358). Since gene-gene and 
gene-environm ent in te ractions are also involved in therapy response, the m ain goal in 
pharm acogenom ic research is to incorporate genom ic in fo rm ation  w ith  dem ographic 
and environm enta l covariates to obtain a genotype-to-phenotype map w hich can be 
used to personalize a trea tm ent regim en for a disease. Such a m ultivaria te  analysis 
fo r therapy response in RA is e legantly shown in the study of W essels and colleagues 
(359). In th is  study, a c lin ica l pharm acogenetic m odel was developed w hich can be 
used to predict m ethotrexate (MTX) response in patients w ith  RA. This m odel included 
fou r po lym orph ism  located in MTX response candidate genes (AM PD1, ATIC, ITPA and 
MTHFD1) together w ith  sex, rheum atoid factor, sm oking sta tus and the disease activity 
score (DAS). Using th is  model, 60% percent of the patients were categorized as e ither 
a MTX responder or non-responder, whereas only 32% of the patients were catego­
rized when a non-genetic m odel was applied. They conclude from  th is  com parison 
tha t pharm acogenetic is of great value fo r predicting response to MTX (359). I suggest 
tha t such a pharm acogenetic m odel is also developed fo r anti-TN F trea tm ent. At th is 
m om ent it is too early to point at the specific DNA varian ts that should be included in 
th is  model. However, in the next few years these w ill be identified by large in te rna tiona l 
GWAS studies. Potentia lly  im portan t phenotypic and environm enta l factors that need 
to be taken into account regarding anti-TN F response are the fo rm ation  of antibodies 
directed against anti-TN F agents and sm oking. Some stud ies suggest tha t both may 








fo rm ation  against b io logica ls is increasingly suggested to be one of the m echanism s of 
drug fa ilure (360). Dose and frequency ad justm ents of anti-TN F therapy due to in su ffi­
cient response are often applied in RA patients (29;361). In addition, many patients who 
fa il to respond to the firs t anti-TN F agent, benefit from  a sw itch to a second anti-TN F 
agent. This suggests a m echanism  of neutra liz ing  antibodies directed against the firs t 
used anti-TN F agent (362;363). Indeed, several s tudies showed a corre la tion  between 
c lin ica l response and the fo rm ation  of anti-TN F antibodies (201;364-368). In the study 
of Hyrich and co -w orkers it is suggested that sm oking is associated w ith  anti-TN F 
non-response. They reported lower response rates among RA patients, p a rticu la rly  in 
patients receiving in flix im ab (200).
When such pharm acogenetic m odels are developed fo r several RA trea tm ent 
strategies, it w il l increase the possib ility  to identify the best trea tm ent regim en for each 
ind ividual patient. Thereby, the identifica tion  of RA severity genes w ill make it possible 
to diagnose patients w ith  rapid disease developm ent in an early stage. This w ill result 
in a more aggressive and targeted trea tm ent soon a fte r diagnosis.
However, it is m ethodo log ica lly dem anding to investigate the re la tionsh ip  be­
tween several (genetic and environm enta l) factors as these factors may be in te r-re la ted  
in varying degrees between RA patients. Therefore, com pleteness of in fo rm ation  and 
non-biased recru itm en t of the study cohorts is c ruc ia l fo r the re liab ility  of results.
> FUTURE RESEARCH 
P E R S P E C T I V E
Pharm acogenetic stud ies reported so fa r are only beginning to unravel the 
genetic com plexity underlying the m echanism s of an ti-TN F response. In the next few 
years the focus w ill sh ift from  the hypothesis-driven pharm acogenom ics approaches 
tow ards the non-hypothesis  driven approaches in w h ich the entire  genome, tran - 
scrip tom e and proteom e is screened fo r relevant varia tion associated w ith  response 
to an ti-TN F  trea tm ent. In addition, the technique of next generation sequencing (or 
resequencing) is very prom ising (369;370). This technique o ffers high th roughput 
sequencing of the entire  genome fo r re lative ly  low costs, thereby providing in fo rm a ­
tion on lite ra lly  every nucleotide in the genome. W ith in three to five years th is  tech ­
nique w ill be standard fo r genom ic screening of large patient cohorts. Genomic data 
from  such screens (GWAS o r next generation sequencing) w ill be com bined w ith  data 
obtained from  transc rip to m ic  and pro teom ic screens using soph istica ted s ta tis tica l 
m ethods fo r the iden tifica tion  of m arkers  that can p red ic t trea tm e n t outcom e in a 
subs tan tia l part of the patients (371 ). However, these large genom e-w ide screens on 
the DNA, RNA and protein levels w ill only be successfu l if they are applied on large 
w e ll-cha rac te rized  cohorts. Therefore, m u lticen te r pharm acogenom ics co llabora tions 
should concentra te  on co llecting  these w e ll-de fined  patient cohorts, w h ich provide 
su ffic ien t s ta tis tica l power to detect the supposedly sm a ll genetic effects associated 
w ith  trea tm en t outcom e and /o r disease course.
A lthough pharm acogenetic testing is yet in its early infancy in complex d is ­
eases, the proposed approaches w ill m ost certa in ly  lead to the identifica tion of m arkers 
fo r anti-TN F therapy response resu lting  in a more personalized trea tm ent strategy.
The application of ta ilo r-m ade ' personalized m edicine in the daily c lin ic  w ill be of great 
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Rheumatoid a rth ritis  (RA) is a comm on chronic in flam m atory disease that may 
lead to severe jo in t destruction and disability. The exact cause of RA rem ains to be e luc i­
dated but it is generally accepted that both genetic and environm ental factors play a role 
in in itiation and outcome of the disease. Since there is no cure for RA, therapeutic in te r­
vention is focused on m inim izing jo in t damage and functional loss. One of the m ost widely 
used treatm ent approaches for RA patients w ith  active disease is tum our necrosis factor 
(TNF) neutralization. Anti-TNF treatm ent is highly effective, however, approximately 30% 
of the RA patients treated w ith  TNF-blocking agents fa il to show clin ica l improvement 
in itia lly  o r loose response after short or longlasting therapy. Non-response, together 
w ith  the occurrence of toxicities and the high costs of TNF-blocking agents have driven 
the search for genetic m arkers to predict treatm ent response, since a better insight into 
the pharm acogenetics of anti-TNF therapy may facilitate the choice for the m ost suitable 
medication and/or dosing regimen for an individual patient in daily c lin ica l practice.
Goal of th is  thesis is the identifica tion  of genetic m arkers w hich are able to 
predict anti-TN F therapy outcom e in patients w ith  RA. Since it can be assumed that 
overlapping (in flam m atory) genes have a c ritica l role in both anti-TN F response and the 
pathogenesis of RA, we also aimed at identify ing genetic m arkers associated w ith  RA 
disease severity and radiologic jo in t damage.
This thesis consists of two parts. The firs t part focuses on the identification of poly­
m orphism s responsible for anti-TNF (non-)response and disease severity in a hypothesis 
driven manner. Following a general introduction, chapter 2 gives an overview of the current 
literature concerning anti-TNF pharmacogenetics, as w e ll as technologies currently in use 
for the identification of genetic markers associated w ith anti-TNF outcome. In chapter 3 to 6 
three polymorphisms in candidate genes are investigated for the ir potential role in anti-TNF 
response and/or RA severity using two large patient cohorts. The cohort used to study anti- 
TNF response included patients from the Dutch Rheumatoid A rthritis  Monitoring (DREAM) 
registry w ith detailed information on their response to anti-TNF therapy (infliximab and 
adalimumab). The RA severity cohort consisted of patients from a long-term  observational 
early inception cohort who are regularly monitored for the ir disease activity and progression.
In chapte r 3 it was investigated if a (GT)n repeat po lym orph ism  in the heme 
oxygenase-1 (HMOX1) p rom oter is associated w ith  RA susceptib ility , disease severity 
and radiologic jo in t damage. Recently, it was dem onstrated tha t HMOX-activity protects 
against the onset of RA and tha t ind ividuals w ith  sho rt (GT)n-repeats (SS; n<25) induce 





to ta l of 325 w e ll-cha racte rized  RA patients and 273 con tro ls  were investigated. No s ig ­
n ificant d ifferences in genotype or a lle le  frequency were found between RA patients and 
contro ls, but patients w ith  the SS-genotype had a s ign ifican tly  more favorable radiologic 
outcom e over nine years than those carry ing the LL-genotype. These resu lts  suggest 
tha t the HMOX1 gene is involved in RA disease severity.
In chapter 4 the e ffect of a functiona l polym orphism  (676T>G, M196R) in the 
Tum or Necrosis Factor Receptor Super Family 1b (TNFSF1B) gene on disease activity, 
rad io logic jo in t damage and response to in flix im ab and ada lim um ab therapy in patients 
w ith  RA was investigated. For th is  study, DNA was available fo r 234 patients from  the 
DREAM reg is try  and for 248 patients from  the early inception cohort. Analyses showed 
that the 676T>G polym orphism  was not associated w ith  response to anti-TN F m edica­
tion a fte r three o r six m onths of therapy o r w ith  disease severity. These resu lts  suggest 
tha t the TNFRSF1B  676T>G po lym orph ism  does not have a large im pact on e ithe r an ti- 
TNF response or disease severity in our population.
Next, the TNFA -308G>A prom oter polymorphism and its relation to RA disease 
severity (chapter 5) and anti-TNF treatm ent (chapter 6) was investigated. For the analyses 
regarding disease severity and radiologic jo in t damage, a total of 208 patients from the early 
inception cohort were genotyped. To learn more about the mechanism behind the effect of 
the polymorphism, RNA of an additional 66 RA patients was used for TNFA gene expression 
analysis by quantitative PCR. The -308G allele was found associated w ith more radiologic 
jo in t damage progression compared w ith the A allele over 9 years of follow up. No d iffe r­
ences in TNFA gene expression between alleles was observed. These data confirm  that the 
TNFA -308G>A prom oter polymorphism is associated w ith RA severity, but this does not 
seem to be mediated by expression differences between alleles. To investigate the TNFA 
-308G>A prom oter polymorphism and its influence on anti-TNF response, a meta-analysis 
was performed combining data from  13 previously published studies and one unpublished 
dataset from the DREAM registry resulting in a patient cohort of 2829 patients. The two 
subclasses of anti-TNF treatment, i.e. monoclonal anti-TNF antibodies and TNF receptor 
antagonists were analyzed separately. No association was observed between the promoter 
polymorphism and response to treatm ent in this large patient cohort. Therefore, it was con­
cluded that this polymorphism does not play a role in the response to anti-TNF treatment.
The second part of this thesis concentrates on the non-hypothesis driven gene 
discovery technique, whole genome expression profiling, to investigate anti-TNF response 
in RA patients at the transcrip tional level. In chapter 7 a systematic literature search was 
performed and this revealed eight array-based expression profiling studies in RA patients. 
Two of those investigated the response to anti-TNF treatment, the other six were focused 
on studying differences in disease etiology. Results from  these eight studies were compared
to those of linkage and genome-wide association (GWA) studies and two sets of genes were 
extracted: 1) those differentially expressed in more than one study, and 2) genes differen­
tia lly expressed in at least one of the reviewed studies and present in RA linkage or GWA 
loci. Both sets of genes were identified as interesting candidate genes for fu rther study in 
RA and potentially in anti-TNF treatm ent response. One of these genes was also identified 
in a genome-wide expression profiling studies focusing on RA susceptibility.
Subsequently, in chapter 8, a genom e-w ide expression pro filing  study was pe r­
form ed to identify gene expression signatures predicting anti-TN F therapy outcom e in a 
patient cohort of 42 RA patients. F irst, the valid ity of two previously published gene sets 
predictive of anti-TN F trea tm ent outcom e was tested in ou r patient cohort. Analyses 
revealed a sensitiv ity  of 71% and a specific ity  of 61% and 28%, respectively, fo r the two 
previously published gene sets. Secondly, w hole-genom e expression pro filing  identified 
a new predictive gene expression s ignature  of 113 genes whose expression predicted 
therapy response w ith  a sensitiv ity of 79% and a specific ity  of 84%. These 113 genes 
associated w ith  anti-TN F trea tm ent response point out to specific pathways fo r fu rth e r 
study into the m echanism s of anti-TN F action. These resu lts  con firm  that gene expres­
sion p ro filing  p rio r to trea tm ent is a usefu l too l to predict anti-TN F (non-)response.
Expression analysis at the level of exons also revealed that two adjacent exons in the 
SIRPB1 gene were decreased in expression in the anti-TNF non-responders when compared 
to the responders. In chapter 9 the decrease in expression of these two exons in the SIRPB1 
gene was fu rthe r investigated for its involvement in anti-TNF response. The decrease in 
expression was validated and replicated by Q-PCR in a combined cohort of 76 RA patients 
from the DREAM registry and the Autoimmune Bio-m arkers Collaborative Network (AB- 
CoN) cohort. Further analysis revealed that the decrease in expression was a direct result of 
two partly overlapping deletions in the SIRPB1 gene. However, no association was observed 
between the two DNA deletions and anti-TNF response in a larger cohort of 466 RA patients 
treated w ith anti-TNF medication. Despite the in itial results, it was concluded that the 
observed association at the RNA level could not be confirmed at the DNA level and that the 
SIRPB1 deletions are probably not associated w ith the response to anti-TNF treatment.
In the genera l d iscussion (chapter 10) the resu lts  of the research presented 
in th is  thesis are b rie fly  sum m arized and placed in a broader perspective concerning 
pharm acogenetics and its role in the daily trea tm ent of RA in a c lin ica l setting. Several 
d iffe ren t approaches fo r pharm acogenetic research are discussed. Future studies 
should improve and in tegrate d iffe ren t approaches on m u ltip le  levels (DNA, RNA and 
protein expression) to identify those (genetic) m arkers responsible for therapy outcome 
in RA. Once identified and validated for the ir c lin ica l use, these pharm acogenetic m a rk ­







Reumatoïde a rtr it is  is een veel voorkom ende ontstekingsziekte die kan leiden tot 
ernstige gewrichtsschade en to t verlies van functie  van de aangedane gewrichten. De 
oorzaak van RA is grotendeels onbekend m aar het w ordt a lgemeen aangenom en dat 
zowel genetische als om gevingsfactoren een ro l spelen in het ontstaan en het verloop 
van de ziekte. RA kan niet worden genezen en daarom is de behandeling van de ziekte 
erop gerich t om gewrichtsschade en functie  verlies van de gew richten zoveel m ogelijk  
te beperken. Een van de m eest toegepaste therapieën bij RA patiënten m et een actief 
ziektebeeld is neu tra lisa tie  van tu m o r necrosis factor (TNF). A nti-TN F therapie is zeer 
succesvol, echter, ongeveer 30% van de behandelde RA patiënten reageert onvoldoende 
na de s ta rt van de behandeling of na enige tijd van behandelen. Gezien het percentage 
patienten dat onvoldoende reageert, samen m et de b ijw erkingen en hoge kosten van 
anti-TN F therapie, is het waardevol om in staat te zijn de u itkom st van anti-TN F the ra ­
pie te kunnen voorspellen voordat daadw erke lijk  m et de therapie w ordt begonnen. Het 
onderzoeksveld van de farm acogenetica rich t zich op het identificeren van genetische 
varia tie  die veran tw oorde lijk  is voor het versch illend reageren van patienten op m edica­
tie. Beter inzicht in de farm acogenetica van anti-TN F therapie m aakt het m oge lijk  om 
de keuze voor het type anti-TN F m edicatie en hoogte van de dosering beter af te s te m ­
men op de individuele patiënt.
Doel van d it p roe fsch rift is het identificeren van genetische variatie  die het 
m oge lijk  m aakt om te voorspellen hoe RA patienten zullen gaan reageren op anti-TN F 
medicatie. Omdat w ordt aangenom en dat de (in flam m atoire) genen verantw oorde lijk  
voor de response op anti-TN F m edicatie  en voor ziekte e rns t/ac tiv ite it grotendeels 
overlappen, is d it p roe fsch rift er ook gerich t op het identificeren van genetische variatie 
veran tw oorde lijk  voor ziekte e rnst en radio logisch gewrichtsschade.
Dit p roe fsch rift betaat uit twee delen. Het eerste deel r ich t zich op de iden­
tifica tie  van po lym orfism en veran tw oorde lijk  voor anti-TN F (non-)response op een 
hypothese gedreven manier. Na een algem ene in troductie  w ord t in hoofdtuk 2 een 
overzicht gegeven van de actuele lite ra tu u r betreffende anti-TN F farm acogenetica en 
de huidige technieken die gebru ik t worden voor de identificatie  van genetische variatie. 
In hoofdstuk 3 to t en m et 6 worden achtereenvolgens drie po lym orfism en in kandidaat 
genen onderzocht op hun (potentiële) ro l in anti-TN F response en/of RA ziekte ernst. 
Voor deze studies is gebru ik t gem aakt van twee grote RA patiënten cohorten.Voor het 
onderzoek naar anti-TN F response is geb ru ik t gem aakt van het Dutch Rheumatoid 






over de response van patiënten op anti-TN F m edicatie (in flix im ab en adalim um ab). Voor 
onderzoek naar RA ziekte e rns t is gebru ik  gem aakt van een lange te rm ijn  observation- 
eel cohort, w aarin patiënten meteen naar de diagnose worden geïncludeerd en worden 
gevolgd m et betrekking tot hun ziekte activ ite it en ziekte ernst.
In hoofdstuk 3 w ordt onderzocht of een (GT)n repeat po lym orfism e in de heme 
oxygenase-1 (HMOX1) p rom oter is geassocieerd m et RA gevoeligheid, ziekte activ ite it en 
radio logische gewrichtsschade. Onlangs is aangetoond dat HMOX activ ite it bescherm d 
tegen het ontstaan van RA en dat individuen m et korte (GT)n repeats (SS; n<25) sne lle r 
hogere niveau's van HMOX1 activ ite it induceren dan individuen m et lange repeats (LL; 
n>25). In to taal zijn 325 goed gekarakteriseerde RA patiënten en 273 controle personen 
bestudeerd. Er zijn geen sign ificanten versch illen  in genotype of a lle l frequenties gev­
onden tussen RA patiënten en controle personen, m aar patiënten m et een SS genotype 
hadden na negen ja a r s ign ifican t m inder radio logische schade ontw ikke ld  dan pa tien t­
en m et een LL genotype. Deze resu lta ten suggereren dat het HMOX1 gen betrokken is 
bij RA ziekte ernst.
In hoofdstuk 4 w ordt het effect onderzocht van een functonee l polym orfism e 
(676T>G, M196R) in het Tum or Necrosis Factor Receptor Super Family 1b (TNFRSF1B] 
gen op ziekte activite it, radio logische schade en de response op in flix im ab en ada li­
m um ab therapie in patiënten m et RA. Voor deze studie was DNA beschikbaar van 234 
patiënten uit het DREAM cohort en 248 patiënten u it het lange te rm ijn  observationeel 
cohort. Analyse laat zien dat het 676T>G po lym orfism e niet is geassocieerd m et re ­
sponse op anti-TN F m edicatie  na drie  of zes maanden. Daarnaast is in deze studie het 
po lym orfism e ook niet geassocieerd m et RA ziekte ernst. Deze resu lta ten suggereren 
dat het TNFRSF1B 676T>G po lym orfism e geen grote invloed heeft op zowel anti-TNF 
response als RA ziekte e rnst in deze populatie.
Vervolgens is onderzocht of het TNFA -308G>A prom oter po lym orfism e is 
geassocieerd m et RA ziekte e rnst/rad io log ische  schade (hoofdstuk 5) en response op 
anti-TN F m edicatie (hoofdstuk 6). Voor de analyses m et betrekking to t RA ziekte ernst 
en radiologische schade zijn 208 patiënten van het lange te rm ijn  obervationeel cohort 
gegenotypeerd. Om m eer inzicht te krijgen in het m echanism e achter het e ffect van het 
po lym orfism e, is RNA van 66 additionele patiënten gebru ik t voor TNFA gen expressie 
analyse door m idde l van quantitative PCR. Het -308G a lle l bleek geassocieerd te zijn 
m et een grotere toenam e in radiologische gewrichtsschade na negen ja a r in ve rge li­
jk ing  m et het A alle l. Geen versch illen  in TNFA expressie tussen het G en A a lle l zijn 
waargenom en. Deze data bevestigen dat het TNFA -308G>A po lym orfism e is geasso­
cieerd m et RA ziekte ernst, m aar w ordt w aa rsch ijn lijk  niet gemedieerd door expres­
sie versch illen  tussen de alle len. Om het TNFA -308G>A po lym orfism e te bestuderen 
in relatie to t anti-TN F response, is een m eta-analyse uitgevoerd w aarb ij 13 eerder
gepubliceerde studies plus een ongepubliceerde dataset u it het DREAM cohort zijn 
samengevoegd. Dit resulteerde in een dataset van 2829 patiënten. De twee sub-k lassen 
anti-TN F m edicatie, m onoclonale antilicham en en TNF receptor antagonisten, zijn 
apart geanalyseerd. Geen associatie is aangetoond tussen het prom oter polym orfism e 
en de response op anti-TN F m edicatie. Geconcludeerd is dat het po lym orfism e geen rol 
spee lt in de response op anti-TN F m edicatie.
Het tweede gedeelte van d it p roe fsch rift r ich t zich op de techniek van genoom - 
w ijd  expressie p ro file ring  voor het bestuderen van anti-TN F response in RA patiënten. 
Deze techniek m aakt het m oge lijk  de response op anti-TN F m edicatie  te onderzoeken 
op een n iet-hypothese gedreven manier. In hoofdstuk 7 zijn, m et behulp van een 
system atische lite ra tu u r analyse, acht expression p ro filing  stud ies m et RA patiënten 
geïdentificeerd. Twee van deze studies hebben de response op anti-TN F m edicatie 
bestudeerd, de andere zes hebben zich gerich t op versch illen  in RA ziekte etiologie. De 
resu lta ten uit deze acht stud ies zijn vergeleken m et resu lta ten uit linkage en genoom - 
w ijde associatie (GWA) stud ies en h ie ru it zijn twee sets van genen naar voren gekomen: 
1) genen die d iffe ren tiee l to t expressie kwam en in m eer dan één studie, en 2) genen 
die d iffe ren tiee l tot expressie kwam en in m instens één van de acht stud ies en die 
voorkom en in linkage of (GWA) loci. Beide genensets zijn in teressante kandidaat genen 
voor verdere studie naar RA en de response op anti-TN F m edicatie.
In hoofdstuk 8 w ordt m et behulp van genoom -w ijde expressie p ro file rings in 42 
RA patiënten een expressie pro fie l van 113 genen aangetoond dat in staat is anti-TNF 
responsers te kunnen onderscheiden van anti-TN F non-responders m et een sens itiv ­
ite it van 79% en een spec ific ite it van 84%. Deze 113 genen geasocieerd m et anti-TN F 
response duiden specifieke transductie rou tes aan die verder bestudeerd kunnen 
worden m et betrekking tot de achterliggende m echanism en van anti-TN F response. 
Daarnaast is het patiënten cohort van 42 RA patiënten gebru ik t om de va lid ite it van 2 
eerder verschenen expressie profie len te testen. Analyse laat een sens itiv ite it van 71% 
zien voor beide expressie profie len en een spec ific ite it van 61% en 28%.
Expressie analyse op exon niveau laat twee aangrenzende exonen in het SIRPB1 
gen zien waarvan de expressie is verlaagd in anti-TN F non-responders ten opzichte van 
responders. In hoofdstuk 9 w ordt deze afnam e in expressie verder bestudeerd. De ve r­
laagde expressie van deze twee exonen in anti-TN F non-responders werd gevalideerd 
en gerepliceerd m et quantita tive PCR in een gecombineerd cohort van 76 RA patiënten 
afkom stig  u it het DREAM reg is te r en het A u to im m une B io -m arke rs  Collaborative N et­
w ork  (ABCoN) cohort. Verdere analyse laat zien dat de afnam e in expressie een direct 
gevolg was van twee gedee lte lijk  overlappende deleties in het SIRPB1 gen. Echter, er 
bleek geen associatie te zijn tussen de twee DNA deleties en anti-TN F response in een 






bevindingen op RNA niveau konden niet bevestigd worden op DNA niveau en e r moet 
geconcludeerd worden dat de deleties in het SIRPB1 gen w aa rsch ijn lijk  niet geassoci­
eerd zijn m et anti-TN F response.
In de algem ene d iscussie (hoofdstuk 10) worden de resu lta ten van d it p roef­
s ch rift samen gevat en geplaatst in een breder perspectie f betreffende de fa rm acoge­
netica en de ro l daarvan bij de behandeling van RA in de k lin iek. Verschillende bena­
deringen voor farm acogenetisch onderzoek worden besproken. Toekomstige studies 
zullen versch illende strateg ieën op m eerdere niveau's (DNA, RNA, eiwit) moeten ve r­
beteren en integreren om zo (genetische) m arkers  te kunnen identificeren die ve ran t­
w oorde lijk  zijn voor therapie u itkom sten in RA. Eenmaal geïdentificeerd en gevalideerd 
voor k lin isch  gebru ik, zullen deze farm acogenetische m arkers veel bijdragen aan de 
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> DANKWOORD
Klaar! Hèhè..het zit erop! A lleen nog dat dankwoord schrijven. Iets wat ik e igen­
lijk  a l weken voor me u it schuif. Im m ers, het dankwoord mag dan het m inst w e ten ­
schappelijke zijn van een proe fschrift, het is vaak w el het m eest gelezen (en meest 
bediscussieerde) deel. De d ruk lig t dus hoog en m orgen m oet toch echt het hele zaakje 
naar de drukker. Ik mag w e l opschieten...
Ik had dit p roe fsch rift niet kunnen schrijven zonder de hulp van een groot aantal 
m ensen zowel binnen als buiten het w etenschappelijke wereldje. Die mensen w il ik 
graag h ie r bedanken.
Marieke, jou w il ik als eerste bedanken. Eerst a ls onoffic iële  begeleider, la te r als 
offic ië le  coprom oter was jij het m eest betrokken bij m ijn  onderzoek. Bedankt voor je 
steun, adviezen en vertrouwen. Wij zijn allebei recht door zee en doorgaans zitten we op 
één lijn. Dat ge ld t zowel in w etenschappelijke als niet w etenschappelijke zin. Zo hebben 
we tijdens ons ve rb lijf in New York m et z'n tweeën vrese lijk  moeten lachen om de (in 
onze ogen) sch ijnhe ilige  en s lijm e rige  m an ie r waarop Am erikanen m et e lkaar omgaan 
("Good fo r you, purple is really your co lo r!" "Oh, thank you!" "You're welcom e!").
Barbara, jij hebt m ij in 2004 aangenom en als ju n io r onderzoeker w aardoor ik de 
kans heb gekregen om een echte onderzoeker te worden. Onze w erkbesprekingen (sa­
men m et Marieke) waren zeer inspirerend, vaak verzon je de ene paper na de andere. 
Daarnaast zorgde je  e r a ltijd  voor dat ik niet de details u it het oog verloor als ik w eer te 
sne l over de m aterie  heen denderde. Dank voor je  steun en vertrouw en in m ij bij m ijn 
eerste stappen in m ijn  wetenschappelijke  carrière.
Pilar, jou w il ik bedanken voor je advies en prettige begeleiding vanuit Reuma­
tologie. Toen ik begon als ju n io r onderzoeker w is t ik weinig van reum atische ziekten en 
ik kon a ltijd  bij je  te recht voor reum a-vraagjes. Daarnaast w il ik je  bedanken voor het 
a ltijd  sne l en uitvoerig nakijken en corrigeren van m ijn  m anuscrip ten. Ook jij was altijd 
recht door zee, w at voor m ij prettig  w erkte . Ik heb dan ook vaak tijdens het verwerken 
van jo u w  correcties moeten g lim lachen om je com m entaar (vaak in ‘Caps Lock'): ERIK, 
SNAP HIER NIKS VAN, TE LANG. KORTER! Mede door jo u w  correcties zijn m ijn  papers 
korter, bondiger en leesbaarder geworden.
Piet, jou w il ik voora l bedanken voor de kans die je  m ij hebt gegeven om mijn 
studie te presenteren aan de leden van de DREAM Registry. H ierdoor werd het m ogelijk  
om ook in ziekenhuizen buiten N ijm egen DNA sam ples te verzamelen.
Han, bedankt dat ik binnen de afdeling Antropogenetica d it onderzoek heb 





Mascha, toen ik in 2004 bij ju llie  in de groep begon, had jij m ij ingeschaald als 
tran ce -tru tje '. Achteraf bleek dat volgens m ij a llem aa l w e l mee te vallen en la te r 
stonden we dan ook sam en bij een optreden van een of andere vage Belgische artiest. 
Wat het w erk  betreft, jij bent de beste M LPA-er die ik ken! Zet jou in de hoek m et 600 
DNA sam ples en het kom t a llem aa l dik voor mekaar. Ik heb de afgelopen ja ren vreselijk  
moeten lachen om jouw  hum or en absurde m an ie r van denken (mensen die jou ken­
nen, weten precies wat ik bedoel). Dit m aakt sam enwerken m et jou zeer prettig . Alleen 
jouw  gezang op het lab is w e rke lijk  niet om aan te horen, ik heb af en toe nog steeds 
een hoge pieptoon in m ijn  oren.
W ietske en Jaap, ju llie  w il ik bedanken voor het koppelen van de genetische data 
aan de k lin ische data. A ltijd  kon ik bij ju llie  te recht als ik w eer een update nodig had of 
vragen had over het een of ander. Zonder ju llie  geen analyses1
Sita, bedankt voor je  advies en hulp bij de s ta tis tiek. Er is w e rke lijk  geen paper 
geweest dat ik jou niet heb opgebeld m et vragen: "Ik w il d it en dat toetsen, kan dat/m ag 
da t/s laa t dat ergens op?" Gewoon lekker aftaggen die boel!
Alle collega's van de researchgroep M u ltifac to riee l bedankt voor alle hulp, d is ­
cussies en gezelligheid.
Joris, bedankt dat jij het m oge lijk  hebt gem aakt dat ik m ijn onderzoek kon pre­
senteren op het hoofdkantoor van A ffym etrix  in San Francisco. Daarna een superstoer 
weekend gehad in downtown San Francisco (bike the bay) en vervolgens een roadtrip 
van San Francisco naar de ASHG in San Diego ("Hoe kwam  dat nou, dat ongeluk?"). Jij 
houdt m isschien nog w e l m eer van lekker eten en gezelligheid dan ik. Het leek er soms 
dan ook op dat onze roadtrip  voora l bestond uit het rijden van restaurant naar restau­
rant. Bedankt voor de leuke tijd (over Ibiza zullen we het h ier m aar niet hebben).
Ik ben ook veel dank verschuld igd aan alle collega's van Antropogenetica die e i­
gen lijk  a llang geen collega 's m eer zijn maar, vrienden zijn geworden. Bedankt voor alle 
gezelligheid binnen en buiten het lab. A ltijd  reden voor een b iertje  en de ‘Vrijdag Fuik 
avond' is een begrip geworden binnen de afdeling. Overdag a llem aa l keurige w e ten ­
schappers, m aar 's avonds in de k ro e g . Er is dan ook heel w at afgehengst daar in die 
Fuik, m aar helaas kan ik het e r niet over hebben want w at in de Fuik gebeurt, b lijft in 
de Fuik! Barpersoneel van café de Fuik ook bedankt. Zonder ju llie  was dit p roe fschrift 
niet m oge lijk  geweest.
En hoewel het fie tsen e r de laatste tijd bij in geschoten is, ook alle Antropo fie ts ­
vrienden bedankt (het m oet m aar eens afgelopen zijn m et die m ateriaa l pech smoes).
Ook ben ik veel dank verschuld igd aan m ijn paranim fen. Remco (vuile hufter!), 
we hebben het af en toe zwaar gehad tussen al die serieuze m ultifacto-vrouw en. Jouw 
vrese lijk  slechte sm aak voor hum or ("Er zit w at op je neus") sloot perfect aan bij m ijn 
hum or en ik heb daarom m et veel p lezier m et je sam en gewerkt. Daarnaast m oet ik je
bedanken voor a l die keren dat jij voor m ij naar de St M aartensklin iek bent gefie tst om 
daar bloed sam ples op te halen als ik w eer eens quasi-in te ressan t be langrijkere  zaken 
te doen had. Gaat dat lukken s traks  m et dat glaasje w a te r inschenken tijdens m ijn 
verdediging?
Relphie, w ij waren al vrienden voordat we goed en w el in de gaten hadden wat 
die wetenschap nu precies in hield (dat weten we nog steeds niet, m aar dat hoeft 
niemand te weten). Ongelooflijk hoeveel foute en ord inaire vakantie-e ilanden w ij heb­
ben afgestru ind! Ik heb vrese lijk  veel lo l en plezier gehad tijdens onze queeste naar 
de m eest idyllische taverne van Kos. Om nog m aar te zwijgen over die keer dat onze 
huurauto was w eggesleept of die keer in de kroeg dat onze peperdure drankjes (wie 
d rink t e r dan ook absint?!) zo uit onze handen werden getrokken door een paar verve­
lende m utsen. Ik hoop dat we nog lang bevriend blijven, want e r zijn vast nog w e l m eer 
ord inaire vakantie-e ilanden.
Familie, vrienden en bekenden, bedankt voor alle steun en interesse.
Pap en mam, ondanks dat het vaak m oe ilijk  was om in begrijpe lijke  taa l te 
verwoorden waarm ee ik nu precies bezig was, waren ju llie  a ltijd  geïnteresseerd in m ijn 
onderzoek. Het is nu e inde lijk  af! Bedankt voor ju llie  steun.
Lieve Eefke, jij s teunt m ij in a lles w at ik doe. Ik hoop dat je  dat nog lang b lijft 
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